

## STN Columbus

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 DEC 18 CA/CAPLUS pre-1967 chemical substance index entries enhanced  
with preparation role  
NEWS 4 DEC 18 CA/CAPLUS patent kind codes updated  
NEWS 5 DEC 18 MARPAT to CA/CAPLUS accession number crossover limit increased  
to 50,000  
NEWS 6 DEC 18 MEDLINE updated in preparation for 2007 reload  
NEWS 7 DEC 27 CA/CAPLUS enhanced with more pre-1907 records  
NEWS 8 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals  
NEWS 9 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded  
NEWS 10 JAN 16 IPC version 2007.01 thesaurus available on STN  
NEWS 11 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data  
NEWS 12 JAN 22 CA/CAPLUS updated with revised CAS roles  
NEWS 13 JAN 22 CA/CAPLUS enhanced with patent applications from India  
NEWS 14 JAN 29 PHAR reloaded with new search and display fields  
NEWS 15 JAN 29 CAS Registry Number crossover limit increased to 300,000 in  
multiple databases  
NEWS 16 FEB 15 PATDPASPC enhanced with Drug Approval numbers  
NEWS 17 FEB 15 RUSSIAPAT enhanced with pre-1994 records  
NEWS 18 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality  
NEWS 19 FEB 26 MEDLINE reloaded with enhancements  
NEWS 20 FEB 26 EMBASE enhanced with Clinical Trial Number field  
NEWS 21 FEB 26 TOXCENTER enhanced with reloaded MEDLINE  
NEWS 22 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements  
NEWS 23 FEB 26 CAS Registry Number crossover limit increased from 10,000  
to 300,000 in multiple databases  
NEWS 24 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format  
NEWS 25 MAR 16 CASREACT coverage extended  
NEWS 26 MAR 20 MARPAT now updated daily  
NEWS 27 MAR 22 LWPI reloaded  
NEWS 28 MAR 30 RDISCLOSURE reloaded with enhancements  
NEWS 29 MAR 30 INPADOCDB will replace INPADOC on STN  
NEWS 30 APR 02 JICST-EPLUS removed from database clusters and STN  
  
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 21:02:01 ON 06 APR 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 21:02:13 ON 06 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 APR 2007 HIGHEST RN 929247-80-3  
DICTIONARY FILE UPDATES: 5 APR 2007 HIGHEST RN 929247-80-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> e sildenafil/cn


E1	1	SILD (STREPTOCOCCUS PYOGENES GENE SILD)/CN
E2	1	SILDATE/CN
E3	1 -->	SILDENAFIL/CN
E4	1	SILDENAFIL ACETATE/CN
E5	1	SILDENAFIL ASCORBATE/CN
E6	1	SILDENAFIL CITRATE/CN
E7	1	SILDENAFIL FUMARATE/CN
E8	1	SILDENAFIL HYDROBROMIDE/CN
E9	1	SILDENAFIL HYDROCHLORIDE/CN
E10	1	SILDENAFIL LACTATE/CN
E11	1	SILDENAFIL MALEATE/CN
E12	1	SILDENAFIL MESILATE/CN

=> s e3

L1 1 SILDENAFIL/CN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 139755-83-2 REGISTRY  
ED Entered STN: 20 Mar 1992  
CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-1,6-dihydro-1-methyl-3-propyl- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 1H-Pyrazolo[4,3-d]pyrimidine, piperazine deriv.  
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI)  
OTHER NAMES:  
CN 5-[2-Ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one  
CN Revatio  
CN Sildenafil  
MF C22 H30 N6 O4 S  
CI COM  
SR CA  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPIUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB\*, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU  
(\*File contains numerically searchable property data)  
Other Sources: WHO



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1113 REFERENCES IN FILE CA (1907 TO DATE)  
 24 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 1122 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> e vardenafil/cn

E1	1	VARD/CN
E2	1	VARDAX/CN
E3	1	--> VARDENAFIL/CN
E4	1	VARDENAFIL DIHYDROCHLORIDE/CN
E5	1	VARDENAFIL HYDROCHLORIDE/CN
E6	1	VARDHAK/CN
E7	1	VARDHMAN/CN
E8	1	VAREBIAN/CN
E9	1	VARENICLINE/CN
E10	1	VARENICLINE TARTRATE/CN
E11	1	VARENNESITE/CN
E12	1	VARENNESITE ((MN0.5-1FE0-0.5)2NA8((OH)0.5-1CL0-0.5)2(SI2O5)5 .12H2O)/CN

=> s e3

L2 1 VARDENAFIL/CN

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 224785-90-4 REGISTRY

ED Entered STN: 11 Jun 1999

CN Imidazo[5,1-f][1,2,4]triazin-4(1H)-one, 2-[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]phenyl]-5-methyl-7-propyl- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Piperazine, 1-[[3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl- (9CI)

OTHER NAMES:

CN 2-[2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

CN Nuviva

CN Vardenafil


MF C23 H32 N6 O4 S

CI COM

SR CA

LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, EMBASE, HSDB\*, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PHAR, PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(\*File contains numerically searchable property data)



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

311 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 314 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> e tadalafil/cn


E1 1 TADA3L PROTEIN (XENOPUS TROPICALIS CLONE MGC:79575 IMAGE:697  
 8809 GENE TADA3L)/CN  
 E2 1 TADAB/CN  
 E3 1 --> TADALAFIL/CN  
 E4 1 TADB/CN  
 E5 1 TADB (PASTEURELLA MULTOCIDA STRAIN IL1403 CLONE PM70 GENE TA  
 DB)/CN  
 E6 1 TADB (VIBRIO PARAHAEMOLYTICUS STRAIN O3:K6 GENE VPA0725)/CN  
 E7 1 TADB PILUS ASSEMBLY PROTEIN (RHIZOBIUM ETLI STRAIN CFN 42 PL  
 ASMID P42E)/CN  
 E8 1 TADB PROTEIN (CHLOROBIUM TEPIDUM STRAIN TLS GENE TADB)/CN  
 E9 1 TADB-LIKE PROTEIN (PLASMID PBD2 GENE PBD2.017)/CN  
 E10 2 TADB-LIKE PROTEIN INVOLVED IN PILUS FORMATION AND/OR PROTEIN  
 SECRETION (VIBRIO FISCHERI STRAIN ES114)/CN  
 E11 1 TADC (PASTEURELLA MULTOCIDA STRAIN IL1403 CLONE PM70 GENE TA  
 DC)/CN  
 E12 1 TADC (VIBRIO PARAHAEMOLYTICUS STRAIN O3:K6 GENE VPA0726)/CN

=> s e3

L3 1. TADALAFIL/CN

=> d

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN  
 RN 171596-29-5 REGISTRY  
 ED Entered STN: 21 Dec 1995  
 CN C1=CC2=C(C(=C1)C(=O)N2)C3=CC=CC=C3C4=CC=CC=C4C5=CC=CC=C5C6=CC=CC=C6C7=CC=CC=C7C8=CC=CC=C8C9=CC=CC=C9C10=CC=CC=C10C11=CC=CC=C11C12=CC=CC=C12C13=CC=CC=C13C14=CC=CC=C14C15=CC=CC=C15C16=CC=CC=C16C17=CC=CC=C17C18=CC=CC=C18C19=CC=CC=C19C20=CC=CC=C20C21=CC=CC=C21C22=CC=CC=C22C23=CC=CC=C23C24=CC=CC=C24C25=CC=CC=C25C26=CC=CC=C26C27=CC=CC=C27C28=CC=CC=C28C29=CC=CC=C29C30=CC=CC=C30C31=CC=CC=C31C32=CC=CC=C32C33=CC=CC=C33C34=CC=CC=C34C35=CC=CC=C35C36=CC=CC=C36C37=CC=CC=C37C38=CC=CC=C38C39=CC=CC=C39C40=CC=CC=C40C41=CC=CC=C41C42=CC=CC=C42C43=CC=CC=C43C44=CC=CC=C44C45=CC=CC=C45C46=CC=CC=C46C47=CC=CC=C47C48=CC=CC=C48C49=CC=CC=C49C50=CC=CC=C50C51=CC=CC=C51C52=CC=CC=C52C53=CC=CC=C53C54=CC=CC=C54C55=CC=CC=C55C56=CC=CC=C56C57=CC=CC=C57C58=CC=CC=C58C59=CC=CC=C59C60=CC=CC=C60C61=CC=CC=C61C62=CC=CC=C62C63=CC=CC=C63C64=CC=CC=C64C65=CC=CC=C65C66=CC=CC=C66C67=CC=CC=C67C68=CC=CC=C68C69=CC=CC=C69C70=CC=CC=C70C71=CC=CC=C71C72=CC=CC=C72C73=CC=CC=C73C74=CC=CC=C74C75=CC=CC=C75C76=CC=CC=C76C77=CC=CC=C77C78=CC=CC=C78C79=CC=CC=C79C80=CC=CC=C80C81=CC=CC=C81C82=CC=CC=C82C83=CC=CC=C83C84=CC=CC=C84C85=CC=CC=C85C86=CC=CC=C86C87=CC=CC=C87C88=CC=CC=C88C89=CC=CC=C89C90=CC=CC=C90C91=CC=CC=C91C92=CC=CC=C92C93=CC=CC=C93C94=CC=CC=C94C95=CC=CC=C95C96=CC=CC=C96C97=CC=CC=C97C98=CC=CC=C98C99=CC=CC=C99C100=CC=CC=C100C101=CC=CC=C101C102=CC=CC=C102C103=CC=CC=C103C104=CC=CC=C104C105=CC=CC=C105C106=CC=CC=C106C107=CC=CC=C107C108=CC=CC=C108C109=CC=CC=C109C110=CC=CC=C110C111=CC=CC=C111C112=CC=CC=C112C113=CC=CC=C113C114=CC=CC=C114C115=CC=CC=C115C116=CC=CC=C116C117=CC=CC=C117C118=CC=CC=C118C119=CC=CC=C119C120=CC=CC=C120C121=CC=CC=C121C122=CC=CC=C122C123=CC=CC=C123C124=CC=CC=C124C125=CC=CC=C125C126=CC=CC=C126C127=CC=CC=C127C128=CC=CC=C128C129=CC=CC=C129C130=CC=CC=C130C131=CC=CC=C131C132=CC=CC=C132C133=CC=CC=C133C134=CC=CC=C134C135=CC=CC=C135C136=CC=CC=C136C137=CC=CC=C137C138=CC=CC=C138C139=CC=CC=C139C140=CC=CC=C140C141=CC=CC=C141C142=CC=CC=C142C143=CC=CC=C143C144=CC=CC=C144C145=CC=CC=C145C146=CC=CC=C146C147=CC=CC=C147C148=CC=CC=C148C149=CC=CC=C149C150=CC=CC=C150C151=CC=CC=C151C152=CC=CC=C152C153=CC=CC=C153C154=CC=CC=C154C155=CC=CC=C155C156=CC=CC=C156C157=CC=CC=C157C158=CC=CC=C158C159=CC=CC=C159C160=CC=CC=C160C161=CC=CC=C161C162=CC=CC=C162C163=CC=CC=C163C164=CC=CC=C164C165=CC=CC=C165C166=CC=CC=C166C167=CC=CC=C167C168=CC=CC=C168C169=CC=CC=C169C170=CC=CC=C170C171=CC=CC=C171C172=CC=CC=C172C173=CC=CC=C173C174=CC=CC=C174C175=CC=CC=C175C176=CC=CC=C176C177=CC=CC=C177C178=CC=CC=C178C179=CC=CC=C179C180=CC=CC=C180C181=CC=CC=C181C182=CC=CC=C182C183=CC=CC=C183C184=CC=CC=C184C185=CC=CC=C185C186=CC=CC=C186C187=CC=CC=C187C188=CC=CC=C188C189=CC=CC=C189C190=CC=CC=C190C191=CC=CC=C191C192=CC=CC=C192C193=CC=CC=C193C194=CC=CC=C194C195=CC=CC=C195C196=CC=CC=C196C197=CC=CC=C197C198=CC=CC=C198C199=CC=CC=C199C200=CC=CC=C200C201=CC=CC=C201C202=CC=CC=C202C203=CC=CC=C203C204=CC=CC=C204C205=CC=CC=C205C206=CC=CC=C206C207=CC=CC=C207C208=CC=CC=C208C209=CC=CC=C209C210=CC=CC=C210C211=CC=CC=C211C212=CC=CC=C212C213=CC=CC=C213C214=CC=CC=C214C215=CC=CC=C215C216=CC=CC=C216C217=CC=CC=C217C218=CC=CC=C218C219=CC=CC=C219C220=CC=CC=C220C221=CC=CC=C221C222=CC=CC=C222C223=CC=CC=C223C224=CC=CC=C224C225=CC=CC=C225C226=CC=CC=C226C227=CC=CC=C227C228=CC=CC=C228C229=CC=CC=C229C230=CC=CC=C230C231=CC=CC=C231C232=CC=CC=C232C233=CC=CC=C233C234=CC=CC=C234C235=CC=CC=C235C236=CC=CC=C236C237=CC=CC=C237C238=CC=CC=C238C239=CC=CC=C239C240=CC=CC=C240C241=CC=CC=C241C242=CC=CC=C242C243=CC=CC=C243C244=CC=CC=C244C245=CC=CC=C245C246=CC=CC=C246C247=CC=CC=C247C248=CC=CC=C248C249=CC=CC=C249C250=CC=CC=C250C251=CC=CC=C251C252=CC=CC=C252C253=CC=CC=C253C254=CC=CC=C254C255=CC=CC=C255C256=CC=CC=C256C257=CC=CC=C257C258=CC=CC=C258C259=CC=CC=C259C260=CC=CC=C260C261=CC=CC=C261C262=CC=CC=C262C263=CC=CC=C263C264=CC=CC=C264C265=CC=CC=C265C266=CC=CC=C266C267=CC=CC=C267C268=CC=CC=C268C269=CC=CC=C269C270=CC=CC=C270C271=CC=CC=C271C272=CC=CC=C272C273=CC=CC=C273C274=CC=CC=C274C275=CC=CC=C275C276=CC=CC=C276C277=CC=CC=C277C278=CC=CC=C278C279=CC=CC=C279C280=CC=CC=C280C281=CC=CC=C281C282=CC=CC=C282C283=CC=CC=C283C284=CC=CC=C284C285=CC=CC=C285C286=CC=CC=C286C287=CC=CC=C287C288=CC=CC=C288C289=CC=CC=C289C290=CC=CC=C290C291=CC=CC=C291C292=CC=CC=C292C293=CC=CC=C293C294=CC=CC=C294C295=CC=CC=C295C296=CC=CC=C296C297=CC=CC=C297C298=CC=CC=C298C299=CC=CC=C299C300=CC=CC=C300C301=CC=CC=C301C302=CC=CC=C302C303=CC=CC=C303C304=CC=CC=C304C305=CC=CC=C305C306=CC=CC=C306C307=CC=CC=C307C308=CC=CC=C308C309=CC=CC=C309C310=CC=CC=C310C311=CC=CC=C311C312=CC=CC=C312C313=CC=CC=C313C314=CC=CC=C314C315=CC=CC=C315C316=CC=CC=C316C317=CC=CC=C317C318=CC=CC=C318C319=CC=CC=C319C320=CC=CC=C320C321=CC=CC=C321C322=CC=CC=C322C323=CC=CC=C323C324=CC=CC=C324C325=CC=CC=C325C326=CC=CC=C326C327=CC=CC=C327C328=CC=CC=C328C329=CC=CC=C329C330=CC=CC=C330C331=CC=CC=C331C332=CC=CC=C332C333=CC=CC=C333C334=CC=CC=C334C335=CC=CC=C335C336=CC=CC=C336C337=CC=CC=C337C338=CC=CC=C338C339=CC=CC=C339C340=CC=CC=C340C341=CC=CC=C341C342=CC=CC=C342C343=CC=CC=C343C344=CC=CC=C344C345=CC=CC=C345C346=CC=CC=C346C347=CC=CC=C347C348=CC=CC=C348C349=CC=CC=C349C350=CC=CC=C350C351=CC=CC=C351C352=CC=CC=C352C353=CC=CC=C353C354=CC=CC=C354C355=CC=CC=C355C356=CC=CC=C356C357=CC=CC=C357C358=CC=CC=C358C359=CC=CC=C359C360=CC=CC=C360C361=CC=CC=C361C362=CC=CC=C362C363=CC=CC=C363C364=CC=CC=C364C365=CC=CC=C365C366=CC=CC=C366C367=CC=CC=C367C368=CC=CC=C368C369=CC=CC=C369C370=CC=CC=C370C371=CC=CC=C371C372=CC=CC=C372C373=CC=CC=C373C374=CC=CC=C374C375=CC=CC=C375C376=CC=CC=C376C377=CC=CC=C377C378=CC=CC=C378C379=CC=CC=C379C380=CC=CC=C380C381=CC=CC=C381C382=CC=CC=C382C383=CC=CC=C383C384=CC=CC=C384C385=CC=CC=C385C386=CC=CC=C386C387=CC=CC=C387C388=CC=CC=C388C389=CC=CC=C389C390=CC=CC=C390C391=CC=CC=C391C392=CC=CC=C392C393=CC=CC=C393C394=CC=CC=C394C395=CC=CC=C395C396=CC=CC=C396C397=CC=CC=C397C398=CC=CC=C398C399=CC=CC=C399C400=CC=CC=C400C401=CC=CC=C401C402=CC=CC=C402C403=CC=CC=C403C404=CC=CC=C404C405=CC=CC=C405C406=CC=CC=C406C407=CC=CC=C407C408=CC=CC=C408C409=CC=CC=C409C410=CC=CC=C410C411=CC=CC=C411C412=CC=CC=C412C413=CC=CC=C413C414=CC=CC=C414C415=CC=CC=C415C416=CC=CC=C416C417=CC=CC=C417C418=CC=CC=C418C419=CC=CC=C419C420=CC=CC=C420C421=CC=CC=C421C422=CC=CC=C422C423=CC=CC=C423C424=CC=CC=C424C425=CC=CC=C425C426=CC=CC=C426C427=CC=CC=C427C428=CC=CC=C428C429=CC=CC=C429C430=CC=CC=C430C431=CC=CC=C431C432=CC=CC=C432C433=CC=CC=C433C434=CC=CC=C434C435=CC=CC=C435C436=CC=CC=C436C437=CC=CC=C437C438=CC=CC=C438C439=CC=CC=C439C440=CC=CC=C440C441=CC=CC=C441C442=CC=CC=C442C443=CC=CC=C443C444=CC=CC=C444C445=CC=CC=C445C446=CC=CC=C446C447=CC=CC=C447C448=CC=CC=C448C449=CC=CC=C449C450=CC=CC=C450C451=CC=CC=C451C452=CC=CC=C452C453=CC=CC=C453C454=CC=CC=C454C455=CC=CC=C455C456=CC=CC=C456C457=CC=CC=C457C458=CC=CC=C458C459=CC=CC=C459C460=CC=CC=C460C461=CC=CC=C461C462=CC=CC=C462C463=CC=CC=C463C464=CC=CC=C464C465=CC=CC=C465C466=CC=CC=C466C467=CC=CC=C467C468=CC=CC=C468C469=CC=CC=C469C470=CC=CC=C470C471=CC=CC=C471C472=CC=CC=C472C473=CC=CC=C473C474=CC=CC=C474C475=CC=CC=C475C476=CC=CC=C476C477=CC=CC=C477C478=CC=CC=C478C479=CC=CC=C479C480=CC=CC=C480C481=CC=CC=C481C482=CC=CC=C482C483=CC=CC=C483C484=CC=CC=C484C485=CC=CC=C485C486=CC=CC=C486C487=CC=CC=C487C488=CC=CC=C488C489=CC=CC=C489C490=CC=CC=C490C491=CC=CC=C491C492=CC=CC=C492C493=CC=CC=C493C494=CC=CC=C494C495=CC=CC=C495C496=CC=CC=C496C497=CC=CC=C497C498=CC=CC=C498C499=CC=CC=C499C500=CC=CC=C500C501=CC=CC=C501C502=CC=CC=C502C503=CC=CC=C503C504=CC=CC=C504C505=CC=CC=C505C506=CC=CC=C506C507=CC=CC=C507C508=CC=CC=C508C509=CC=CC=C509C510=CC=CC=C510C511=CC=CC=C511C512=CC=CC=C512C513=CC=CC=C513C514=CC=CC=C514C515=CC=CC=C515C516=CC=CC=C516C517=CC=CC=C517C518=CC=CC=C518C519=CC=CC=C519C520=CC=CC=C520C521=CC=CC=C521C522=CC=CC=C522C523=CC=CC=C523C524=CC=CC=C524C525=CC=CC=C525C526=CC=CC=C526C527=CC=CC=C527C528=CC=CC=C528C529=CC=CC=C529C530=CC=CC=C530C531=CC=CC=C531C532=CC=CC=C532C533=CC=CC=C533C534=CC=CC=C534C535=CC=CC=C535C536=CC=CC=C536C537=CC=CC=C537C538=CC=CC=C538C539=CC=CC=C539C540=CC=CC=C540C541=CC=CC=C541C542=CC=CC=C542C543=CC=CC=C543C544=CC=CC=C544C545=CC=CC=C545C546=CC=CC=C546C547=CC=CC=C547C548=CC=CC=C548C549=CC=CC=C549C550=CC=CC=C550C551=CC=CC=C551C552=CC=CC=C552C553=CC=CC=C553C554=CC=CC=C554C555=CC=CC=C555C556=CC=CC=C556C557=CC=CC=C557C558=CC=CC=C558C559=CC=CC=C559C560=CC=CC=C560C561=CC=CC=C561C562=CC=CC=C562C563=CC=CC=C563C564=CC=CC=C564C565=CC=CC=C565C566=CC=CC=C566C567=CC=CC=C567C568=CC=CC=C568C569=CC=CC=C569C570=CC=CC=C570C571=CC=CC=C571C572=CC=CC=C572C573=CC=CC=C573C574=CC=CC=C574C575=CC=CC=C575C576=CC=CC=C576C577=CC=CC=C577C578=CC=CC=C578C579=CC=CC=C579C580=CC=CC=C580C581=CC=CC=C581C582=CC=CC=C582C583=CC=CC=C583C584=CC=CC=C584C585=CC=CC=C585C586=CC=CC=C586C587=CC=CC=C587C588=CC=CC=C588C589=CC=CC=C589C590=CC=CC=C590C591=CC=CC=C591C592=CC=CC=C592C593=CC=CC=C593C594=CC=CC=C594C595=CC=CC=C595C596=CC=CC=C596C597=CC=CC=C597C598=CC=CC=C598C599=CC=CC=C599C600=CC=CC=C600C601=CC=CC=C601C602=CC=CC=C602C603=CC=CC=C603C604=CC=CC=C604C605=CC=CC=C605C606=CC=CC=C606C607=CC=CC=C607C608=CC=CC=C608C609=CC=CC=C609C610=CC=CC=C610C611=CC=CC=C611C612=CC=CC=C612C613=CC=CC=C613C614=CC=CC=C614C615=CC=CC=C615C616=CC=CC=C616C617=CC=CC=C617C618=CC=CC=C618C619=CC=CC=C619C620=CC=CC=C620C621=CC=CC=C621C622=CC=CC=C622C623=CC=CC=C623C624=CC=CC=C624C625=CC=CC=C625C626=CC=CC=C626C627=CC=CC=C627C628=CC=CC=C628C629=CC=CC=C629C630=CC=CC=C630C631=CC=CC=C631C632=CC=CC=C632C633=CC=CC=C633C634=CC=CC=C634C635=CC=CC=C635C636=CC=CC=C636C637=CC=CC=C637C638=CC=CC=C638C639=CC=CC=C639C640=CC=CC=C640C641=CC=CC=C641C642=CC=CC=C642C643=CC=CC=C643C644=CC=CC=C644C645=CC=CC=C645C646=CC=CC=C646C647=CC=CC=C647C648=CC=CC=C648C649=CC=CC=C649C650=CC=CC=C650C651=CC=CC=C651C652=CC=CC=C652C653=CC=CC=C653C654=CC=CC=C654C655=CC=CC=C655C656=CC=CC=C656C657=CC=CC=C657C658=CC=CC=C658C659=CC=CC=C659C660=CC=CC=C660C661=CC=CC=C661C662=CC=CC=C662C663=CC=CC=C663C664=CC=CC=C664C665=CC=CC=C665C666=CC=CC=C666C667=CC=CC=C667C668=CC=CC=C668C669=CC=CC=C669C670=CC=CC=C670C671=CC=CC=C671C672=CC=CC=C672C673=CC=CC=C673C674=CC=CC=C674C675=CC=CC=C675C676=CC=CC=C676C677=CC=CC=C677C678=CC=CC=C678C679=CC=CC=C679C680=CC=CC=C680C681=CC=CC=C681C682=CC=CC=C682C683=CC=CC=C683C684=CC=CC=C684C685=CC=CC=C685C686=CC=CC=C686C687=CC=CC=C687C688=CC=CC=C688C689=CC=CC=C689C690=CC=CC=C690C691=CC=CC=C691C692=CC=CC=C692C693=CC=CC=C693C694=CC=CC=C694C695=CC=CC=C695C696=CC=CC=C696C697=CC=CC=C697C698=CC=CC=C698C699=CC=CC=C699C700=CC=CC=C700C701=CC=CC=C701C702=CC=CC=C702C703=CC=CC=C703C704=CC=CC=C704C705=CC=CC=C705C706=CC=CC=C706C707=CC=CC=C707C708=CC=CC=C708C709=CC=CC=C709C710=CC=CC=C710C711=CC=CC=C711C712=CC=CC=C712C713=CC=CC=C713C714=CC=CC=C714C715=CC=CC=C715C716=CC=CC=C716C717=CC=CC=C717C718=CC=CC=C718C719=CC=CC=C719C720=CC=CC=C720C721=CC=CC=C721C722=CC=CC=C722C723=CC=CC=C723C724=CC=CC=C724C725=CC=CC=C725C726=CC=CC=C726C727=CC=CC=C727C728=CC=CC=C728C729=CC=CC=C729C730=CC=CC=C730C731=CC=CC=C731C732=CC=CC=C732C733=CC=CC=C733C734=CC=CC=C734C735=CC=CC=C735C736=CC=CC=C736C737=CC=CC=C737C738=CC=CC=C738C739=CC=CC=C739C740=CC=CC=C740C741=CC=CC=C741C742=CC=CC=C742C743=CC=CC=C743C744=CC=CC=C744C745=CC=CC=C745C746=CC=CC=C746C747=CC=CC=C747C748=CC=CC=C748C749=CC=CC=C749C750=CC=CC=C750C751=CC=CC=C751C752=CC=CC=C752C753=CC=CC=C753C754=CC=CC=C754C755=CC=CC=C755C756=CC=CC=C756C757=CC=CC=C757C758=CC=CC=C758C759=CC=CC=C759C760=CC=CC=C760C761=CC=CC=C761C762=CC=CC=C762C763=CC=CC=C763C764=CC=CC=C764C765=CC=CC=C765C766=CC=CC=C766C767=CC=CC=C767C768=CC=CC=C768C769=CC=CC=C769C770=CC=CC=C770C771=CC=CC=C771C772=CC=CC=C772C773=CC=CC=C773C774=CC=CC=C774C775=CC=CC=C775C776=CC=CC=C776C777=CC=CC=C777C778=CC=CC=C778C779=CC=CC=C779C780=CC=CC=C780C781=CC=CC=C781C782=CC=CC=C782C783=CC=CC=C783C784=CC=CC=C784C785=CC=CC=C785C786=CC=CC=C786C787=CC=CC=C787C788=CC=CC=C788C789=CC=CC=C789C790=CC=CC=C790C791=CC=CC=C791C792=CC=CC=C792C793=CC=CC=C793C794=CC=CC=C794C795=CC=CC=C795C796=CC=CC=C796C797=CC=CC=C797C798=CC=CC=C798C799=CC=CC=C799C800=CC=CC=C800C801=CC=CC=C801C802=CC=CC=C802C803=CC=CC=C803C804=CC=CC=C804C805=CC=CC=C805C806=CC=CC=C806C807=CC=CC=C807C808=CC=CC=C808C809=CC=CC=C809C810=CC=CC=C810C811=CC=CC=C811C812=CC=CC=C812C813=CC=CC=C813C814=CC=CC=C814C815=CC=CC=C815C816=CC=CC=C816C817=CC=CC=C817C818=CC=CC=C818C819=CC=CC=C819C820=CC=CC=C820C821=CC=CC=C821C822=CC=CC=C822C823=CC=CC=C823C824=CC=CC=C824C825=CC=CC=C825C826=CC=CC=C826C827=CC=CC=C827C828=CC=CC=C828C829=CC=CC=C829C830=CC=CC=C830C831=CC=CC=C831C832=CC=CC=C832C833=CC=CC=C833C834=CC=CC=C834C835=CC=CC=C835C836=CC=CC=C836C837=CC=CC=C837C838=CC=CC=C838C839=CC=CC=C839C840=CC=CC=C840C841=CC=CC=C841C842=CC=CC=C842C843=CC=CC=C843C844=CC=CC=C844C845=CC=CC=C845C846=CC=CC=C846C847=CC=CC=C847C848=CC=CC=C848C849=CC=CC=C849C850=CC=CC=C850C851=CC=CC=C851C852=CC=CC=C852C853=CC=CC=C853C854=CC=CC=C854C855=CC=CC=C855C856=CC=CC=C856C857=CC=CC=C857C858=CC=CC=C858C859=CC=CC=C859C860=CC=CC=C860C861=CC=CC=C861C862=CC=CC=C862C863=CC=CC=C863C864=CC=CC=C864C865=CC=CC=C865C866=CC=CC=C866C867=CC=CC=C867C868=CC=CC=C868C869=CC=CC=C869C870=CC=CC=C870C871=CC=CC=C871C872=CC=CC=C872C873=CC=CC=C873C874=CC=CC=C874C875=CC=CC=C875C876=CC=CC=C876C877=CC=CC=C877C878=CC=CC=C878C879=CC=CC=C879C880=CC=CC=C880C881=CC=CC=C881C882=CC=CC=C882C883=CC=CC=C883C884=CC=CC=C884C885=CC=CC=C885C886=CC=CC=C886C887=CC=CC=C887C888=CC=CC=C888C889=CC=CC=C889C890=CC=CC=C890C891=CC=CC=C891C892=CC=CC=C892C893=CC=CC=C893C894=CC=CC=C894C895=CC=CC=C895C896=CC=CC=C896C897=CC=CC=C897C898=CC=CC=C898C899=CC=CC=C899C900=CC=CC=C900C901=CC=CC=C901C902=CC=CC=C902C903=CC=CC=C903C904=CC=CC=C904C905=CC=CC=C905C906=CC=CC=C906C907=CC=CC=C907C908=CC=CC=C908C909=CC=CC=C909C910=CC=CC=C910C911=CC=CC=C911C912=CC=CC=C912C913=CC=CC=C913C914=CC=CC=C914C915=CC=CC=C915C916=CC=CC=C916C917=CC=CC=C917C918=CC=CC=C918C919=CC=CC=C919C920=CC=CC=C920C921=CC=CC=C921C922=CC=CC=C922C923=CC=CC=C923C924=CC=CC=C924C925=CC=CC=C925C926=CC=CC=C926C927=CC=CC=C927C928=CC=CC=C928C929=CC=CC=C929C930=CC=CC=C930C931=CC=CC=C931C932=CC=CC=C932C933=CC=CC=C933C934=CC=CC=C934C935=CC=CC=C935C936=CC=CC=C936C937=CC=CC=C937C938=CC=CC=C938C939=CC=CC=C939C940=CC=CC=C940C941=CC=CC=C941C942=CC=CC=C942C943=CC=CC=C943C944=CC=CC=C944C945=CC=CC=C945C946=CC=CC=C946C947=CC=CC=C947C948=CC=CC=C948C949=CC=CC=C949C950=CC=CC=C950C951=CC=CC=C951C952=CC=CC=C952C953=CC=CC=C953C954=CC=CC=C954C955=CC=CC=C955C956=CC=CC=C956C957=CC=CC=C957C958=CC=CC=C958C959=CC=CC=C959C960=CC=CC=C960C961=CC=CC=C961C962=CC=CC=C962C963=CC=CC=C963C964=CC=CC=C964C965=CC=CC=C965C966=CC=CC=C966C967=CC=CC=C967C968=CC=CC=C968C969=CC=CC=C969C970=CC=CC=C970C971=CC=CC=C971C972=CC=CC=C972C973=CC=CC=C973C974=CC=CC=C974C975=CC=CC=C975C976=CC=CC=C976C977=CC=CC=C977C978=CC=CC=C978C9



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

393 REFERENCES IN FILE CA (1907 TO DATE)  
 6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 399 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline  
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
22.05	22.26

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 21:03:50 ON 06 APR 2007

FILE LAST UPDATED: 6 Apr 2007 (20070406/UP). FILE COVERS 1950 TO DATE.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 21:02:01 ON 06 APR 2007)

FILE 'REGISTRY' ENTERED AT 21:02:13 ON 06 APR 2007

	E SILDENAFIL/CN
L1	1 S E3
	E VARDENAFIL/CN
L2	1 S E3
	E TADALAFIL/CN
L3	1 S E3

FILE 'MEDLINE' ENTERED AT 21:03:50 ON 06 APR 2007

=> d l1

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:end

=> dhis

DHIS IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
 For a list of commands available to you in the current file, enter  
 "HELP COMMANDS" at an arrow prompt (=>).

=> d his

(FILE 'HOME' ENTERED AT 21:02:01 ON 06 APR 2007)

FILE 'REGISTRY' ENTERED AT 21:02:13 ON 06 APR 2007

	E SILDENAFIL/CN
L1	1 S E3
	E VARDENAFIL/CN
L2	1 S E3
	E TADALAFIL/CN
L3	1 S E3

FILE 'MEDLINE' ENTERED AT 21:03:50 ON 06 APR 2007

=> s l1

```

L4          2323 L1

=> s 12
L5          247 L2

=> s 13
L6          0 L3

=> s (sildenafil or vardenafil or tadalafil)
          2913 SILDENAFIL
          384 VARDENAFIL
          414 TADALAFIL
L7          3219 (SILDENAFIL OR VARDENAFIL OR TADALAFIL)

=> s 14 or 15
L8          2450 L4 OR L5

=> s 17 or 18
L9          3219 L7 OR L8

=> s (clitoral stimul? or clitoral sensi? or female erect?)
          514 CLITORAL
          918548 STIMUL?
          23 CLITORAL STIMUL?
              (CLITORAL(W)STIMUL?)
          514 CLITORAL
          824345 SENSI?
          3 CLITORAL SENSI?
              (CLITORAL(W)SENSI?)
          4649628 FEMALE
          15371 ERECT?
          2 FEMALE ERECT?
              (FEMALE(W)ERECT?)
L10         28 (CLITORAL STIMUL? OR CLITORAL SENSI? OR FEMALE ERECT?)

=> s 19 and 110
L11         2 L9 AND L10

=> d 1-2

L11 ANSWER 1 OF 2      MEDLINE on STN
Full Text
AN 2004435495      MEDLINE
DN PubMed ID: 15333581
TI The neurovascular mechanism of clitoral erection: nitric oxide and
cGMP-stimulated activation of BKCa channels.
AU Gragasin Ferrante S; Michelakis Evangelos D; Hogan Angie; Moudgil Rohit;
Hashimoto Kyoko; Wu Xichen; Bonnet Sandra; Haromy Al; Archer Stephen L
CS Department of Medicine (Cardiology) and the Vascular Biology Group,
University of Alberta, Edmonton, Canada.
NC R01-HL071115 (NHLBI)
SO The FASEB journal : official publication of the Federation of American
Societies for Experimental Biology, (2004 Sep) Vol. 18, No. 12, pp.
1382-91.
Journal code: 8804484. E-ISSN: 1530-6860.
CY United States
DT (IN VITRO)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Priority Journals
EM 200504
ED Entered STN: 3 Sep 2004
Last Updated on STN: 6 Apr 2005
Entered Medline: 5 Apr 2005

L11 ANSWER 2 OF 2      MEDLINE on STN
Full Text
AN 1999194034      MEDLINE
DN PubMed ID: 10096370
TI Safety and efficacy of sildenafil in postmenopausal women with sexual

```

dysfunction.  
AU Kaplan S A; Reis R B; Kohn I J; Ikeguchi E F; Laor E; Te A E; Martins A C  
CS Department of Urology, Columbia University, New York, New York 10032, USA.  
SO Urology, (1999 Mar) Vol. 53, No. 3, pp. 481-6.  
Journal code: 0366151. ISSN: 0090-4295.  
CY United States  
DT (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199904  
ED Entered STN: 4 May 1999  
Last Updated on STN: 13 Jan 2000  
Entered Medline: 22 Apr 1999

=> d an ti au so ab kwic 2

L11 ANSWER 2 OF 2 MEDLINE on STN

Full Text

AN 1999194034 MEDLINE

TI Safety and efficacy of **sildenafil** in postmenopausal women with sexual dysfunction.

AU Kaplan S A; Reis R B; Kohn I J; Ikeguchi E F; Laor E; Te A E; Martins A C  
SO Urology, (1999 Mar) Vol. 53, No. 3, pp. 481-6.  
Journal code: 0366151. ISSN: 0090-4295.

AB OBJECTIVES: **Sildenafil** has been demonstrated to be safe and effective in the treatment of men with erectile dysfunction. The role of **sildenafil** in treating women with sexual dysfunction has heretofore not been reported. The purpose of this preliminary study was to ascertain the response of postmenopausal women with self-described sexual dysfunction treated with **sildenafil** for 3 months. METHODS: Thirty-three consecutive postmenopausal women with sexual dysfunction based on history were entered in this open-label, nonrandomized study. All patients received 50 mg of **sildenafil**. Efficacy was assessed at weeks 4, 8, and 12 using a newly developed 9-item, self-administered Index of Female Sexual Function (IFSF) and a global efficacy question ([GEQ] Did treatment improve your sexual function?). The IFSF quantifies the domains of desire, quality of sexual intercourse, overall satisfaction with sexual function, orgasm, lubrication, and clitoral sensation. RESULTS: Of the group, 30 women (91 %) completed the study and were available for follow-up at 3 months. Mean baseline IFSF score before therapy was 24.8+/-9.8. Mean usage of **sildenafil** was 3.1+/-1.4 times per week for the duration of the study. The IFSF score improved to 29.5+/-7.6, 30.3+/-8.5, and 31.4+/-10.4 at 4, 8, and 12 weeks, respectively (P = 0.25). Mean scores for questions 2 (lubrication), 8 (orgasm), and 9 (clitoral sensation) improved by 23.2%, 7.4%, and 31.3%, respectively, at 12 weeks. Seven women (21%) noted improvement on the GEQ. Overall, only 6 (18.1%) of 33 patients had a significant (more than 60% improvement in IFSF score) therapeutic response. Clitoral discomfort and "hypersensitivity" occurred in 7 women (21%), 3 of whom withdrew from the study. Other side effects, which did not result in withdrawal from the study, included headache (n = 5), dizziness (n = 4) and dyspepsia (n = 3). CONCLUSIONS: The data suggest that **sildenafil** is well tolerated in postmenopausal women with sexual dysfunction. Overall sexual function did not improve significantly, although there were changes in vaginal lubrication and **clitoral sensitivity**. The role of **sildenafil** in treating sexual dysfunction in various cohorts of women remains to be determined.

TI Safety and efficacy of **sildenafil** in postmenopausal women with sexual dysfunction.

AB OBJECTIVES: **Sildenafil** has been demonstrated to be safe and effective in the treatment of men with erectile dysfunction. The role of **sildenafil** in treating women with sexual dysfunction has heretofore not been reported. The purpose of this preliminary study was to ascertain the response of postmenopausal women with self-described sexual dysfunction treated with **sildenafil** for 3 months. METHODS: Thirty-three consecutive postmenopausal women with sexual dysfunction based on history were entered in this open-label, nonrandomized study. All patients received 50 mg of **sildenafil**. Efficacy was assessed at weeks 4, 8, and 12 using a newly developed 9-item, self-administered Index of Female Sexual Function. study and were available for follow-up at 3 months. Mean baseline IFSF score before therapy was 24.8+/-9.8. Mean usage of **sildenafil** was

3.1+/-1.4 times per week for the duration of the study. The IFSF score improved to 29.5+/-7.6, 30.3+/-8.5, and 31.4+/-10.4. . . . study, included headache (n = 5), dizziness (n = 4) and dyspepsia (n = 3).  
 CONCLUSIONS: The data suggest that sildenafil is well tolerated in postmenopausal women with sexual dysfunction. Overall sexual function did not improve significantly, although there were changes in vaginal lubrication and clitoral sensitivity. The role of sildenafil in treating sexual dysfunction in various cohorts of women remains to be determined.

RN 139755-83-2 (sildenafil)

=> file uspatall  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
3.23	25.49

FILE 'USPATFULL' ENTERED AT 21:08:06 ON 06 APR 2007  
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 21:08:06 ON 06 APR 2007  
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d his

(FILE 'HOME' ENTERED AT 21:02:01 ON 06 APR 2007)

FILE 'REGISTRY' ENTERED AT 21:02:13 ON 06 APR 2007

	E SILDENAFIL/CN
L1	1 S E3
	E VARDENAFIL/CN
L2	1 S E3
	E TADALAFIL/CN
L3	1 S E3

FILE 'MEDLINE' ENTERED AT 21:03:50 ON 06 APR 2007

L4	2323 S L1
L5	247 S L2
L6	0 S L3
L7	3219 S (SILDENAFIL OR VARDENAFIL OR TADALAFIL)
L8	2450 S L4 OR L5
L9	3219 S L7 OR L8
L10	28 S (CLITORAL STIMUL? OR CLITORAL SENSI? OR FEMALE ERECT?)
L11	2 S L9 AND L10

FILE 'USPATFULL, USPAT2' ENTERED AT 21:08:06 ON 06 APR 2007

=> s l1 or l2 or l3  
 L12 430 L1 OR L2 OR L3

=> s (sildenafil or vardenafil or tadalafil)  
 L13 2092 (SILDENAFIL OR VARDENAFIL OR TADALAFIL)

=> s (clitoral stimul? or clitoral sensi? or female erect?)  
 L14 188 (CLITORAL STIMUL? OR CLITORAL SENSI? OR FEMALE ERECT?)

=> s l12 or l13  
 L15 2151 L12 OR L13

=> s l14 and l15  
 L16 48 L14 AND L15

=> s (sildenafil or vardenafil or tadalafil)/clm  
 L17 406 (SILDENAFIL OR VARDENAFIL OR TADALAFIL)/CLM

=> s (clitoral stimul? or clitoral sensi? or female erect?)/clm  
 L18 25 (CLITORAL STIMUL? OR CLITORAL SENSI? OR FEMALE ERECT?)/CLM

=> s l12 or l17  
 L19 590 L12 OR L17

=> s l18 and l19



L20 1 L18 AND L19

=> d

L20 ANSWER 1 OF 1 USPATFULL on STN

Full Text

AN 2005:214622 USPATFULL  
TI Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of vardenafil for the treatment of female sexual dysfunction  
IN Thompson, James M., Cincinnati, OH, UNITED STATES  
Thompson, Justin R., Cincinnati, OH, UNITED STATES  
Thompson, Ronald J., Ft. Thomas, KY, UNITED STATES  
PI US 2005186294 A1 20050825  
AI US 2005-105228 A1 20050413 (11)  
RLI Continuation-in-part of Ser. No. US 2003-731692, filed on 9 Dec 2003, PENDING Division of Ser. No. US 2001-4091, filed on 23 Oct 2001, GRANTED, Pat. No. US 6702733 Continuation of Ser. No. US 2000-520110, filed on 7 Mar 2000, GRANTED, Pat. No. US 6322493 Continuation-in-part of Ser. No. US 1999-469959, filed on 21 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-414250, filed on 7 Oct 1999, GRANTED, Pat. No. US 6224541 Continuation-in-part of Ser. No. US 1999-340227, filed on 1 Jul 1999, GRANTED, Pat. No. US 6179775  
DT Utility  
FS APPLICATION  
LN.CNT 458  
INCL INCLM: 424/739.000  
INCLS: 424/742.000; 424/745.000; 424/747.000; 514/565.000; 604/001.000  
NCL NCLM: 424/739.000  
NCLS: 424/742.000; 424/745.000; 424/747.000; 514/565.000; 604/001.000  
IC [7]  
ICM A61K031-198  
ICS A61M035-00; A61K035-78  
IPCI A61K0031-198 [ICM,7]; A61K0031-185 [ICM,7,C\*]; A61M0035-00 [ICS,7]; A61K0035-78 [ICS,7]  
IPCR A61H0019-00 [I,C\*]; A61H0019-00 [I,A]; A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0031-045 [I,C\*]; A61K0031-045 [I,A]; A61K0031-185 [I,C\*]; A61K0031-198 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 116 1-48

L16 ANSWER 1 OF 48 USPATFULL on STN

Full Text

AN 2006:289260 USPATFULL  
TI Cyclopentapyridine and tetrahydroquinoline derivatives  
IN Lefker, Bruce A., Galas Ferry, CT, UNITED STATES  
Liu, Kevin K. -C., East Lyme, CT, UNITED STATES  
Chen, Hou, Salem, CT, UNITED STATES  
Coffey, Steven Blair, Pawcatuck, CT, UNITED STATES  
PA Pfizer, Inc (U.S. corporation)  
PI US 2006247254 A1 20061102  
AI US 2006-395327 A1 20060331 (11)  
PRAI US 2006-762159P 20060126 (60)  
US 2005-667184P 20050331 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3713  
INCL INCLM: 514/253.040  
INCLS: 544/362.000; 544/363.000; 514/253.060  
NCL NCLM: 514/253.040  
NCLS: 514/253.060; 544/362.000; 544/363.000  
IC IPCI A61K0031-496 [I,A]; C07D0403-04 [I,A]; C07D0403-00 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 2 OF 48 USPATFULL on STN

Full Text

AN 2005:318125 USPATFULL  
TI Peroxide compounds for the prevention and treatment of sexual dysfunction in humans  
IN Buyuktimkin, Servet, Robbinsville, NJ, UNITED STATES

Buyuktimkin, Nadir, Robbinsville, NJ, UNITED STATES  
 Yeager, James L., Lake Forest, IL, UNITED STATES  
 PI US 2005276865 A1 20051215  
 AI US 2005-131520 A1 20050518 (11)  
 PRAI US 2004-572904P 20040520 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1071  
 INCL INCLM: 424/616.000  
 INCLS: 514/568.000  
 NCL NCLM: 424/616.000  
 NCLS: 514/568.000  
 IC [7]  
 ICM A61K031-19  
 ICS A61K033-40  
 IPCI A61K0031-19 [ICM,7]; A61K0031-185 [ICM,7,C\*]; A61K0033-40 [ICS,7]  
 IPCR A61K0031-185 [I,C\*]; A61K0031-19 [I,A]; A61K0033-40 [I,C\*];  
 A61K0033-40 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 3 OF 48 USPATFULL on STN

Full Text

AN 2005:214622 USPATFULL  
 TI Method of using a compound of menthol and L-arginine as a preparation  
 for the topical delivery of vardenafil for the treatment of female  
 sexual dysfunction  
 IN Thompson, James M., Cincinnati, OH, UNITED STATES  
 Thompson, Justin R., Cincinnati, OH, UNITED STATES  
 Thompson, Ronald J., Ft. Thomas, KY, UNITED STATES  
 PI US 2005186294 A1 20050825  
 AI US 2005-105228 A1 20050413 (11)  
 RLI Continuation-in-part of Ser. No. US 2003-731692, filed on 9 Dec 2003,  
 PENDING Division of Ser. No. US 2001-4091, filed on 23 Oct 2001,  
 GRANTED, Pat. No. US 6702733 Continuation of Ser. No. US 2000-520110,  
 filed on 7 Mar 2000, GRANTED, Pat. No. US 6322493 Continuation-in-part  
 of Ser. No. US 1999-469959, filed on 21 Dec 1999, ABANDONED  
 Continuation-in-part of Ser. No. US 1999-414250, filed on 7 Oct 1999,  
 GRANTED, Pat. No. US 6224541 Continuation-in-part of Ser. No. US  
 1999-340227, filed on 1 Jul 1999, GRANTED, Pat. No. US 6179775  
 DT Utility  
 FS APPLICATION  
 LN.CNT 458  
 INCL INCLM: 424/739.000  
 INCLS: 424/742.000; 424/745.000; 424/747.000; 514/565.000; 604/001.000  
 NCL NCLM: 424/739.000  
 NCLS: 424/742.000; 424/745.000; 424/747.000; 514/565.000; 604/001.000  
 IC [7]  
 ICM A61K031-198  
 ICS A61M035-00; A61K035-78  
 IPCI A61K0031-198 [ICM,7]; A61K0031-185 [ICM,7,C\*]; A61M0035-00  
 [ICS,7]; A61K0035-78 [ICS,7]  
 IPCR A61H0019-00 [I,C\*]; A61H0019-00 [I,A]; A61K0009-00 [I,C\*];  
 A61K0009-00 [I,A]; A61K0031-045 [I,C\*]; A61K0031-045 [I,A];  
 A61K0031-185 [I,C\*]; A61K0031-198 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 4 OF 48 USPATFULL on STN

Full Text

AN 2005:105565 USPATFULL  
 TI 5-HT receptor ligands and uses thereof  
 IN Chiang, Phoebe, East Lyme, CT, UNITED STATES  
 Novomisle, William A., Stonington, CT, UNITED STATES  
 Welch, Willard M. JR., Mystic, CT, UNITED STATES  
 Guzman-Perez, Angel, Stonington, CT, UNITED STATES  
 DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES  
 Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES  
 Liu, Kevin K., East Lyme, CT, UNITED STATES  
 PA Pfizer Inc (U.S. corporation)  
 PI US 2005090503 A1 20050428  
 AI US 2004-922058 A1 20040819 (10)  
 RLI Division of Ser. No. US 2002-163881, filed on 5 Jun 2002, PENDING  
 PRAI US 2001-299953P 20010621 (60)

DT Utility  
FS APPLICATION  
LN.CNT 4033  
INCL INCLM: 514/252.110  
INCLS: 544/357.000  
NCL NCLM: 514/252.110  
NCLS: 544/357.000  
IC [7]  
ICM A61K031-497  
ICS C07D043-14  
IPCI A61K0031-497 [ICM,7]; A61K0031-4965 [ICM,7,C\*]; C07D0043-14  
[ICS,7]  
IPCR C07D0239-00 [I,C\*]; C07D0239-46 [I,A]; C07D0241-00 [I,C\*];  
C07D0241-20 [I,A]; C07D0401-00 [I,C\*]; C07D0401-12 [I,A];  
C07D0409-00 [I,C\*]; C07D0409-12 [I,A].  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 5 OF 48 USPATFULL on STN

Full Text

AN 2005:82051 USPATFULL  
TI Compounds for the treatment of female sexual dysfunction  
IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM  
Wayman, Christopher Peter, Sandwich, UNITED KINGDOM  
PA Pfizer Inc. (non-U.S. corporation)  
PI US 2005070499 A1 20050331  
AI US 2003-686349 A1 20031015 (10)  
RLI Division of Ser. No. US 2000-708392, filed on 8 Nov 2000, GRANTED, Pat.  
No. US 6734186  
PRAI GB 1999-26437 19991108  
GB 2000-4021 20000218  
GB 2000-13001 20000526  
GB 2000-16563 20000705  
GB 2000-17141 20000712  
US 2000-175161P 20000107 (60)  
US 2000-192962P 20000329 (60)  
US 2000-217479P 20000711 (60)  
US 2000-221014P 20000727 (60)  
US 2000-221093P 20000727 (60)

DT Utility  
FS APPLICATION  
LN.CNT 7202  
INCL INCLM: 514/047.000  
NCL NCLM: 514/047.000  
IC [7]  
ICM A61K031-7076  
IPCI A61K0031-7076 [ICM,7]; A61K0031-7042 [ICM,7,C\*]  
IPCR A61K0031-00 [I,C\*]; A61K0031-00 [I,A]; A61K0031-185 [I,C\*];  
A61K0031-192 [I,A]; A61K0031-195 [I,A]; A61K0031-352 [I,C\*];  
A61K0031-352 [I,A]; A61K0031-4015 [I,C\*]; A61K0031-4015 [I,A];  
A61K0031-44 [I,C\*]; A61K0031-44 [I,A]; A61K0031-4412 [I,C\*];  
A61K0031-4412 [I,A]; A61K0031-4985 [I,C\*]; A61K0031-4985 [I,A];  
A61K0031-519 [I,C\*]; A61K0031-519 [I,A]; A61K0031-52 [I,A];  
A61K0031-55 [I,C\*]; A61K0031-55 [I,A]; A61K0038-43 [I,C\*];  
A61K0038-46 [I,A]; C12Q0001-44 [I,C\*]; C12Q0001-44 [I,A];  
G01N0033-50 [I,C\*]; G01N0033-50 [I,A]; G01N0033-53 [I,C\*];  
G01N0033-53 [I,A]; G01N0033-68 [I,C\*]; G01N0033-68 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 6 OF 48 USPATFULL on STN

Full Text

AN 2005:63614 USPATFULL  
TI 5-HT receptor ligands and uses thereof  
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES  
Novomisle, William A., Stonington, CT, UNITED STATES  
Welch, Willard M., JR.; Mystic, CT, UNITED STATES  
PA Pfizer Inc (U.S. corporation)  
PI US 2005054656 A1 20050310  
AI US 2004-942346 A1 20040916 (10)  
RLI Division of Ser. No. US 2002-156884, filed on 28 May 2002, GRANTED, Pat.  
No. US 6825198  
PRAI US 2001-299953P 20010621 (60)  
DT Utility

FS APPLICATION  
LN.CNT 3890  
INCL INCLM: 514/252.110  
INCLS: 514/252.140; 544/295.000; 544/357.000; 514/252.180; 514/252.190  
NCL NCLM: 514/252.110  
NCLS: 514/252.140; 514/252.180; 514/252.190; 544/295.000; 544/357.000  
IC [7]  
ICM A61K031-497  
ICS A61K031-506; C07D043-14  
IPCI A61K0031-497 [ICM,7]; A61K0031-4965 [ICM,7,C\*]; A61K0031-506 [ICS,7]; C07D0043-14 [ICS,7]  
IPCR A61P0025-00 [I,C\*]; A61P0025-28 [I,A]; C07D0239-00 [I,C\*]; C07D0239-46 [I,A]; C07D0241-00 [I,C\*]; C07D0241-20 [I,A]; C07D0401-00 [I,C\*]; C07D0401-12 [I,A]; C07D0409-00 [I,C\*]; C07D0409-12 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 7 OF 48 USPATFULL on STN

Full Text

AN 2005:38129 USPATFULL  
TI 5-HT receptor ligands and uses thereof  
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES  
Novomisle, William A., Stonington, CT, UNITED STATES  
Welch, Willard M., JR., Mystic, CT, UNITED STATES  
PA Pfizer Inc (U.S. corporation)  
PI US 2005032809 A1 20050210  
US 6995159 B2 20060207  
AI US 2004-942345 A1 20040916 (10)  
RLI Division of Ser. No. US 2002-156884, filed on 28 May 2002, GRANTED, Pat. No. US 6825198  
PRAI US 2001-299953P 20010621 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2990  
INCL INCLM: 514/252.110  
INCLS: 514/252.140; 544/295.000; 544/357.000  
NCL NCLM: 514/252.180; 514/252.110  
NCLS: 514/252.190; 514/252.200; 544/295.000; 514/252.140; 544/357.000  
IC [7]  
ICM A61K031-497  
ICS A61K031-506; C07D043-14  
IPCI A61K0031-497 [ICM,7]; A61K0031-4965 [ICM,7,C\*]; A61K0031-506 [ICS,7]; C07D0043-14 [ICS,7]  
IPCI-2 A61K0031-497 [I,A]; A61K0031-4965 [I,C\*]; C07D0403-00 [I,A]  
IPCR A61P0025-00 [I,C\*]; A61P0025-28 [I,A]; C07D0239-00 [I,C\*]; C07D0239-46 [I,A]; C07D0241-00 [I,C\*]; C07D0241-20 [I,A]; C07D0401-00 [I,C\*]; C07D0401-12 [I,A]; C07D0409-00 [I,C\*]; C07D0409-12 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A]; C07D0403-00 [I,C]; C07D0403-00 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 8 OF 48 USPATFULL on STN

Full Text

AN 2005:24055 USPATFULL  
TI 5-HT receptor ligands and uses thereof  
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES  
Novomisle, William A., Stonington, CT, UNITED STATES  
Welch, Willard M., JR., Mystic, CT, UNITED STATES  
Guzman-Perez, Angel, Stonington, CT, UNITED STATES  
DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES  
Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES  
Liu, Kevin K., East Lyme, CT, UNITED STATES  
PA Pfizer Inc (U.S. corporation)  
PI US 2005020604 A1 20050127  
AI US 2004-922198 A1 20040819 (10)  
RLI Division of Ser. No. US 2002-163881, filed on 5 Jun 2002, PENDING  
PRAI US 2001-299953P 20010621 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4284  
INCL INCLM: 514/252.110  
INCLS: 544/357.000

NCL NCLM: 514/252.110  
 NCLS: 544/357.000  
 IC [7]  
 ICM A61K031-497  
 IPCI A61K0031-497 [ICM,7]; A61K0031-4965 [ICM,7,C\*]  
 IPCR C07D0239-00 [I,C\*]; C07D0239-46 [I,A]; C07D0241-00 [I,C\*];  
 C07D0241-20 [I,A]; C07D0401-00 [I,C\*]; C07D0401-12 [I,A];  
 C07D0409-00 [I,C\*]; C07D0409-12 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 9 OF 48 USPATFULL on STN  
Full Text  
 AN 2005:23998 USPATFULL  
 TI Compounds for the treatment of female sexual dysfunction  
 IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM  
 Wayman, Christopher Peter, Sandwich, UNITED KINGDOM  
 PA Pfizer Inc. (non-U.S. corporation)  
 PI US 2005020547 A1 20050127  
 AI US 2003-686282 A1 20031015 (10)  
 RLI Division of Ser. No. US 2000-708392, filed on 8 Nov 2000, GRANTED, Pat.  
 No. US 6734186  
 PRAI GB 1999-26437 19991108  
 GB 2000-4021 20000218  
 GB 2000-13001 20000526  
 GB 2000-16563 20000705  
 GB 2000-17141 20000712  
 US 2000-175161P 20000107 (60)  
 US 2000-192962P 20000329 (60)  
 US 2000-217479P 20000711 (60)  
 US 2000-221014P 20000727 (60)  
 US 2000-221093P 20000727 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 7195  
 INCL INCLM: 514/169.000  
 NCL NCLM: 514/169.000  
 IC [7]  
 ICM A61K031-56  
 IPCI A61K0031-56 [ICM,7]  
 IPCR A61K0031-00 [I,C\*]; A61K0031-00 [I,A]; A61K0031-185 [I,C\*];  
 A61K0031-192 [I,A]; A61K0031-195 [I,A]; A61K0031-352 [I,C\*];  
 A61K0031-352 [I,A]; A61K0031-4015 [I,C\*]; A61K0031-4015 [I,A];  
 A61K0031-44 [I,C\*]; A61K0031-44 [I,A]; A61K0031-4412 [I,C\*];  
 A61K0031-4412 [I,A]; A61K0031-4985 [I,C\*]; A61K0031-4985 [I,A];  
 A61K0031-519 [I,C\*]; A61K0031-519 [I,A]; A61K0031-52 [I,A];  
 A61K0031-55 [I,C\*]; A61K0031-55 [I,A]; A61K0038-43 [I,C\*];  
 A61K0038-46 [I,A]; C12Q0001-44 [I,C\*]; C12Q0001-44 [I,A];  
 G01N0033-50 [I,C\*]; G01N0033-50 [I,A]; G01N0033-53 [I,C\*];  
 G01N0033-53 [I,A]; G01N0033-68 [I,C\*]; G01N0033-68 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 10 OF 48 USPATFULL on STN  
Full Text  
 AN 2004:326954 USPATFULL  
 TI Method of using a compound of menthol and L-arginine as a preparation  
 for the topical delivery of a 5-phosphodiesterase inhibitor for the  
 treatment of female sexual dysfunction  
 IN Thompson, Ronald J., Ft. Thomas, KY, UNITED STATES  
 Thompson, James M., Cincinnati, OH, UNITED STATES  
 PI US 2004258774 A1 20041223  
 AI US 2004-803148 A1 20040317 (10)  
 RLI Continuation-in-part of Ser. No. US 2003-731692, filed on 9 Dec 2003,  
 PENDING Division of Ser. No. US 2001-4091, filed on 23 Oct 2001,  
 GRANTED, Pat. No. US 6702733 Continuation of Ser. No. US 2000-520110,  
 filed on 7 Mar 2000, GRANTED, Pat. No. US 6322493 Continuation-in-part  
 of Ser. No. US 1999-469959, filed on 21 Dec 1999, ABANDONED  
 Continuation-in-part of Ser. No. US 1999-414250, filed on 7 Oct 1999,  
 GRANTED, Pat. No. US 6224541 Continuation-in-part of Ser. No. US  
 1999-340227, filed on 1 Jul 1999, GRANTED, Pat. No. US 6179775  
 DT Utility  
 FS APPLICATION  
 LN.CNT 124

INCL INCLM: 424/739.000  
 INCLS: 424/747.000; 424/742.000; 424/765.000; 514/565.000  
 NCL NCLM: 424/739.000  
 NCLS: 424/742.000; 424/747.000; 424/765.000; 514/565.000  
 IC [7]  
 ICM A61K035-78  
 IPCI A61K0035-78 [ICM,7]  
 IPCR A61H0019-00 [I,C\*]; A61H0019-00 [I,A]; A61K0009-00 [I,C\*];  
 A61K0009-00 [I,A]; A61K0031-045 [I,C\*]; A61K0031-045 [I,A];  
 A61K0031-185 [I,C\*]; A61K0031-198 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 11 OF 48 USPATFULL on STN

Full Text

AN 2004:321498 USPATFULL  
 TI Compounds for the treatment of female sexual dysfunction  
 IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM  
 Wayman, Christopher Peter, Sandwich, UNITED KINGDOM  
 PA Pfizer Inc (non-U.S. corporation)  
 PI US 2004254153 A1 20041216  
 AI US 2003-686390 A1 20031015 (10)  
 RLI Division of Ser. No. US 2000-708392, filed on 8 Nov 2000, GRANTED, Pat.  
 No. US 6734186  
 PRAI GB 1999-26437 19991108  
 GB 2000-4021 20000218  
 GB 2000-13001 20000526  
 GB 2000-16563 20000705  
 GB 2000-17141 20000712  
 US 2000-175161P 20000107 (60)  
 US 2000-192962P 20000329 (60)  
 US 2000-217479P 20000711 (60)  
 US 2000-221014P 20000727 (60)  
 US 2000-221093P 20000727 (60)

DT Utility  
 FS APPLICATION

LN.CNT 7207

INCL INCLM: 514/171.000

INCLS: 514/047.000

NCL NCLM: 514/171.000

NCLS: 514/047.000

IC [7]

ICM A61K031-56

ICS A61K031-7076

IPCI A61K0031-56 [ICM,7]; A61K0031-7076 [ICS,7]; A61K0031-7042  
 [ICS,7,C\*]

IPCR A61K0031-00 [I,C\*]; A61K0031-00 [I,A]; A61K0031-185 [I,C\*];  
 A61K0031-192 [I,A]; A61K0031-195 [I,A]; A61K0031-352 [I,C\*];  
 A61K0031-352 [I,A]; A61K0031-4015 [I,C\*]; A61K0031-4015 [I,A];  
 A61K0031-44 [I,C\*]; A61K0031-44 [I,A]; A61K0031-4412 [I,C\*];  
 A61K0031-4412 [I,A]; A61K0031-4985 [I,C\*]; A61K0031-4985 [I,A];  
 A61K0031-519 [I,C\*]; A61K0031-519 [I,A]; A61K0031-52 [I,A];  
 A61K0031-55 [I,C\*]; A61K0031-55 [I,A]; A61K0038-43 [I,C\*];  
 A61K0038-46 [I,A]; C12Q0001-44 [I,C\*]; C12Q0001-44 [I,A];  
 G01N0033-50 [I,C\*]; G01N0033-50 [I,A]; G01N0033-53 [I,C\*];  
 G01N0033-53 [I,A]; G01N0033-68 [I,C\*]; G01N0033-68 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 12 OF 48 USPATFULL on STN

Full Text

AN 2004:116764 USPATFULL  
 TI Compounds for the treatment of female sexual dysfunction  
 IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM  
 Wayman, Christopher Peter, Sandwich, UNITED KINGDOM  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 6734186 B1 20040511  
 AI US 2000-708392 20001108 (9)  
 PRAI GB 1999-26437 19991108  
 GB 2000-4021 20000218  
 GB 2000-13001 20000526  
 GB 2000-16563 20000705  
 GB 2000-17141 20000712  
 US 2000-221093P 20000727 (60)

US 2000-221014P 20000727 (60)  
 US 2000-217479P 20000711 (60)  
 US 2000-192962P 20000329 (60)  
 US 2000-175161P 20000107 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 7110  
 INCL INCLM: 514/263.100  
 INCLS: 544/224.000; 544/242.000  
 NCL NCLM: 514/263.100  
 NCLS: 544/224.000; 544/242.000  
 IC [7]  
 ICM A01N043-90  
 ICS A61K031-52; C07D237-00; C07D237-02; C07D239-00  
 IPCI A01N0043-90 [ICM,7]; A61K0031-52 [ICS,7]; A61K0031-519  
 [ICS,7,C\*]; C07D0237-00 [ICS,7]; C07D0237-02 [ICS,7]; C07D0237-00  
 [ICS,7,C\*]; C07D0239-00 [ICS,7]  
 IPCR A61K0031-00 [I,C\*]; A61K0031-00 [I,A]; A61K0031-185 [I,C\*];  
 A61K0031-192 [I,A]; A61K0031-195 [I,A]; A61K0031-352 [I,C\*];  
 A61K0031-352 [I,A]; A61K0031-4015 [I,C\*]; A61K0031-4015 [I,A];  
 A61K0031-44 [I,C\*]; A61K0031-44 [I,A]; A61K0031-4412 [I,C\*];  
 A61K0031-4412 [I,A]; A61K0031-4985 [I,C\*]; A61K0031-4985 [I,A];  
 A61K0031-519 [I,C\*]; A61K0031-519 [I,A]; A61K0031-52 [I,C\*];  
 A61K0031-55 [I,C\*]; A61K0031-55 [I,A]; A61K0038-43 [I,C\*];  
 A61K0038-46 [I,A]; C12Q0001-44 [I,C\*]; C12Q0001-44 [I,A];  
 G01N0033-50 [I,C\*]; G01N0033-50 [I,A]; G01N0033-53 [I,C\*];  
 G01N0033-53 [I,A]; G01N0033-68 [I,C\*]; G01N0033-68 [I,A]  
 EXF 514/258; 514/263.1; 544/262; 544/224; 544/242  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 13 OF 48 USPATFULL on STN

Full Text

AN 2004:114715 USPATFULL  
 TI Treatment of sexual dysfunction  
 IN Gonzalez, Maria Isabel, Sandwich, UNITED KINGDOM  
 Higginbottom, Michael, Sandwich, UNITED KINGDOM  
 Naylor, Alisdair Mark, Sandwich, UNITED KINGDOM  
 Pinnock, Robert Denham, Ann Arbor, MI, UNITED STATES  
 Pritchard, Martyn Clive, Sandwich, UNITED KINGDOM  
 Stock, Herman Thijs, Sandwich, UNITED KINGDOM  
 Van Der Graaf, Pieter Hadewijn, Sandwich, UNITED KINGDOM  
 Wayman, Christopher Peter, Sandwich, UNITED KINGDOM  
 PI US 2004087561 A1 20040506  
 AI US 2003-416934 A1 20031204 (10)  
 WO 2001-GB5018 20011114  
 PRAI GB 2001-9910 20010423  
 GB 2001-11037 20010504  
 WO 2000-GB4380 20001117  
 DT Utility  
 FS APPLICATION  
 LN.CNT 5490  
 INCL INCLM: 514/169.000  
 INCLS: 514/288.000; 514/573.000; 514/567.000; 514/002.000; 424/094.630  
 NCL NCLM: 514/169.000  
 NCLS: 424/094.630; 514/002.000; 514/288.000; 514/567.000; 514/573.000  
 IC [7]  
 ICM A61K038-00  
 ICS A61K031-56; A61K031-48; A61K031-198; A61K031-557  
 IPCI A61K0038-00 [ICM,7]; A61K0031-56 [ICS,7]; A61K0031-48 [ICS,7];  
 A61K0031-198 [ICS,7]; A61K0031-185 [ICS,7,C\*]; A61K0031-557  
 [ICS,7]  
 IPCR A61K0031-165 [I,C\*]; A61K0031-165 [I,A]; A61K0031-17 [I,C\*];  
 A61K0031-17 [I,A]; A61K0031-18 [I,C\*]; A61K0031-18 [I,A];  
 A61K0031-185 [I,C\*]; A61K0031-196 [I,A]; A61K0031-395 [I,C\*];  
 A61K0031-395 [I,A]; A61K0031-4015 [I,C\*]; A61K0031-4015 [I,A];  
 A61K0031-433 [I,C\*]; A61K0031-433 [I,A]; A61K0031-4412 [I,C\*];  
 A61K0031-4412 [I,A]; A61K0031-4523 [I,C\*]; A61K0031-454 [I,A];  
 A61K0045-00 [I,C\*]; A61K0045-06 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 14 OF 48 USPATFULL on STN

Full Text

AN 2004:83187 USPATFULL  
 TI Bombesin antagonists  
 IN Higginbottom, Michael, Sandwich, UNITED KINGDOM  
 Kesten, Suzanne Ross, Ann Arbor, MI, UNITED STATES  
 Lewthwaite, Russell Andrew, Sandwich, UNITED KINGDOM  
 Pritchard, Martyn Clive, Sandwich, UNITED KINGDOM  
 Rawson, David James, Sandwich, UNITED KINGDOM  
 Schelkun, Robert Michael, Ann Arbor, MI, UNITED STATES  
 Yuen, Po-Wai, Ann Arbor, MI, UNITED STATES  
 PA Pfizer Inc. (non-U.S. corporation)  
 PI US 2004063643 A1 20040401  
 AI US 2003-425758 A1 20030428 (10)  
 PRAI GB 2002-10239 20020503  
 US 2002-398132P 20020723 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 5369  
 INCL INCLM: 514/019.000  
 INCLS: 514/237.800; 514/357.000; 514/408.000; 544/159.000; 546/336.000;  
 548/561.000  
 NCL NCLM: 514/019.000  
 NCLS: 514/237.800; 514/357.000; 514/408.000; 544/159.000; 546/336.000;  
 548/561.000  
 IC [7]  
 ICM A61K038-04  
 ICS A61K031-537; A61K031-44; A61K031-40  
 IPCI A61K0038-04 [ICM,7]; A61K0031-537 [ICS,7]; A61K0031-44 [ICS,7];  
 A61K0031-40 [ICS,7]  
 IPCR C07C0275-00 [I,C\*]; C07C0275-28 [I,A]; C07D0207-00 [I,C\*];  
 C07D0207-335 [I,A]; C07D0211-00 [I,C\*]; C07D0211-26 [I,A];  
 C07D0213-00 [I,C\*]; C07D0213-38 [I,A]; C07D0213-40 [I,A];  
 C07D0213-56 [I,A]; C07D0213-65 [I,A]; C07D0213-85 [I,A];  
 C07D0233-00 [I,C\*]; C07D0233-54 [I,A]; C07D0235-00 [I,C\*];  
 C07D0235-14 [I,A]; C07D0239-00 [I,C\*]; C07D0239-26 [I,A];  
 C07D0257-00 [I,C\*]; C07D0257-04 [I,A]; C07D0277-00 [I,C\*];  
 C07D0277-64 [I,A]; C07D0295-00 [I,C\*]; C07D0295-182 [I,A];  
 C07D0295-185 [I,A]; C07D0309-00 [I,C\*]; C07D0309-04 [I,A];  
 C07D0333-00 [I,C\*]; C07D0333-20 [I,A]; C07D0333-58 [I,A];  
 C07D0401-00 [I,C\*]; C07D0401-12 [I,A]; C07D0405-00 [I,C\*];  
 C07D0405-04 [I,A]; C07D0405-12 [I,A]; C07D0409-00 [I,C\*];  
 C07D0409-12 [I,A]; C07D0413-00 [I,C\*]; C07D0413-12 [I,A];  
 C07D0417-00 [I,C\*]; C07D0417-12 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 15 OF 48 USPATFULL on STN

Full Text

AN 2004:77410 USPATFULL  
 TI Method of colpoplasty  
 IN Matlock, David L., Los Angeles, CA, UNITED STATES  
 PI US 2004059190 A1 20040325  
 AI US 2003-461894 A1 20030613 (10)  
 PRAI US 2002-394947P 20020708 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1095  
 INCL INCLM: 600/038.000  
 NCL NCLM: 600/038.000  
 IC [7]  
 ICM A61F005-00  
 IPCI A61F0005-00 [ICM,7]  
 IPCR A61B [I,S]; A61F0005-00 [I,C\*]; A61F0005-00 [I,A]; A61K0031-575  
 [I,C\*]; A61K0031-575 [I,A]

L16 ANSWER 16 OF 48 USPATFULL on STN

Full Text

AN 2004:19457 USPATFULL  
 TI Treatment of female sexual dysfunction with phosphodiesterase inhibitors  
 IN Place, Virgil A., Kawaihae, HI, UNITED STATES  
 Wilson, Leland F., Menlo Park, CA, UNITED STATES  
 Doherty, Paul C., JR., Cupertino, CA, UNITED STATES  
 Hanamoto, Mark S., Belmont, CA, UNITED STATES  
 Spivack, Alfred P., Menlo Park, CA, UNITED STATES



Gesundheit, Neil, Los Altos, CA, UNITED STATES  
 Bennett, Sean R., Denver, CO, UNITED STATES  
 Doherty, Jane, Cupertino, CA, UNITED STATES LR

PI US 2004014761 A1 20040122  
 AI US 2002-279039 A1 20021022 (10)  
 RLI Continuation-in-part of Ser. No. US 2000-499959, filed on 8 Feb 2000,  
 GRANTED, Pat. No. US 6469016 Division of Ser. No. US 1998-181316, filed  
 on 27 Oct 1998, ABANDONED Continuation-in-part of Ser. No. US  
 1997-959064, filed on 28 Oct 1997, GRANTED, Pat. No. US 5877216  
 Continuation-in-part of Ser. No. US 1997-959057, filed on 28 Oct 1997,  
 ABANDONED

DT Utility  
 FS APPLICATION  
 LN.CNT 1429  
 INCL INCLM: 514/247.000  
 INCLS: 514/259.410; 514/264.100; 514/314.000; 514/389.000; 514/255.060  
 NCL NCLM: 514/247.000  
 NCLS: 514/255.060; 514/259.410; 514/264.100; 514/314.000; 514/389.000  
 IC [7]  
 ICM A61K031-519  
 ICS A61K031-4965; A61K031-50; A61K031-4709  
 IPCI A61K0031-519 [ICM,7]; A61K0031-4965 [ICS,7]; A61K0031-50 [ICS,7];  
 A61K0031-4709 [ICS,7]  
 IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0009-02 [I,C\*];  
 A61K0009-02 [I,A]; A61K0009-127 [I,C\*]; A61K0009-127 [I,A];  
 A61K0031-00 [I,C\*]; A61K0031-00 [I,A]; A61K0031-15 [I,C\*];  
 A61K0031-15 [I,A]; A61K0031-21 [I,C\*]; A61K0031-21 [I,A];  
 A61K0031-28 [I,C\*]; A61K0031-295 [I,A]; A61K0031-4164 [I,C\*];  
 A61K0031-4178 [I,A]; A61K0031-4353 [I,C\*]; A61K0031-437 [I,A];  
 A61K0031-4427 [I,C\*]; A61K0031-4427 [I,A]; A61K0031-4439 [I,A];  
 A61K0031-444 [I,A]; A61K0031-4704 [I,C\*]; A61K0031-4704 [I,A];  
 A61K0031-48 [I,C\*]; A61K0031-48 [I,A]; A61K0031-4985 [I,C\*];  
 A61K0031-4985 [I,A]; A61K0031-501 [I,C\*]; A61K0031-501 [I,A];  
 A61K0031-502 [I,C\*]; A61K0031-502 [I,A]; A61K0031-519 [I,C\*];  
 A61K0031-519 [I,A]; A61K0031-5375 [I,C\*]; A61K0031-5377 [I,A];  
 A61K0031-538 [I,A]; A61K0031-557 [I,C\*]; A61K0031-557 [I,A];  
 A61K0031-5575 [I,A]; A61K0031-5585 [I,A]; A61K0031-56 [I,C\*];  
 A61K0031-56 [I,A]; A61K0045-00 [I,C\*]; A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 17 OF 48 USPATFULL on STN

Full Text

AN 2003:325098 USPATFULL  
 TI Indole derivatives as pde5-inhibitors  
 IN Orme, Mark W, Seattle, WA, UNITED STATES  
 Sawyer, Jason Scott, Indianapolis, IN, UNITED STATES  
 Schultze, Lisa M, Woodinville, WA, UNITED STATES

PI US 2003229080 A1 20031211  
 US 6878711 B2 20050412  
 AI US 2003-398720 A1 20030409 (10)  
 WO 2001-US31364 20011009

DT Utility  
 FS APPLICATION  
 LN.CNT 987  
 INCL INCLM: 514/222.800  
 INCLS: 514/249.000; 544/009.000; 544/343.000  
 NCL NCLM: 514/250.000; 514/222.800  
 NCLS: 544/005.000; 544/009.000; 544/342.000; 544/343.000; 514/249.000  
 IC [7]  
 ICM A61K031-549  
 ICS C07D498-14; A61K031-498; C07D487-14  
 IPCI A61K0031-549 [ICM,7]; C07D0498-14 [ICS,7]; C07D0498-00  
 [ICS,7,C\*]; A61K0031-498 [ICS,7]; C07D0487-14 [ICS,7];  
 C07D0487-00 [ICS,7,C\*]  
 IPCI-2 C07D0487-14 [ICM,7]; C07D0487-22 [ICS,7]; C07D0487-00 [ICS,7,C\*];  
 A61K0031-4985 [ICS,7]; A61P0015-10 [ICS,7]; A61P0015-00  
 [ICS,7,C\*]  
 IPCR A61K0031-498 [I,C\*]; A61K0031-498 [I,A]; A61K0031-549 [I,C\*];  
 A61K0031-549 [I,A]; C07D0471-00 [I,C\*]; C07D0471-14 [I,A];  
 C07D0513-00 [I,C\*]; C07D0513-14 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 18 OF 48 USPATFULL on STN

Full Text

AN 2003:300913 USPATFULL  
TI Methods, compositions, and kits for enhancing female sexual desire and responsiveness  
IN Neal, Gary W., Knoxville, TN, UNITED STATES  
PI US 2003212139 A1 20031113  
AI US 2003-412555 A1 20030411 (10)  
RLI Division of Ser. No. US 2001-880188, filed on 12 Jun 2001, GRANTED, Pat. No. US 6593369 Continuation of Ser. No. US 1999-391412, filed on 8 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 1997-954122, filed on 20 Oct 1997, ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 1248  
INCL INCLM: 514/573.000  
INCLS: 514/530.000  
NCL NCLM: 514/573.000  
NCLS: 514/530.000  
IC [7]  
ICM A61K031-557  
IPCI A61K0031-557 [ICM,7]  
IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0031-557 [I,C\*]; A61K0031-557 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 19 OF 48 USPATFULL on STN

Full Text

AN 2003:294885 USPATFULL  
TI 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for sexual disfunction  
IN Wei, Edward T., Berkeley, CA, UNITED STATES  
PI US 2003207903 A1 20031106  
AI US 2002-191481 A1 20020708 (10)  
RLI Continuation-in-part of Ser. No. US 2002-139193, filed on 2 May 2002, PENDING  
DT Utility  
FS APPLICATION  
LN.CNT 721  
INCL INCLM: 514/269.000  
NCL NCLM: 514/269.000  
IC [7]  
ICM A61K031-513  
IPCI A61K0031-513 [ICM,7]  
IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0031-00 [I,C\*]; A61K0031-00 [I,A]; A61K0031-513 [I,C\*]; A61K0031-513 [I,A]; A61K0031-56 [I,C\*]; A61K0031-56 [I,A]; A61K0031-57 [I,C\*]; A61K0031-573 [I,A]; A61K0045-00 [I,C\*]; A61K0045-06 [I,A]; A61M0015-08 [N,C\*]; A61M0015-08 [N,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 20 OF 48 USPATFULL on STN

Full Text

AN 2003:294873 USPATFULL  
TI Combination therapy for modulating the human sexual response  
IN Podolski, Joseph S., The Woodlands, TX, UNITED STATES  
PA Zonagen, Inc. (U.S. corporation)  
PI US 2003207891 A1 20031106  
AI US 2003-462888 A1 20030617 (10)  
RLI Continuation of Ser. No. US 2000-717955, filed on 21 Nov 2000, ABANDONED Continuation of Ser. No. US 2000-403623, filed on 1 Feb 2000, PENDING A 371 of International Ser. No. WO 1998-US10230, filed on 19 May 1998, PENDING  
PRAI US 1997-49947P 19970519 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 929  
INCL INCLM: 514/252.160  
INCLS: 514/408.000; 514/002.000  
NCL NCLM: 514/252.160  
NCLS: 514/002.000; 514/408.000  
IC [7]

ICM A61K031-519  
 ICS A61K031-4172; A61K038-17  
 IPCI A61K0031-519 [ICM,7]; A61K0031-4172 [ICS,7]; A61K0031-4164  
 [ICS,7,C\*]; A61K0038-17 [ICS,7]  
 IPCR A61K0031-505 [I,C\*]; A61K0031-505 [I,A]; A61K0045-00 [I,C\*];  
 A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 21 OF 48 USPATFULL on STN

Full Text

AN 2003:271544 USPATFULL  
 TI Use of halogenated heterocyclic compounds in the treatment of sexual  
 dysfunction and cardiovascular disease  
 IN Cutler, Neal R., Los Angeles, CA, UNITED STATES  
 PA R.T. Alamo Ventures I, LLC, Beverly Hills, CA (U.S. corporation)  
 PI US 2003191152 A1 20031009  
 US 7041677 B2 20060509  
 AI US 2002-282286 A1 20021028 (10)  
 PRAI US 2002-403033P 20020813 (60)  
 US 2002-361150P 20020301 (60)  
 US 2002-361146P 20020301 (60)  
 US 2002-360829P 20020301 (60)  
 US 2002-360954P 20020301 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3811  
 INCL INCLM: 514/312.000  
 NCL NCLM: 514/312.000  
 NCLS: 514/299.000; 514/305.000; 514/306.000; 514/307.000; 514/311.000;  
 514/708.000  
 IC [7]  
 ICM A61K031-47  
 IPCI A61K0031-47 [ICM,7]  
 IPCI-2 A61K0031-47 [I,A]; A61K0031-44 [I,A]; A61K0031-41 [I,A]  
 IPCR A61K0031-47 [I,C\*]; A61K0031-47 [I,A]; A61K0031-47 [I,A];  
 A61K0031-41 [I,C]; A61K0031-41 [I,A]; A61K0031-44 [I,C];  
 A61K0031-44 [I,A]; A61K0031-47 [I,C]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 22 OF 48 USPATFULL on STN

Full Text

AN 2003:181501 USPATFULL  
 TI 5-HT receptor ligands and uses thereof  
 IN Chiang, Phoebe, East Lyme, CT, UNITED STATES  
 Novomisle, William A., Stonington, CT, UNITED STATES  
 Welch, Willard M., JR., Mystic, CT, UNITED STATES  
 Guzman-Perez, Angel, Stonington, CT, UNITED STATES  
 DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES  
 Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES  
 Liu, Kevin K., East Lyme, CT, UNITED STATES  
 PI US 2003125334 A1 20030703  
 US 6894050 B2 20050517  
 AI US 2002-163881 A1 20020605 (10)  
 PRAI US 2001-299953P 20010621 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 5231  
 INCL INCLM: 514/252.110  
 INCLS: 544/357.000  
 NCL NCLM: 514/252.110  
 NCLS: 544/357.000  
 IC [7]  
 ICM A61K031-497  
 ICS C07D043-04  
 IPCI A61K0031-497 [ICM,7]; A61K0031-4965 [ICM,7,C\*]; C07D0043-04  
 [ICS,7]  
 IPCI-2 C07D0241-20 [ICM,7]; C07D0241-00 [ICM,7,C\*]; C07D0401-12 [ICS,7];  
 C07D0401-00 [ICS,7,C\*]; C07D0409-12 [ICS,7]; C07D0409-00  
 [ICS,7,C\*]; A61K0031-497 [ICS,7]; A61K0031-4965 [ICS,7,C\*];  
 A61P0025-28 [ICS,7]; A61P0025-00 [ICS,7,C\*]  
 IPCR C07D0239-00 [I,C\*]; C07D0239-46 [I,A]; C07D0241-00 [I,C\*];  
 C07D0241-20 [I,A]; C07D0401-00 [I,C\*]; C07D0401-12 [I,A];

C07D0409-00 [I,C\*]; C07D0409-12 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 23 OF 48 USPATFULL on STN

Full Text

AN 2003:153438 USPATFULL  
TI 5-HT receptor ligands and uses thereof  
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES  
Novomisle, William A., Stonington, CT, UNITED STATES  
Welch, Willard M., JR., Mystic, CT, UNITED STATES  
PI US 2003105106 A1 20030605  
US 6825198 B2 20041130  
AI US 2002-156884 A1 20020528 (10)  
PRAI US 2001-299953P 20010621 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3888  
INCL INCLM: 514/252.110  
INCLS: 514/252.140; 544/295.000; 544/357.000  
NCL NCLM: 514/252.140; 514/252.110  
NCLS: 544/295.000; 544/357.000  
IC [7]  
ICM A61K031-496  
ICS C07D043-14; C07D043-04  
IPCI A61K0031-496 [ICM,7]; C07D0043-14 [ICS,7]; C07D0043-04 [ICS,7]  
IPCI-2 C07D0024-120 [ICM,7]; C07D0401-12 [ICS,7]; C07D0401-00  
[ICS,7,C\*]; C07D0409-12 [ICS,7]; C07D0409-00 [ICS,7,C\*];  
A61K0031-497 [ICS,7]; A61K0031-4965 [ICS,7,C\*]; A61P0025-28  
[ICS,7]; A61P0025-00 [ICS,7,C\*]  
IPCR A61P0025-00 [I,C\*]; A61P0025-28 [I,A]; C07D0239-00 [I,C\*];  
C07D0239-46 [I,A]; C07D0241-00 [I,C\*]; C07D0241-20 [I,A];  
C07D0401-00 [I,C\*]; C07D0401-12 [I,A]; C07D0409-00 [I,C\*];  
C07D0409-12 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 24 OF 48 USPATFULL on STN

Full Text

AN 2003:134652 USPATFULL  
TI Novel alpha adrenergic agents  
IN Miller, Duane D., Germantown, TN, UNITED STATES  
Hong, Seoung-Soo, Cheongju, KOREA, REPUBLIC OF  
PI US 2003092741 A1 20030515  
US 6919357 B2 20050719  
AI US 2002-215547 A1 20020809 (10)  
PRAI US 2001-311320P 20010810 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 719  
INCL INCLM: 514/341.000  
INCLS: 514/370.000; 514/397.000; 514/401.000; 514/402.000; 546/272.700;  
548/190.000; 548/312.700; 548/312.100; 548/315.400; 548/314.700;  
548/326.500  
NCL NCLM: 514/400.000; 514/341.000  
NCLS: 548/332.500; 514/370.000; 514/397.000; 514/401.000; 514/402.000;  
546/272.700; 548/190.000; 548/312.100; 548/312.700; 548/314.700;  
548/315.400; 548/326.500  
IC [7]  
ICM C07D417-02  
ICS C07D403-02; C07D049-02; C07D045-02; A61K031-4439; A61K031-427;  
A61K031-4178  
IPCI C07D0417-02 [ICM,7]; C07D0417-00 [ICM,7,C\*]; C07D0403-02 [ICS,7];  
C07D0403-00 [ICS,7,C\*]; C07D0049-02 [ICS,7]; C07D0045-02 [ICS,7];  
A61K0031-4439 [ICS,7]; A61K0031-4427 [ICS,7,C\*]; A61K0031-427  
[ICS,7]; A61K0031-4178 [ICS,7]; A61K0031-4164 [ICS,7,C\*]  
IPCI-2 A61K0031-4168 [ICM,7]; A61K0031-4164 [ICM,7,C\*]; C07D0233-88  
[ICS,7]; C07D0233-00 [ICS,7,C\*]  
IPCR A61K0031-4164 [I,C\*]; A61K0031-4168 [I,A]; A61K0031-4178 [I,A];  
A61K0031-427 [I,C\*]; A61K0031-427 [I,A]; A61K0031-4427 [I,C\*];  
A61K0031-4427 [I,A]; C07D0233-00 [I,C\*]; C07D0233-52 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 25 OF 48 USPATFULL on STN

Full Text

AN 2003:4131 USPATFULL  
TI Combination therapy for modulating the human sexual response  
IN Podolski, Joseph S., The Woodlands, TX, UNITED STATES  
PA ZONAGEN, INC. (U.S. corporation)  
PI US 2003004170 A1 20030102  
AI US 2002-217575 A1 20020813 (10)  
RLI Division of Ser. No. US 2000-403623, filed on 1 Feb 2000, PENDING A 371  
of International Ser. No. WO 1998-US10230, filed on 19 May 1998, PENDING  
PRAI US 1997-49947P 19970519 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 927  
INCL INCLM: 514/252.160  
INCLS: 514/012.000; 514/401.000  
NCL NCLM: 514/252.160  
NCLS: 514/012.000; 514/401.000  
IC [7]  
ICM A61K038-17  
ICS A61K031-519  
IPCI A61K0038-17 [ICM,7]; A61K0031-519 [ICS,7]  
IPCR A61K0031-505 [I,C\*]; A61K0031-505 [I,A]; A61K0045-00 [I,C\*];  
A61K0045-06 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 26 OF 48 USPATFULL on STN

Full Text

AN 2002:338074 USPATFULL  
TI Method and compositions for the treatment or amelioration of female  
sexual dysfunction  
IN Heaton, Jeremy P. W., Gananoque, CANADA  
Adams, Michael A., Kingston, CANADA  
PI US 2002193442 A1 20021219  
US 6756407 B2 20040629  
AI US 2002-126933 A1 20020422 (10)  
RLI Division of Ser. No. US 1999-336088, filed on 18 Jun 1999, GRANTED, Pat.  
No. US 6395744 Continuation-in-part of Ser. No. US 1998-102987, filed on  
22 Jun 1998, PENDING Continuation-in-part of Ser. No. US 1995-546498,  
filed on 20 Oct. 1995, GRANTED, Pat. No. US 5770606 Continuation-in-part  
of Ser. No. US 1994-231250, filed on 22 Apr 1994, ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 1068  
INCL INCLM: 514/579.000  
NCL NCLM: 514/573.000; 514/579.000  
NCLS: 514/284.000; 514/772.600  
IC [7]  
ICM A61K031-13  
IPCI A61K0031-13 [ICM,7]  
IPCI-2 A61K0031-19 [ICM,7]; A61K0031-185 [ICM,7,C\*]; A61K0031-557  
[ICS,7]  
IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0031-403 [I,C\*];  
A61K0031-4045 [I,A]; A61K0031-405 [I,A]; A61K0031-472 [I,C\*];  
A61K0031-472 [I,A]; A61K0031-473 [I,C\*]; A61K0031-473 [I,A];  
A61K0031-48 [I,C\*]; A61K0031-48 [I,A]; A61K0031-485 [I,C\*];  
A61K0031-485 [I,A]; A61K0031-506 [I,C\*]; A61K0031-506 [I,A];  
A61K0031-565 [I,C\*]; A61K0031-565 [I,A]; A61K0038-10 [I,C\*];  
A61K0038-11 [I,A]; A61K0038-12 [I,C\*]; A61K0038-12 [I,A];  
A61K0049-00 [I,C\*]; A61K0049-00 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 27 OF 48 USPATFULL on STN

Full Text

AN 2002:301556 USPATFULL  
TI Treatment of sexual dysfunction  
IN Gonzalez, Maria Isabel, Cambridge, UNITED KINGDOM  
Higginbottom, Michael, Cambridge, UNITED KINGDOM  
Stock, Herman Thijs, Wijchen, NETHERLANDS  
Pritchard, Martyn Clive, Huntingdon, UNITED KINGDOM  
Pinnock, Robert Denham, Cambridgeshire, UNITED KINGDOM  
Van Der Graaf, Pieter Hadewijn, Kent, UNITED KINGDOM  
Naylor, Alisdair Mark, Kent, UNITED KINGDOM

Wayman, Christopher Peter, Kent, UNITED KINGDOM

PI US 2002169101 A1 20021114

AI US 2001-999284 A1 20011115 (9)

RLI Continuation-in-part of Ser. No. US 2001-759777, filed on 12 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-700165, filed on 9 Nov 2000, PENDING A 371 of International Ser. No. WO 2000-GB1787, filed on 10 May 2000, UNKNOWN

PRAI GB 2001-9910 20010423

GB 2001-11037 20010504

US 1999-133355P 19990510 (60)

DT Utility

FS APPLICATION

LN.CNT 5522

INCL INCLM: 514/001.000

NCL NCLM: 514/001.000

IC [7]

ICM A61K031-00

IPCI A61K0031-00 [ICM,7]

IPCR A61K0031-00 [I,C\*]; A61K0031-00 [I,A]; A61K0031-165 [I,C\*]; A61K0031-165 [I,A]; A61K0031-17 [I,C\*]; A61K0031-17 [I,A]; A61K0031-18 [I,C\*]; A61K0031-18 [I,A]; A61K0031-185 [I,C\*]; A61K0031-196 [I,A]; A61K0031-395 [I,C\*]; A61K0031-395 [I,A]; A61K0031-4015 [I,C\*]; A61K0031-4015 [I,A]; A61K0031-403 [I,C\*]; A61K0031-404 [I,A]; A61K0031-433 [I,C\*]; A61K0031-433 [I,A]; A61K0031-4412 [I,C\*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4523 [I,C\*]; A61K0031-454 [I,A]; A61K0031-565 [I,C\*]; A61K0031-565 [I,A]; A61K0045-00 [I,C\*]; A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 28 OF 48 USPATFULL on STN

Full Text

AN 2002:295077 USPATFULL

TI Method and compositions for the treatment or amelioration of female sexual dysfunction

IN Heaton, Jeremy P. W., Kingston, CANADA

Adams, Michael A., Kingston, CANADA

PI US 2002165122 A1 20021107

AI US 2002-136387 A1 20020502 (10)

RLI Continuation of Ser. No. US 1998-102987, filed on 22 Jun 1998, PENDING Continuation-in-part of Ser. No. US 1995-546498, filed on 20 Oct 1995, GRANTED, Pat. No. US 5770606 Continuation-in-part of Ser. No. US 1994-231250, filed on 22 Apr 1994, ABANDONED

DT Utility

FS APPLICATION

LN.CNT 717

INCL INCLM: 514/001.000

NCL NCLM: 514/001.000

IC [7]

ICM A61K031-00

IPCI A61K0031-00 [ICM,7]

IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0031-403 [I,C\*]; A61K0031-4045 [I,A]; A61K0031-405 [I,A]; A61K0031-472 [I,C\*]; A61K0031-472 [I,A]; A61K0031-473 [I,C\*]; A61K0031-473 [I,A]; A61K0031-48 [I,C\*]; A61K0031-48 [I,A]; A61K0031-485 [I,C\*]; A61K0031-485 [I,A]; A61K0031-506 [I,C\*]; A61K0031-506 [I,A]; A61K0031-565 [I,C\*]; A61K0031-565 [I,A]; A61K0038-10 [I,C\*]; A61K0038-11 [I,A]; A61K0038-12 [I,C\*]; A61K0038-12 [I,A]; A61K0049-00 [I,C\*]; A61K0049-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT..

L16 ANSWER 29 OF 48 USPATFULL on STN

Full Text

AN 2002:266337 USPATFULL

TI The treatment of sexual dysfunction with enantiomers

IN Cutler, Neal R., Los Angeles, CA, UNITED STATES

Sramek, John, Irvine, CA, UNITED STATES

PA R.T. Alamo Ventures I, L.L.C., Beverly Hills, CA, UNITED STATES (U.S. corporation)

PI US 2002147217 A1 20021010

AI US 2001-770704 A1 20010126 (9)

DT Utility

FS APPLICATION  
LN.CNT 1198  
INCL INCLM: 514/314.000  
NCL NCLM: 514/314.000  
IC [7]  
ICM A61K031-47  
IPCI A61K0031-47 [ICM,7]  
IPCR A61K0031-47 [I,C\*]; A61K0031-47 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 30 OF 48 USPATFULL on STN

Full Text

AN 2002:262363 USPATFULL  
TI Carboline derivatives as cGMP phosphodiesterase inhibitors  
IN Bombrun, Agnes, Monnetier Mornex, FRANCE  
Gellibert, Fran.cedilla.oise, Paris Cedex, FRANCE  
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)  
PI US 6462047 B1 20021008  
WO 2000015639 20000323  
AI US 2001-744859 20010516 (9)  
WO 1998-EP6050 19980916  
20010516 PCT 371 date  
DT Utility  
FS GRANTED  
LN.CNT 1490  
INCL INCLM: 514/253.030  
INCLS: 514/252.180; 514/256.000; 514/275.000; 514/292.000; 544/332.000;  
544/335.000; 544/361.000; 546/085.000  
NCL NCLM: 514/253.030  
NCLS: 514/252.180; 514/256.000; 514/275.000; 514/292.000; 544/332.000;  
544/335.000; 544/361.000; 546/085.000  
IC [7]  
ICM A61K031-437  
ICS A61K031-496; A61K031-506; C07D471-04; C07D239-02; C07D401-14  
IPCI A61K0031-437 [ICM,7]; A61K0031-4353 [ICM,7,C\*]; A61K0031-496  
[ICS,7]; A61K0031-506 [ICS,7]; C07D0471-04 [ICS,7]; C07D0471-00  
[ICS,7,C\*]; C07D0239-02 [ICS,7]; C07D0239-00 [ICS,7,C\*];  
C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C\*]  
IPCR A61K0031-4353 [I,C\*]; A61K0031-437 [I,A]; A61K0031-4427 [I,C\*];  
A61K0031-444 [I,A]; A61K0031-506 [I,C\*]; A61K0031-506 [I,A];  
A61K0045-00 [I,C\*]; A61K0045-00 [I,A]; A61P0001-00 [I,C\*];  
A61P0001-00 [I,A]; A61P0001-04 [I,A]; A61P0007-00 [I,C\*];  
A61P0007-02 [I,A]; A61P0009-00 [I,C\*]; A61P0009-10 [I,A];  
A61P0009-12 [I,A]; A61P0011-00 [I,C\*]; A61P0011-00 [I,A];  
A61P0011-02 [I,A]; A61P0011-06 [I,A]; A61P0013-00 [I,C\*];  
A61P0013-12 [I,A]; A61P0015-00 [I,C\*]; A61P0015-10 [I,A];  
A61P0027-00 [I,C\*]; A61P0027-02 [I,A]; A61P0029-00 [I,C\*];  
A61P0029-00 [I,A]; A61P0035-00 [I,C\*]; A61P0035-00 [I,A];  
A61P0037-00 [I,C\*]; A61P0037-08 [I,A]; A61P0043-00 [I,C\*];  
A61P0043-00 [I,A]; C07D0471-00 [I,C\*]; C07D0471-04 [I,A]  
EXF 514/292; 514/256; 514/275; 514/253.03; 514/252.18; 546/85; 544/361;  
544/332; 544/335  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 31 OF 48 USPATFULL on STN

Full Text

AN 2002:243641 USPATFULL  
TI Treatment of erectile dysfunction  
IN Mills, Thomas M., Augusta, GA, UNITED STATES  
Wingard, Christopher J., Augusta, GA, UNITED STATES  
Webb, R. Clinton, Matinez, GA, UNITED STATES  
Lewis, Ronald W., Augusta, GA, UNITED STATES  
Chitaley, Kanchan, Augusta, GA, UNITED STATES  
PI US 2002132832 A1 20020919  
AI US 2002-40010 A1 20020104 (10)  
PRAI US 2001-260062P 20010105 (60)  
US 2001-267296P 20010208 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1386  
INCL INCLM: 514/352.000  
NCL NCLM: 514/352.000

IC [7]  
ICM A61K031-4409  
IPCI A61K0031-4409 [ICM,7]  
IPCR A61K0031-4409 [I,C\*]; A61K0031-4409 [I,A]; A61K0045-00 [I,C\*];  
A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 32 OF 48 USPATFULL on STN

Full Text

AN 2002:133870 USPATFULL  
TI Composition to boost libido  
IN Reyes, Joe, Troy, MI, UNITED STATES  
PI US 2002068728 A1 20020606  
US 6803060 B2 20041012  
AI US 2001-927995 A1 20010810 (9)  
PRAI US 2000-230656P 20000907 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 612  
INCL INCLM: 514/182.000  
NCL NCLM: 424/769.000; 514/182.000  
NCLS: 424/725.000; 424/757.000; 514/177.000; 514/178.000; 514/181.000;  
514/458.000; 514/561.000

IC [7]  
ICM A61K031-56  
IPCI A61K0031-56 [ICM,7]  
IPCI-2 A61K0035-78 [ICM,7]; A61K0031-56 [ICS,7]; A61K0031-355 [ICS,7];  
A61K0031-352 [ICS,7,C\*]; A61K0031-195 [ICS,7]; A61K0031-185  
[ICS,7,C\*]  
IPCR A61K0031-56 [I,C\*]; A61K0031-56 [I,A]; A61K0045-00 [I,C\*];  
A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 33 OF 48 USPATFULL on STN

Full Text

AN 2002:122643 USPATFULL  
TI Method and compositions for the treatment or amelioration of female  
sexual dysfunction  
IN Adams, Michael A., Kingston, CANADA  
Heaton, Jeremy P. W., Gananoque, CANADA  
PA Queen's University at Kingston, Kingston, CANADA (non-U.S. corporation)  
PI US 6395744 B1 20020528  
AI US 1999-336088 19990618 (9)  
RLI Continuation-in-part of Ser. No. US 1998-102987, filed on 22 Jun 1998  
Continuation-in-part of Ser. No. US 1995-546498, filed on 20 Oct 1995,  
now patented, Pat. No. US 5770606 Continuation-in-part of Ser. No. US  
1994-231250, filed on 22 Apr 1994, now abandoned  
DT Utility  
FS GRANTED  
LN.CNT 1218  
INCL INCLM: 514/284.000  
INCLS: 514/573.000; 514/772.600  
NCL NCLM: 514/284.000  
NCLS: 514/573.000; 514/772.600

IC [7]  
ICM A61K031-44  
IPCI A61K0031-44 [ICM,7]  
IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0031-403 [I,C\*];  
A61K0031-4045 [I,A]; A61K0031-405 [I,A]; A61K0031-472 [I,C\*];  
A61K0031-472 [I,A]; A61K0031-473 [I,C\*]; A61K0031-473 [I,A];  
A61K0031-48 [I,C\*]; A61K0031-48 [I,A]; A61K0031-485 [I,C\*];  
A61K0031-485 [I,A]; A61K0031-506 [I,C\*]; A61K0031-506 [I,A];  
A61K0031-565 [I,C\*]; A61K0031-565 [I,A]; A61K0038-10 [I,C\*];  
A61K0038-11 [I,A]; A61K0038-12 [I,C\*]; A61K0038-12 [I,A];  
A61K0049-00 [I,C\*]; A61K0049-00 [I,A]

EXF 514/772.6; 514/284; 514/573

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 34 OF 48 USPATFULL on STN

Full Text

AN 2002:8529 USPATFULL  
TI METHODS, COMPOSITIONS, AND KITS FOR ENHANCING FEMALE SEXUAL DESIRE AND



RESPONSIVENESS  
 IN NEAL, GARY W., KNOXVILLE, TN, UNITED STATES  
 PI US 2002004529 A1 20020110  
 AI US 1997-954122 A1 19971020 (8)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 989  
 INCL INCLM: 514/573.000  
 NCL NCLM: 514/573.000  
 IC [7]  
 ICM A61K031-47  
 ICS A61K031-557; A61K031-19  
 IPCI A61K0031-47 [ICM,7]; A61K0031-557 [ICS,7]; A61K0031-19 [ICS,7];  
 A61K0031-185 [ICS,7,C\*]  
 IPCR A61K0047-12 [I,C\*]; A61K0047-12 [I,A]; A61K0009-00 [I,C\*];  
 A61K0009-00 [I,A]; A61K0031-557 [I,C\*]; A61K0031-557 [I,A];  
 A61K0031-5575 [I,A]; A61K0047-22 [I,C\*]; A61K0047-22 [I,A];  
 A61P0015-00 [I,C\*]; A61P0015-00 [I,A]; A61P0043-00 [I,C\*];  
 A61P0043-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 35 OF 48 USPATFULL on STN

Full Text

AN 2001:212470 USPATFULL  
 TI Methods, compositions, and kits for enhancing female sexual desire and  
 responsiveness  
 IN Neal, Gary W., Knoxville, TN, United States  
 PI US 2001044467 A1 20011122  
 US 6593369 B2 20030715  
 AI US 2001-880188 A1 20010612 (9)  
 RLI Continuation of Ser. No. US 1999-391412, filed on 8 Sep 1999, ABANDONED  
 Continuation-in-part of Ser. No. US 1997-954122, filed on 20 Oct 1997,  
 PENDING  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1284  
 INCL INCLM: 514/573.000  
 INCLS: 514/530.000  
 NCL NCLM: 514/573.000  
 NCLS: 514/874.000; 514/530.000  
 IC [7]  
 ICM A61K031-5575  
 IPCI A61K0031-5575 [ICM,7]; A61K0031-557 [ICM,7,C\*]  
 IPCI-2 A61K0031-19 [ICM,7]; A61K0031-185 [ICM,7,C\*]; A61K0031-557  
 [ICS,7]  
 IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0031-557 [I,C\*];  
 A61K0031-557 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 36 OF 48 USPATFULL on STN

Full Text

AN 2001:158350 USPATFULL  
 TI Prostaglandin E1/F2 in combination with prostaglandin F2 $\alpha$  for  
 enhancing female sexual arousal  
 IN Scott, Nathan Earl, 610 Laguna Rd., Fullerton, CA, United States 92835  
 PI US 6291528 B1 20010918  
 AI US 1999-422031 19991020 (9)  
 RLI Continuation-in-part of Ser. No. WO 1998-US26609, filed on 15 Dec 1998  
 Continuation-in-part of Ser. No. US 1998-38378, filed on 11 Mar 1998,  
 now patented, Pat. No. US 5962528 Continuation-in-part of Ser. No. US  
 1998-5087, filed on 9 Jan 1998, now abandoned Continuation-in-part of  
 Ser. No. US 1997-992946, filed on 18 Dec 1997, now patented, Pat. No. US  
 5981593 Continuation-in-part of Ser. No. US 1993-90483, filed on 12 Jul  
 1993, now patented, Pat. No. US 5708031, issued on 13 Jan 1998  
 Continuation of Ser. No. US 1992-860107, filed on 30 Mar 1992, now  
 abandoned Continuation of Ser. No. US 1991-725350, filed on 3 Jul 1991,  
 now abandoned  
 DT Utility  
 FS GRANTED  
 LN.CNT 1054  
 INCL INCLM: 514/573.000  
 NCL NCLM: 514/573.000

IC [7]  
ICM A61K031-5575  
IPCI A61K0031-5575 [ICM,7]; A61K0031-557 [ICM,7,C\*]  
IPCR A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61K0031-557 [I,A];  
A61K0031-557 [I,C\*]; A61K0031-5575 [I,A]  
EXF 514/573  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 37 OF 48 USPATFULL on STN

Full Text

AN 2000:150177 USPATFULL  
TI Chemical compounds  
IN Daugan, Alain Claude-Marie, Marly le Roi Cedex, France  
LaBaudiniere, Richard Frederick, Collegeville, PA, United States  
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)  
PI US 6143757 20001107  
AI US 1998-154619 19980916 (9)  
RLI Continuation-in-part of Ser. No. WO 1996-EP3023, filed on 11 Jul 1996  
DT Utility  
FS Granted  
LN.CNT 1803  
INCL INCLM: 514/285.000  
INCLS: 514/277.000; 514/279.000; 514/284.000; 514/287.000; 514/359.000  
NCL NCLM: 514/285.000  
NCLS: 514/277.000; 514/279.000; 514/284.000; 514/287.000; 514/359.000  
IC [7]  
ICM A61K031-44  
IPCI A61K0031-44 [ICM,7]  
IPCR C07D0471-00 [I,C\*]; C07D0471-14 [I,A]  
EXF 514/277; 514/279; 514/284; 514/285; 514/287; 514/359  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 38 OF 48 USPATFULL on STN

Full Text

AN 2000:150166 USPATFULL  
TI Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of  
preparation and use  
IN Daugan, Alain Claude-Marie, Marly le Roi Cedex, France  
Gellibert, Francoise, Marly le Roi Cedex, France  
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)  
PI US 6143746 20001107  
AI US 1998-154051 19980916 (9)  
RLI Continuation-in-part of Ser. No. WO 1995-EP183, filed on 19 Jan 1995,  
now patented, Pat. No. WO 5859006 which is a continuation-in-part of  
Ser. No. WO 1996-EP3025, filed on 11 Jul 1996, now patented, Pat. No. WO  
5981527 which is a continuation-in-part of Ser. No. WO 1996-EP3024,  
filed on 11 Jul 1996  
PRAI GB 1994-1090 19940121  
GB 1995-14465 19950714  
GB 1995-14474 19950714  
DT Utility  
FS Granted  
LN.CNT 3174  
INCL INCLM: 514/249.000  
INCLS: 514/250.000; 514/292.000  
NCL NCLM: 514/249.000  
NCLS: 514/250.000; 514/292.000  
IC [7]  
ICM A61K031-50  
IPCI A61K0031-50 [ICM,7]  
IPCR C07D0471-00 [I,C\*]; C07D0471-14 [I,A]  
EXF 514/249; 514/250; 514/292  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 39 OF 48 USPATFULL on STN

Full Text

AN 2000:37808 USPATFULL  
TI Carboline derivatives  
IN Bombrun, Agnes, Paris, France  
PA Icos Corporation, Bothell, WA, United States (U.S. corporation)  
PI US 6043252 20000328  
AI US 1998-154052 19980916 (9)

RLI Continuation-in-part of Ser. No. WO 1997-EP2277, filed on 5 May 1997  
 DT Utility  
 FS Granted  
 LN.CNT 4016  
 INCL INCLM: 514/292.000  
 INCLS: 546/085.000  
 NCL NCLM: 514/292.000  
 NCLS: 546/085.000  
 IC [7]  
 ICM A61K031-44  
 IPCI A61K0031-44 [ICM,7]  
 IPCR C07D0471-00 [I,C\*]; C07D0471-04 [I,A]  
 EXF 514/292; 546/85  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 40 OF 48 USPAT2 on STN

Full Text

AN 2005:38129 USPAT2  
 TI 5-HT receptor ligands and uses thereof  
 IN Chiang, Phoebe, East Lyme, CT, UNITED STATES  
 Novomisle, William A., Stonington, CT, UNITED STATES  
 Welch, Jr., Willard M., Mystic, CT, UNITED STATES  
 PA Pfizer Inc., New York, NY, UNITED STATES (U.S. corporation)  
 PI US 6995159 B2 20060207  
 AI US 2004-942345 20040916 (10)  
 RLI Division of Ser. No. US 2002-156884, filed on 28 May 2002, Pat. No. US 6825198  
 PRAI US 2001-299953P 20010621 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2931  
 INCL INCLM: 514/252.180  
 INCLS: 514/252.190; 514/252.200; 544/295.000  
 NCL NCLM: 514/252.180; 514/252.110  
 NCLS: 514/252.190; 514/252.200; 544/295.000; 514/252.140; 544/357.000  
 IC IPCI A61K0031-497 [ICM,7]; A61K0031-4965 [ICM,7,C\*]; A61K0031-506 [ICS,7]; C07D0043-14 [ICS,7]  
 IPCI-2 A61K0031-497 [I,A]; A61K0031-4965 [I,C\*]; C07D0403-00 [I,A]  
 IPCR A61P0025-00 [I,C\*]; A61P0025-28 [I,A]; C07D0239-00 [I,C\*]; C07D0239-46 [I,A]; C07D0241-00 [I,C\*]; C07D0241-20 [I,A]; C07D0401-00 [I,C\*]; C07D0401-12 [I,A]; C07D0409-00 [I,C\*]; C07D0409-12 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A]; C07D0403-00 [I,C]; C07D0403-00 [I,A]  
 EXF 514/252.18; 514/252.19; 514/252.2; 544/295  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 41 OF 48 USPAT2 on STN

Full Text

AN 2003:325098 USPAT2  
 TI Indole derivatives as PDE5-inhibitors  
 IN Orme, Mark W., Seattle, WA, UNITED STATES  
 Sawyer, Jason Scott, Indianapolis, IN, UNITED STATES  
 Schultze, Lisa M., Woodinville, WA, UNITED STATES  
 PA Lilly Icos LLC, Wilmington, DE, UNITED STATES (U.S. corporation)  
 PI US 6878711 B2 20050412  
 WO 2002036593 20020510  
 AI US 2003-398720 20011009 (10)  
 WO 2001-US31364 20011009  
 20030409 PCT 371 date  
 PRAI US 2000-246257P 20001106 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 948  
 INCL INCLM: 514/250.000  
 INCLS: 544/343.000; 544/342.000; 544/009.000; 544/005.000  
 NCL NCLM: 514/250.000; 514/222.800  
 NCLS: 544/005.000; 544/009.000; 544/342.000; 544/343.000; 514/249.000  
 IC [7]  
 ICM C07D487-14  
 ICS C07D487-22; A61K031-4985; A61P015-10  
 IPCI A61K0031-549 [ICM,7]; C07D0498-14 [ICS,7]; C07D0498-00 [ICS,7,C\*]; A61K0031-498 [ICS,7]; C07D0487-14 [ICS,7];

C07D0487-00 [ICS,7,C\*]  
 IPCI-2 C07D0487-14 [ICM,7]; C07D0487-22 [ICS,7]; C07D0487-00 [ICS,7,C\*];  
 A61K0031-4985 [ICS,7]; A61P0015-10 [ICS,7]; A61P0015-00  
 [ICS,7,C\*]  
 IPCR A61K0031-498 [I,C\*]; A61K0031-498 [I,A]; A61K0031-549 [I,C\*];  
 A61K0031-549 [I,A]; C07D0471-00 [I,C\*]; C07D0471-14 [I,A];  
 C07D0513-00 [I,C\*]; C07D0513-14 [I,A]  
 EXF 544/343; 514/250  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 42 OF 48 USPAT2 on STN

Full Text

AN 2003:271544 USPAT2  
 TI Use of monochloroflosequinan in the treatment of sexual dysfunction.  
 IN Cutler, Neal R., Los Angeles, CA, UNITED STATES  
 PA R.T. Alamo Ventures I, LLC, Beverly Hills, CA, UNITED STATES (U.S.  
 corporation)  
 PI US 7041677 B2 20060509  
 AI US 2002-282286 20021028 (10)  
 PRAI US 2002-403033P 20020813 (60)  
 US 2002-361150P 20020301 (60)  
 US 2002-361146P 20020301 (60)  
 US 2002-360829P 20020301 (60)  
 US 2002-360954P 20020301 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 3781  
 INCL INCLM: 514/312.000  
 INCLS: 514/311.000; 514/305.000; 514/708.000; 514/306.000; 514/307.000;  
 514/299.000  
 NCL NCLM: 514/312.000  
 NCLS: 514/299.000; 514/305.000; 514/306.000; 514/307.000; 514/311.000;  
 514/708.000  
 IC IPCI A61K0031-47 [ICM,7]  
 IPCI-2 A61K0031-47 [I,A]; A61K0031-44 [I,A]; A61K0031-41 [I,A]  
 IPCR A61K0031-47 [I,C\*]; A61K0031-47 [I,A]; A61K0031-47 [I,A];  
 A61K0031-41 [I,C]; A61K0031-41 [I,A]; A61K0031-44 [I,C];  
 A61K0031-44 [I,A]; A61K0031-47 [I,C]  
 EXF 514/305; 514/306; 514/299; 514/307; 514/311-708  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 43 OF 48 USPAT2 on STN

Full Text

AN 2003:181501 USPAT2  
 TI 5-HT receptor ligands and uses thereof  
 IN Chiang, Phoebe, East Lyme, CT, UNITED STATES  
 Novomisle, William A., Stonington, CT, UNITED STATES  
 Welch, Jr., Willard M., Mystic, CT, UNITED STATES  
 Guzman-Perez, Angel, Stonington, CT, UNITED STATES  
 DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES  
 Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES  
 Liu, Kevin K., East Lyme, CT, UNITED STATES  
 PA Pfizer Inc., New York, NY, UNITED STATES (U.S. corporation)  
 PI US 6894050 B2 20050517  
 AI US 2002-163881 20020605 (10)  
 PRAI US 2001-299953P 20010621 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 4125  
 INCL INCLM: 514/252.110  
 INCLS: 544/357.000  
 NCL NCLM: 514/252.110  
 NCLS: 544/357.000  
 IC [7]  
 ICM C07D241-20  
 ICS C07D401-12; C07D409-12; A61K031-497; A61P025-28  
 IPCI A61K0031-497 [ICM,7]; A61K0031-4965 [ICM,7,C\*]; C07D0043-04  
 [ICS,7]  
 IPCI-2 C07D0241-20 [ICM,7]; C07D0241-00 [ICM,7,C\*]; C07D0401-12 [ICS,7];  
 C07D0401-00 [ICS,7,C\*]; C07D0409-12 [ICS,7]; C07D0409-00  
 [ICS,7,C\*]; A61K0031-497 [ICS,7]; A61K0031-4965 [ICS,7,C\*];  
 A61P0025-28 [ICS,7]; A61P0025-00 [ICS,7,C\*]

IPCR C07D0239-00 [I,C\*]; C07D0239-46 [I,A]; C07D0241-00 [I,C\*];  
C07D0241-20 [I,A]; C07D0401-00 [I,C\*]; C07D0401-12 [I,A];  
C07D0409-00 [I,C\*]; C07D0409-12 [I,A]  
EXF 544/357; 514/252.11  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 44 OF 48 USPAT2 on STN

Full Text

AN 2003:153438 USPAT2  
TI 5-HT receptor ligands and uses thereof  
IN Chiang, Phoebe, East Lyme, CT, United States  
Novomisle, William A., Stonington, CT, United States  
Welch, Jr., Willard M., Mystic, CT, United States  
PA Pfizer Inc, New York, NY, United States (U.S. corporation)  
PI US 6825198 B2 20041130  
AI US 2002-156884 20020528 (10)  
PRAI US 2001-299953P 20010621 (60)  
DT Utility  
FS GRANTED  
LN.CNT 3176  
INCL INCLM: 514/252.140  
INCLS: 544/295.000  
NCL NCLM: 514/252.140; 514/252.110  
NCLS: 544/295.000; 544/357.000  
IC [7]  
ICM C07D024-120  
ICS C07D401-12; C07D409-12; A61K031-497; A61P025-28  
IPCI A61K0031-496 [ICM,7]; C07D0043-14 [ICS,7]; C07D0043-04 [ICS,7]  
IPCI-2 C07D0024-120 [ICM,7]; C07D0401-12 [ICS,7]; C07D0401-00  
[ICS,7,C\*]; C07D0409-12 [ICS,7]; C07D0409-00 [ICS,7,C\*];  
A61K0031-497 [ICS,7]; A61K0031-4965 [ICS,7,C\*]; A61P0025-28  
[ICS,7]; A61P0025-00 [ICS,7,C\*]  
IPCR A61P0025-00 [I,C\*]; A61P0025-28 [I,A]; C07D0239-00 [I,C\*];  
C07D0239-46 [I,A]; C07D0241-00 [I,C\*]; C07D0241-20 [I,A];  
C07D0401-00 [I,C\*]; C07D0401-12 [I,A]; C07D0409-00 [I,C\*];  
C07D0409-12 [I,A]  
EXF 514/252.14; 544/295  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 45 OF 48 USPAT2 on STN

Full Text

AN 2003:134652 USPAT2  
TI  $\alpha$  adrenergic agents  
IN Miller, Duane D., Germantown, TN, UNITED STATES  
Hong, Seoung-Soo, Cheongju, KOREA, REPUBLIC OF  
PA Molecular Design International Inc., Memphis, TN, UNITED STATES (U.S.  
corporation)  
PI US 6919357 B2 20050719  
AI US 2002-215547 20020809 (10)  
PRAI US 2001-311320P 20010810 (60)  
DT Utility  
FS GRANTED  
LN.CNT 632  
INCL INCLM: 514/332.500  
INCLS: 548/332.500  
NCL NCLM: 514/400.000; 514/341.000  
NCLS: 548/332.500; 514/370.000; 514/397.000; 514/401.000; 514/402.000;  
546/272.700; 548/190.000; 548/312.100; 548/312.700; 548/314.700;  
548/315.400; 548/326.500  
IC [7]  
ICM A61K031-4168  
ICS C07D233-88  
IPCI C07D0417-02 [ICM,7]; C07D0417-00 [ICM,7,C\*]; C07D0403-02 [ICS,7];  
C07D0403-00 [ICS,7,C\*]; C07D0049-02 [ICS,7]; C07D0045-02 [ICS,7];  
A61K0031-4439 [ICS,7]; A61K0031-4427 [ICS,7,C\*]; A61K0031-427  
[ICS,7]; A61K0031-4178 [ICS,7]; A61K0031-4164 [ICS,7,C\*]  
IPCI-2 A61K0031-4168 [ICM,7]; A61K0031-4164 [ICM,7,C\*]; C07D0233-88  
[ICS,7]; C07D0233-00 [ICS,7,C\*]  
IPCR A61K0031-4164 [I,C\*]; A61K0031-4168 [I,A]; A61K0031-4178 [I,A];  
A61K0031-427 [I,C\*]; A61K0031-427 [I,A]; A61K0031-4427 [I,C\*];  
A61K0031-4427 [I,A]; C07D0233-00 [I,C\*]; C07D0233-52 [I,A]  
EXF 548/332.5; 514/392

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 46 OF 48 USPAT2 on STN

Full Text

AN 2002:338074 USPAT2  
TI Method and compositions for the treatment or amelioration of female sexual dysfunction  
IN Heaton, Jeremy P. W., Gananoque, CANADA  
Adams, Michael A., Kingston, CANADA  
PA Queen's University at Kingston, Kingston, CANADA (non-U.S. corporation)  
PI US 6756407 B2 20040629  
AI US 2002-126933 20020422 (10)  
RLI Division of Ser. No. US 1999-336088, filed on 18 Jun 1999, now patented, Pat. No. US 6395744 Continuation-in-part of Ser. No. US 1998-102987, filed on 22 Jun 1998  
DT Utility  
FS GRANTED  
LN.CNT 1241  
INCL INCLM: 514/573.000  
INCLS: 514/284.000; 514/772.600  
NCL NCLM: 514/573.000; 514/579.000  
NCLS: 514/284.000; 514/772.600  
IC [7]  
ICM A61K031-19  
ICS A61K031-557  
IPCI A61K0031-13 [ICM,7]  
IPCI-2 A61K0031-19 [ICM,7]; A61K0031-185 [ICM,7,C\*]; A61K0031-557 [ICS,7]  
IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0031-403 [I,C\*]; A61K0031-4045 [I,A]; A61K0031-405 [I,A]; A61K0031-472 [I,C\*]; A61K0031-472 [I,A]; A61K0031-473 [I,C\*]; A61K0031-473 [I,A]; A61K0031-48 [I,C\*]; A61K0031-48 [I,A]; A61K0031-485 [I,C\*]; A61K0031-485 [I,A]; A61K0031-506 [I,C\*]; A61K0031-506 [I,A]; A61K0031-565 [I,C\*]; A61K0031-565 [I,A]; A61K0038-10 [I,C\*]; A61K0038-11 [I,A]; A61K0038-12 [I,C\*]; A61K0038-12 [I,A]; A61K0049-00 [I,C\*]; A61K0049-00 [I,A]  
EXF 514/284; 514/573; 514/772.6  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 47 OF 48 USPAT2 on STN

Full Text

AN 2002:133870 USPAT2  
TI Composition to boost libido  
IN Reyes, Joe, 1175 Chicago Rd., Troy, MI, United States 48083  
PI US 6803060 B2 20041012  
AI US 2001-927995 20010810 (9)  
PRAI US 2000-230656P 20000907 (60)  
DT Utility  
FS GRANTED  
LN.CNT 579  
INCL INCLM: 424/769.000  
INCLS: 424/757.000; 424/725.000; 424/195.100; 514/177.000; 514/178.000; 514/181.000; 514/458.000; 514/561.000  
NCL NCLM: 424/769.000; 514/182.000  
NCLS: 424/725.000; 424/757.000; 514/177.000; 514/178.000; 514/181.000; 514/458.000; 514/561.000  
IC [7]  
ICM A61K035-78  
ICS A61K031-56; A61K031-355; A61K031-195  
IPCI A61K0031-56 [ICM,7]  
IPCI-2 A61K0035-78 [ICM,7]; A61K0031-56 [ICS,7]; A61K0031-355 [ICS,7]; A61K0031-352 [ICS,7,C\*]; A61K0031-195 [ICS,7]; A61K0031-185 [ICS,7,C\*]  
IPCR A61K0031-56 [I,C\*]; A61K0031-56 [I,A]; A61K0045-00 [I,C\*]; A61K0045-06 [I,A]  
EXF 514/177; 514/178; 514/181; 514/249; 514/256; 514/258; 514/257; 514/261; 514/262; 514/561; 514/458; 424/195.1; 424/769; 424/757; 424/725  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 48 OF 48 USPAT2 on STN

Full Text

AN 2001:212470 USPAT2

TI Methods, compositions, and kits for enhancing female sexual desire and responsiveness  
 IN Neal, Gary W., Knoxville, TN, United States  
 PA Vivus, Inc., Mountain View, CA, United States (U.S. corporation)  
 PI US 6593369 B2 20030715  
 AI US 2001-880188 20010612 (9)  
 RLI Continuation of Ser. No. US 1999-391412, filed on 8 Sep 1999  
 Continuation-in-part of Ser. No. US 1997-954122, filed on 20 Oct 1997, now abandoned  
 DT Utility  
 FS GRANTED  
 LN.CNT 1130  
 INCL INCLM: 514/573.000  
 INCLS: 514/874.000  
 NCL NCLM: 514/573.000  
 NCLS: 514/874.000; 514/530.000  
 IC [7]  
 ICM A61K031-19  
 ICS A61K031-557  
 IPCI A61K0031-5575 [ICM,7]; A61K0031-557 [ICM,7,C\*]  
 IPCI-2 A61K0031-19 [ICM,7]; A61K0031-185 [ICM,7,C\*]; A61K0031-557 [ICS,7]  
 IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0031-557 [I,C\*]; A61K0031-557 [I,A]  
 EXF 514/573; 514/874  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d an ti in pi kwic 1-48

L20 ANSWER 1 OF 1 USPATFULL on STN

Full Text

AN 2005:214622 USPATFULL  
 TI Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of vardenafil for the treatment of female sexual dysfunction  
 IN Thompson, James M., Cincinnati, OH, UNITED STATES  
 Thompson, Justin R., Cincinnati, OH, UNITED STATES  
 Thompson, Ronald J., Ft. Thomas, KY, UNITED STATES  
 PI US 2005186294 A1 20050825  
 CLM What is claimed is:  
 1. A manual application from an applicator of a topical **clitoral sensitizing** combination consisting essentially of L-arginine and a cooling agent comprised of Menthol and **vardenafil**, wherein said combination is applicable manually to the clitoris.  
 . . . contains less than 10% menthol and said combination contains less than 10% L-arginine and said combination contains less than 10% **vardenafil**.  
 . . . cyclic GMP induced production, via the actions of menthol and L-arginine, and the inhibition of the cyclic GMP degradation, by **vardenafil** in said compound, to create said vasodilatation and stimulation of the female clitoris.  
 . . . stimulation of the female clitoris, as recited in claim 17, by the step of: decreasing the dosage of menthol/L-arginine and/or **vardenafil** when topically applied to the female clitoris, to achieve said effective vasodilatation and maximum stimulation of the female clitoris.  
 19. A method to stimulate the female clitoris by the step of: utilizing menthol as a vehicle for **vardenafil** transport across the mucous membrane into the clitoral corpus cavernosa.  
 . . . for the production of cyclic GMP to therefore maximize the vasodilatation of the clitoral corpus cavernosa by the actions of **vardenafil** to inhibit the enzymatic degradation of that cyclic GMP.

=> d an ti in pi kwic 1-48

L20 ANSWER 1 OF 1 USPATFULL on STN

Full Text

AN 2005:214622 USPATFULL

TI Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of vardenafil for the treatment of female sexual dysfunction

IN Thompson, James M., Cincinnati, OH, UNITED STATES

Thompson, Justin R., Cincinnati, OH, UNITED STATES

Thompson, Ronald J., Ft. Thomas, KY, UNITED STATES

PI US 2005186294 A1 20050825

CLM What is claimed is:

1. A manual application from an applicator of a topical **clitoral sensitizing** combination consisting essentially of L-arginine and a cooling agent comprised of Menthol and **vardenafil**, wherein said combination is applicable manually to the clitoris.

. . . contains less than 10% menthol and said combination contains less than 10% L-arginine and said combination contains less than 10% **vardenafil**.

. . . cyclic GMP induced production, via the actions of menthol and L-arginine, and the inhibition of the cyclic GMP degradation, by **vardenafil** in said compound, to create said vasodilatation and stimulation of the female clitoris.

. . . stimulation of the female clitoris, as recited in claim 17, by the step of: decreasing the dosage of menthol/L-arginine and/or **vardenafil** when topically applied to the female clitoris, to achieve said effective vasodilatation and maximum stimulation of the female clitoris.

19. A method to stimulate the female clitoris by the step of: utilizing menthol as a vehicle for **vardenafil** transport across the mucous membrane into the clitoral corpus cavernosa.

. . . for the production of cyclic GMP to therefore maximize the vasodilatation of the clitoral corpus cavernosa by the actions of **vardenafil** to inhibit the enzymatic degradation of that cyclic GMP.

=> d an ti in pi kwic 48

1 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE  
The answer numbers requested are not in the answer set.  
ENTER ANSWER NUMBER OR RANGE (1):end

=> d his

(FILE 'HOME' ENTERED AT 21:02:01 ON 06 APR 2007)

FILE 'REGISTRY' ENTERED AT 21:02:13 ON 06 APR 2007

E SILDENAFIL/CN

L1 1 S E3

E VARDENAFIL/CN

L2 1 S E3

E TADALAFIL/CN

L3 1 S E3

FILE 'MEDLINE' ENTERED AT 21:03:50 ON 06 APR 2007

L4 2323 S L1

L5 247 S L2

L6 0 S L3

L7 3219 S (SILDENAFIL OR VARDENAFIL OR TADALAFIL)

L8 2450 S L4 OR L5

L9 3219 S L7 OR L8

L10 28 S (CLITORAL STIMUL? OR CLITORAL SENSI? OR FEMALE ERECT?)

L11 2 S L9 AND L10

FILE 'USPATFULL, USPAT2' ENTERED AT 21:08:06 ON 06 APR 2007

L12 430 S L1 OR L2 OR L3

L13 2092 S (SILDENAFIL OR VARDENAFIL OR TADALAFIL)



L14 188 S (CLITORAL STIMUL? OR CLITORAL SENSI? OR FEMALE ERECT?)  
 L15 2151 S L12 OR L13  
 L16 48 S L14 AND L15  
 L17 406 S (SILDENAFIL OR VARDENAFIL OR TADALAFIL)/CLM  
 L18 25 S (CLITORAL STIMUL? OR CLITORAL SENSI? OR FEMALE ERECT?)/CLM  
 L19 590 S L12 OR L17  
 L20 1 S L18 AND L19

=> d l16 an ti in pi kwic 1-48

L16 ANSWER 1 OF 48 USPATFULL on STN

Full Text

AN 2006:289260 USPATFULL  
 TI Cyclopentapyridine and tetrahydroquinoline derivatives  
 IN Lefker, Bruce A., Galas Ferry, CT, UNITED STATES  
 Liu, Kevin K. -C., East Lyme, CT, UNITED STATES  
 Chen, Hou, Salem, CT, UNITED STATES  
 Coffey, Steven Blair, Pawcatuck, CT, UNITED STATES  
 PI US 2006247254 A1 20061102  
 DETD . . . . to increased vaginal lubrication via plasma transudation,  
 increased vaginal compliance (relaxation of vaginal smooth muscle) and  
 increases in vaginal and **clitoral sensitivity**.  
 DETD . . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double  
 blind placebo controlled study with crossover to assess effect of  
**sildenafil** on physiological parameters of the female sexual response.  
 J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic.

L16 ANSWER 2 OF 48 USPATFULL on STN

Full Text

AN 2005:318125 USPATFULL  
 TI Peroxide compounds for the prevention and treatment of sexual  
 dysfunction in humans  
 IN Buyuktimkin, Servet, Robbinsville, NJ, UNITED STATES  
 Buyuktimkin, Nadir, Robbinsville, NJ, UNITED STATES  
 Yeager, James L., Lake Forest, IL, UNITED STATES  
 PI US 2005276865 A1 20051215  
 SUMM . . . . to injectable vasodilators (Caverject®, Edex®) to  
 intraurethral inserts (Muse®) to the more recent introduction of  
 oral phosphodiesterase inhibitors such as **sildenafil** citrate  
 (Viagra®), **tadalafil** (Cialis®) and **vardeafil**  
 (Levitra®). Injectable preparations and intraurethral devices can  
 cause local irritation problems.  
 SUMM . . . . only part of what makes the sexual act enjoyable for the woman  
 but also enhances her response to coitus upon **clitoral stimulation**.  
**Clitoral stimulation** can induce local autonomic and somatic reflexes  
 causing vaginal vasocongestion, engorgement, and subsequent  
 transudation, lubricating the introital canal making the . . .

L16 ANSWER 3 OF 48 USPATFULL on STN

Full Text

AN 2005:214622 USPATFULL  
 TI Method of using a compound of menthol and L-arginine as a preparation  
 for the topical delivery of **vardeafil** for the treatment of female  
 sexual dysfunction  
 IN Thompson, James M., Cincinnati, OH, UNITED STATES  
 Thompson, Justin R., Cincinnati, OH, UNITED STATES  
 Thompson, Ronald J., Ft. Thomas, KY, UNITED STATES  
 PI US 2005186294 A1 20050825  
 TI Method of using a compound of menthol and L-arginine as a preparation  
 for the topical delivery of **vardeafil** for the treatment of female  
 sexual dysfunction  
 AB A manual application of a topical **clitoral sensitizing** compound  
 combination in an applicator, consisting essentially of L-arginine and a  
 cooling agent comprised of Menthol and **vardeafil**, wherein the  
 combination is applicable manually to the clitoris.  
 SUMM . . . . "Composition and method of use in treating sexual dysfunction  
 using cGMP-specific PDE-5 inhibitors," Niazi writes of the benefits of  
 using **sildenafil** in combination with L-arginine for the treatment of  
 sexual dysfunction. Applied Mar. 26, 2001, and issued Jan. 15, 2002,  
 U.S. . . . the use of a 5-PDE inhibitor but does not reference a  
 specific vehicle needed to carry a large molecule like **sildenafil**

across the mucous membrane into the corpus cavernosa. In U.S. Pat. No. 6,403,658, titled "Genital Vasodilatation," Niazi references **sildenafil** as a smooth muscle cell relaxant for increasing blood flow to the genitals.

SUMM . . . . . Inhibitors," writes of the potential benefit of using phosphodiesterase inhibitors for the treatment of female sexual dysfunction. This patent references **sildenafil** and **tadalafil** as two phosphodiesterase type-5 specific inhibitors that could be used.

SUMM **Vardenafil**

SUMM . . . . . molecule. Even when topically applied to the mucous membrane, which is more absorptive than hairy skin, the size of the **vardenafil** molecule, a 5 phosphodiesterase inhibitor, with a large molecular weight, 579.2 g/Mol, requires the aid of a vehicle, or absorbing. . . .

SUMM **Vardenafil** is a potent 5 Phosphodiesterase Inhibitor, a molecule that blocks the degradation of cGMP by specifically binding to the catalytic site of 5 Phosphodiesterase molecules. Blount et al, in "Binding of Titrated **Sildenafil**, **Tadalafil**, or **Vardenafil** to the Phosphodiesterase-5 Catalytic Site Displays Potency, Specificity, Heterogeneity, and cGMP Stimulation," found that the "absolute potency values were similar for each inhibitor, and the relative potencies were **vardenafil**>**tadalafil**>**sildenafil**." **Vardenafil**, **sildenafil**, and **tadalafil** are a group of inhibitors that bind restrictively to the catalytic domain of 5 Phosphodiesterase; "all three inhibitors also bind. . . . and  $K_D$  (binding isotherm) values for each of the three inhibitors and were found to be 41:2:1 and 13:2:1 for **vardenafil**, **tadalafil** and **sildenafil**, respectively. The higher potency of **vardenafil** is due to differences in its double ring molecular structure. Blount also reported that increases in temperature closer to the normal human body temperature led to "increased **vardenafil** binding in the presence of cGMP," for 30 degrees Celsius versus 4 degrees Celsius. In vitro testing performed by Blount's group has also confirmed 100% inhibition of 5 Phosphodiesterase activity by the **vardenafil** molecule, where at similar Molar concentrations **sildenafil** and **tadalafil** were only 85% and 75% respectively.

SUMM . . . . . vessels in the mucous membrane of the clitoral tissues and functions as a vehicle to facilitate the transport of the **vardenafil** and L-arginine across the mucous membrane. Menthol has been shown clinically to increase membrane permeability by 2-4 times and decrease. . . . molecular weight 288.42 g/Mol (Kaplan Frischoff et al). This increased permeability from the Menthol component allows both the L-arginine and **vardenafil** to cross the membrane and enter the corpus cavernosa.

SUMM . . . . . be expected from the dual mechanisms of the menthol/L-arginine induction and fueling of cyclic GMP production, and then by the **vardenafil** inhibition of cyclic GMP degradation. In both of the above mechanisms, nitric oxide (NO), is the intermediate signaler, or messenger,. . . . potent vasodilator but is readily degraded as described above. The dual mechanism of action of the combination of menthol/L-arginine and **vardenafil** can be accurately described as different front-end and back-end mechanisms of action. Both the front-end mechanism of action and the. . . .

SUMM . . . . . enzyme, iNOS. The back-end mechanism of action is the PDE-5 inhibition by the action of the potent specific PDE-5 inhibitor, **vardenafil**. By combining the front-end and the back-end mechanisms of action together, multiple benefits can not only be expected, but confirmed by clinical trials using the topical menthol/L-arginine and **vardenafil** to increase blood flow to the clitoris and therefore increase in a woman's sexual responsiveness. One benefit of the combination. . . .

SUMM . . . . . and somewhat obscure rationale, is the utilization of the synergistic dual mechanisms of the action of the menthol/L-arginine and the **vardenafil** to increase the effectiveness of the topical combination with each successive use. McCullough et al studied the effectiveness of oral **sildenafil** in men. Titled "Intercourse success rates with **sildenafil** citrate," McCullough found that **sildenafil** was only 54% effective after its first use to create a penile erection. By the eighth use, the effectiveness of **sildenafil** had increased to 86%. This effect, increased effectiveness with increased usage, is biochemically and physiologically explained by the increasing concentrations. . . .

SUMM . . . . . oxide synthase enzyme concentrations can be expected to increase dramatically; even between the first and second use of the

topical menthol/L-arginine/**varденаfil** combination. This dramatic increase in nitric oxide synthase enzyme concentrations, counter acting the effects of aging, would be expected to. . . corpus cavemosa vasodilatation and maximize women's sexual responsiveness even with the second or third use of the topical combination of menthol/L-arginine/**varденаfil**.

SUMM . . . to the activity level of the nitric oxide synthase isoenzymes. A more specific medical reference relates the in-vitro pathway of **varденаfil** to accomplish vasodilatation and corpus cavemosa smooth muscle dilatation to effect a clitoral or penile erection. Dr. J S Kalsi et al in the February 2003 Journal of Urology reported that **varденаfil** resulted in concentration dependant relaxation of human and rabbit cavernosum in "BA741-2272, a novel nitric oxide independent soluble guanglate cyclase.

SUMM 2004 **Varденаfil** 1%/CSC vs. CSC Clinical Trial

SUMM Each woman was asked to use CSC at least 3 times and then use the **Varденаfil** 1%/CSC at least 3 times before reporting results

SUMM Percentage of Participants (n/N) Reporting an Increase in Rating over CSC

TABLE 2A\*

**Varденаfil** 1%/CSC Percentage Rating  
Increase Over CSC (0-5); 2.5 = CSC

	N=	Arousal Lubrication.	Speed to	Ease of Achieving	Orgasm	Multiple
40-49	45.5%	45.5%	16.3%	81.8%	78.2%	27.3%
50-59	50.0%	55.0%	65.0%	75.0%	75.0%	10.0%
Overall	43.6%	45.4%	75.5%*	77.3%*	77.3%*	21.8%
Avg						

\*Essentially, all participants reported the **Varденаfil** 1%/CSC was a better product than the CSC alone to help achieve more intense orgasms

Combined Data: Added "Value" of **Varденаfil** 1% in the CSC Formula:  
(1+% Rating Inc over CSC)×% Participants Reporting Increase of V1  
% CSC

SUMM 1. Lubrication speed and quality is not improved by **varденаfil** 1%/CSC over CSC

SUMM 2. Increased orgasm percentage and increased orgasm intensity are very significantly improved with the **varденаfil** 1%/CSC compared to the CSC alone

SUMM . . . is the ability to achieve a meaningful orgasm, and all of the validated instruments measure sexual satisfaction for FSD, the **varденаfil** 1%/CSC can be confidently predicted to establish efficacy over placebo with statistically significant results.

DETD . . . invention relates to a manually applicable topical preparation comprising a compound of menthol or a menthol substitute, and L-arginine, and **varденаfil** as that topical compound. This manually applicable compound is to be manually applied directly to a woman's clitoris, for the treatment of female sexual dysfunction. **Varденаfil** in one preferred embodiment may preferably comprise less than 10% of that topical compound.

DETD The invention thus comprises a manual application of a topical **clitoral sensitizing** combination consisting essentially of L-arginine and a cooling agent comprised of menthol and **varденаfil** wherein the combination is applicable manually to the clitoris.

DETD . . . 10% menthol and the combination may contain less than 10% L-arginine and also the combination may contain less than 10% **varденаfil**.

CLM What is claimed is:

1. A manual application from an applicator of a topical **clitoral sensitizing** combination consisting essentially of L-arginine and a cooling agent comprised of Menthol and **varденаfil**, wherein said combination is applicable manually to the clitoris.

. . . contains less than 10% menthol and said combination contains less than 10% L-arginine and said combination contains less than 10% **varденаfil**.

. . . cyclic GMP induced production, via the actions of menthol and L-arginine, and the inhibition of the cyclic GMP degradation, by **vardenafil** in said compound, to create said vasodilatation and stimulation of the female clitoris.

. . . stimulation of the female clitoris, as recited in claim 17, by the step of: decreasing the dosage of menthol/L-arginine and/or **vardenafil** when topically applied to the female clitoris, to achieve said effective vasodilatation and maximum stimulation of the female clitoris.

19. A method to stimulate the female clitoris by the step of: utilizing menthol as a vehicle for **vardenafil** transport across the mucous membrane into the clitoral corpus cavernosa.

. . . for the production of cyclic GMP to therefore maximize the vasodilatation of the clitoral corpus cavernosa by the actions of **vardenafil** to inhibit the enzymatic degradation of that cyclic GMP.

L16 ANSWER 4 OF 48 USPATFULL on STN

Full Text

AN 2005:105565 USPATFULL

TI 5-HT receptor ligands and uses thereof

IN Chiang, Phoebe, East Lyme, CT, UNITED STATES

Novomisle, William A., Stonington, CT, UNITED STATES

Welch, Willard M. JR., Mystic, CT, UNITED STATES

Guzman-Perez, Angel, Stonington, CT, UNITED STATES

DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES

Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES

Liu, Kevin K., East Lyme, CT, UNITED STATES

PI US 2005090503 A1 20050428

DETD . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE<sub>1</sub>) that are injected or administered transurethrally in men and topically to the genitalia in women.

DETD . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or.

DETD More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);

DETD (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphephenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples.

DETD 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433); and.

DETD According to a further aspect the present invention provides a composition for the treatment of MED comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.

DETD . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.

DETD According to a further aspect, the present invention provides a composition for the treatment of FSD comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.

DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and clitoral sensitivity.

DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response.

L16 ANSWER 5 OF 48 USPATFULL on STN

Full Text

AN 2005:82051 USPATFULL  
TI Compounds for the treatment of female sexual dysfunction  
IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM  
Wayman, Christopher Peter, Sandwich, UNITED KINGDOM  
PI US 2005070499 A1 20050331  
SUMM . . . that promote circulation to the male genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, **Sildenafil**), and prostaglandin (PGE<sub>1</sub>-Alprostadil) that are injected or administered transurethtrally in men, and topically to the genitalia in women.  
SUMM . . . engorgement. This will result in increased vaginal lubrication via plasma transudation, increased vaginal compliance and increased genital (e.g. vaginal and clitoral) sensitivity. Hence, the present invention provides a means to restore, or potentiate, the normal sexual arousal response.  
DETD . . . combination with one or more other pharmaceutically active agents, such as a P<sup>cGMP</sup> (such a phosphodiesterase type 5 inhibitor eg **Sildenafil**, or a nitric oxide donor, or a nitric oxide precursor eg L-arginine or inhibitors of arginase) and/or a centrally acting. . . or in the alternative, the agent may be used in combination with one or more of: a PDE5 inhibitor (eg **sildenafil**, **ildenafil** (Bayer BA 38-9456) and IC351 (Cialis, Icos Lilly)), one or more of a nitric oxide donor (eg NMI-921), one or.  
DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and clitoral sensitivity.  
DETD . . . Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805.  
DETD [1153] Kaplan, S. A., Reis, R. B., Kohm, I. J. et al. (1999). Safety and efficacy of **sildenafil** in postmenopausal women with sexual dysfunction. Urology, 53, 481-486.

L16 ANSWER 6 OF 48 USPATFULL on STN

Full Text

AN 2005:63614 USPATFULL  
TI 5-HT receptor ligands and uses thereof  
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES  
Novomisle, William A., Stonington, CT, UNITED STATES  
Welch, Willard M., JR., Mystic, CT, UNITED STATES  
PI US 2005054656 A1 20050310  
DETD . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE<sub>1</sub>) that are injected or administered transurethtrally in men and topically to the genitalia in women.  
DETD . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or.  
DETD [0233] More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);  
DETD [0236] (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples.  
DETD [0237] 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**ildenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433); and.

DETD . . . . aspect the present invention provides a composition for the treatment of MED comprising a compound of the present invention and **sildenafil**.

DETD . . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.

DETD . . . . aspect, the present invention provides a composition for the treatment of FSD comprising a compound of the present invention and **sildenafil**.

DETD . . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.

DETD . . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic.

L16 ANSWER 7 OF 48 USPATFULL on STN

Full Text

AN 2005:38129 USPATFULL

TI 5-HT receptor ligands and uses thereof

IN Chiang, Phoebe, East Lyme, CT, UNITED STATES  
Novomisle, William A., Stonington, CT, UNITED STATES  
Welch, Willard M., JR., Mystic, CT, UNITED STATES

PI US 2005032809 A1 20050210  
US 6995159 B2 20060207

DETD . . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE<sub>1</sub>) that are injected or administered transurethrally in men and topically to the genitalia in women.

DETD . . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or.

DETD [0230] More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);

DETD [0233] (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2', 1':6, 1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples.

DETD [0234] 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5, 1-f][1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5, 1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433);

DETD . . . . aspect the present invention provides a composition for the treatment of MED comprising a compound of the present invention and **sildenafil**.

DETD . . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.

DETD . . . . aspect, the present invention provides a composition for the treatment of FSD comprising a compound of the present invention and **sildenafil**.

DETD . . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.

DETD . . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic.

L16 ANSWER 8 OF 48 USPATFULL on STN

Full Text

AN 2005:24055 USPATFULL  
TI 5-HT receptor ligands and uses thereof  
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES  
Novomisle, William A., Stonington, CT, UNITED STATES  
Welch, Willard M., JR., Mystic, CT, UNITED STATES  
Guzman-Perez, Angel, Stonington, CT, UNITED STATES  
DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES  
Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES  
Liu, Kevin K., East Lyme, CT, UNITED STATES  
PI US 2005020604 A1 20050127  
SUMM . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE<sub>1</sub>) that are injected or administered transurethraly in men and topically to the genitalia in women.  
SUMM . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or . . .  
SUMM [0170] More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)4-ethoxyphenyl]sulphonyl]4-methylpiperazine (see EP-A-0463756);  
SUMM [0173] (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples. . .  
SUMM [0174] 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433);  
SUMM [0176] According to a further aspect the present invention provides a composition for the treatment of MED comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.  
SUMM . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.  
SUMM [0206] According to a further aspect, the present invention provides a composition for the treatment of FSD comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.  
DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and clitoral sensitivity.  
DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic.

L16 ANSWER 9 OF 48 USPATFULL on STN

Full Text

AN 2005:23998 USPATFULL  
TI Compounds for the treatment of female sexual dysfunction  
IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM  
Wayman, Christopher Peter, Sandwich, UNITED KINGDOM  
PI US 2005020547 A1 20050127  
SUMM . . . that promote circulation to the male genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, **Sildenafil**), and prostaglandin (PGE<sub>1</sub>-Alprostadil) that are injected or administered transurethraly in men, and topically to the genitalia in women.  
SUMM . . . engorgement. This will result in increased vaginal lubrication via plasma transudation, increased vaginal compliance and increased genital (e.g. vaginal and clitoral) sensitivity. Hence, the present invention provides a means to restore, or potentiate, the normal sexual arousal response.  
DETD . . . combination with one or more other pharmaceutically active agents, such as a P<sub>CAMP</sub> (such a phosphodiesterase type 5 inhibitor

eg **Sildenafil**, or a nitric oxide donor, or a nitric oxide precursor eg L-arginine or inhibitors of arginase) and/or a centrally acting. . . or in the alternative, the agent may be used in combination with one or more of: a PDE5 inhibitor (eg **sildenafil**, **ildenafil** (Bayer BA 38-9456) and IC351 (Cialis, Icos Lilly)), one or more of a nitric oxide donor (eg NMI-921), one or. . .

DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.  
 DETD . . . Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805.  
 DETD [1155] Kaplan, S. A., Reis, R. B., Kohm, I. J. et al. (1999). Safety and efficacy of **sildenafil** in postmenopausal women with sexual dysfunction. Urology, 53, 481-486.

L16 ANSWER 10 OF 48 USPATFULL on STN

Full Text

AN 2004:326954 USPATFULL  
 TI Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of a 5-phosphodiesterase inhibitor for the treatment of female sexual dysfunction  
 IN Thompson, Ronald J., Ft. Thomas, KY, UNITED STATES  
 Thompson, James M., Cincinnati, OH, UNITED STATES  
 PI US 2004258774 A1 20041223  
 AB A manual application of a topical **clitoral sensitizing** compound combination consisting essentially of L-arginine and a cooling agent comprised of Menthol and a 5-phosphodiesterase inhibitor, wherein the combination. . .  
 SUMM [0003] The compound **Sildenafil**, known by the trademark **Viagra**®, is a 5-phosphodiesterase inhibitor that has proven to be a successful therapy for male erectile dysfunction. **Sildenafil** is an oral tablet. In a double-blind, placebo controlled clinical study of 583 women with diagnosed female sexual dysfunction; oral **sildenafil** was no more effective than a placebo. This study was conducted by Dr. Rosemary Basson.  
 SUMM [0004] Over several years, compounding pharmacists have attempted to develop a topical preparation of **sildenafil** to treat women with female sexual dysfunction, but this has proven less than effective because of the size of the **Sildenafil** molecule. Even when topically applied to the mucous membrane, which is more absorptive than hairy skin, the size of the **sildenafil** molecule requires the aid of a vehicle, or absorbing agent, to allow absorption of the **sildenafil** into the corpus cavernosa of the clitoris. The menthol component of the menthol/L-arginine combination acts as an immediate vasodilator of the vessels in the mucous membrane and functions as a lipophilic vehicle to facilitate the transport of the **Sildenafil** across the mucous membrane.  
 DETD [0009] The invention thus comprises a manual application of a topical **clitoral sensitizing** combination consisting essentially of L-arginine and a cooling agent comprised of Menthol and a 5-phosphodiesterase inhibitor, wherein the combination is. . .  
 CLM What is claimed is:  
 1. A manual application of a topical **clitoral sensitizing** combination consisting essentially of L-arginine and a cooling agent comprised of Menthol and a 5-phosphodiesterase inhibitor, wherein said combination is. . .

L16 ANSWER 11 OF 48 USPATFULL on STN

Full Text

AN 2004:321498 USPATFULL  
 TI Compounds for the treatment of female sexual dysfunction  
 IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM  
 Wayman, Christopher Peter, Sandwich, UNITED KINGDOM  
 PI US 2004254153 A1 20041216  
 SUMM . . . that promote circulation to the male genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, **sildenafil**), and prostaglandin (PGE<sub>1</sub>-Alprostadil) that are injected or administered transurethral<sup>1</sup> in men, and topically to the genitalia in women.  
 SUMM . . . engorgement. This will result in increased vaginal lubrication via plasma transudation, increased vaginal compliance and increased



genital (e.g. vaginal and clitoral) sensitivity. Hence, the present invention provides a means to restore, or potentiate, the normal sexual arousal response.

- DETD . . . combination with one or more other pharmaceutically active agents, such as a P<sup>CGMP</sup> (such a phosphodiesterase type 5 inhibitor eg Sildenafil, or a nitric oxide donor, or a nitric oxide precursor eg L-arginine or inhibitors of arginase) and/or a centrally acting. . . or in the alternative, the agent may be used in combination with one or more of: a PDE5 inhibitor (eg sildenafil, vardenafil (Bayer BA 38-9456) and IC351 (Cialis, Icos Lilly)), one or more of a nitric oxide donor (eg NMI-921), one or. . .
- DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and clitoral sensitivity.
- DETD . . . Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of sildenafil on physiological parameters of the female sexual response. J. Urol., 161, 805.
- DETD [1158] Kaplan, S. A., Reis, R. B., Kohm, I. J. et al. (1999). Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology, 53, 481-486.

L16 ANSWER 12 OF 48 USPATFULL on STN

Full Text

- AN 2004:116764 USPATFULL
- TI Compounds for the treatment of female sexual dysfunction
- IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM  
Wayman, Christopher Peter, Sandwich, UNITED KINGDOM
- PI US 6734186 B1 20040511
- SUMM . . . that promote circulation to the male genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, Sildenafil), and prostaglandin (PGE<sub>1</sub>-Alprostadil) that are injected or administered transurethraly in men, and topically to the genitalia in women.
- SUMM . . . engorgement. This will result in increased vaginal lubrication via plasma transudation, increased vaginal compliance and increased genital (e.g. vaginal and clitoral) sensitivity. Hence, the present invention provides a means to restore, or potentiate, the normal sexual arousal response.
- DETD . . . combination with one or more other pharmaceutically active agents, such as a P<sup>CGMP</sup> (such a phosphodiesterase type 5 inhibitor eg Sildenafil, or a nitric oxide donor, or a nitric oxide precursor eg L-arginine or inhibitors of arginase) and/or a centrally acting. . . or in the alternative, the agent may be used in combination with one or more of: a PDE5 inhibitor (eg sildenafil, vardenafil (Bayer BA 38-9456) and IC351 (Cialis, Icos Lilly)), one or more of a nitric oxide donor (eg NMI-921), one or. . .
- DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and clitoral sensitivity.
- DETD Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of sildenafil on physiological parameters of the female sexual response. J. Urol., 161, 805.
- DETD Kaplan, S. A., Reis, R. B., Kohm, I. J. et al. (1999). Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology, 53, 481-486.

L16 ANSWER 13 OF 48 USPATFULL on STN

Full Text

- AN 2004:114715 USPATFULL
- TI Treatment of sexual dysfunction
- IN Gonzalez, Maria Isabel, Sandwich, UNITED KINGDOM  
Higginbottom, Michael, Sandwich, UNITED KINGDOM  
Naylor, Alisdair Mark, Sandwich, UNITED KINGDOM  
Pinnock, Robert Denham, Ann Arbor, MI, UNITED STATES  
Pritchard, Martyn Clive, Sandwich, UNITED KINGDOM  
Stock, Herman Thijs, Sandwich, UNITED KINGDOM  
Van Der Graaf, Pieter Hadewijn, Sandwich, UNITED KINGDOM  
Wayman, Christopher Peter, Sandwich, UNITED KINGDOM
- PI US 2004087561 A1 20040506
- SUMM . . . be administered orally, therefore obviating the disadvantages

associated with i.c. administration. One such compound that is currently being manufactured is **sildenafil** (Viagra).

DETD . . . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**. Female sexual arousal disorder (FSAD) is a highly prevalent sexual disorder affecting up to 40% of pre-, peri- and postmenopausal.

DETD . . . . . treatment of sexual dysfunction include alprostadil or phentolamine, NO (nitric oxide) enhancers such as L-arginine, and PDE5 inhibitors such as **sildenafil** or a pharmaceutically acceptable salt thereof (Scrip's Complete Guide to Women's Healthcare, p.194-205, 2000) (Sachs B. D., 2000, Benet and Melman, . . . . .

DETD [0457] 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1R-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);

DETD [0468] 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**varidenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine, i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433; and

DETD . . . . . Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805.

IT 58-22-0, Testosterone 71-58-9, Medroxyprogesterone acetate 520-85-4, Medroxyprogesterone 521-18-6, Dihydrotestosterone 37221-79-7, Vasoactive intestinal peptide 37221-79-7D, Vasoactive intestinal peptide, analogs 139755-83-2, Sildenafil 147676-53-7 171596-29-5, IC-351 215297-27-1 224785-90-4, Vardenafil 334826-98-1 334827-47-3 334827-59-7 335077-64-0 335077-70-8 389128-36-3  
(treatment of male sexual dysfunction using neutral endopeptidase inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

L16 ANSWER 14 OF 48 USPATFULL on STN

Full Text

AN 2004:83187 USPATFULL

TI Bombesin antagonists

IN Higginbottom, Michael, Sandwich, UNITED KINGDOM  
Kesten, Suzanne Ross, Ann Arbor, MI, UNITED STATES  
Lewthwaite, Russell Andrew, Sandwich, UNITED KINGDOM  
Pritchard, Martyn Clive, Sandwich, UNITED KINGDOM  
Rawson, David James, Sandwich, UNITED KINGDOM  
Schelkun, Robert Michael, Ann Arbor, MI, UNITED STATES  
Yuen, Po-Wai, Ann Arbor, MI, UNITED STATES

PI US 2004063643 A1 20040401

DETD . . . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors e.g. **Sildenafil**), and prostaglandin (PGE<sub>1</sub>) that are injected or administered transurethrally in men, and topically to the genitalia in women.

DETD [0425] Further suitable PDE5 inhibitors for the use according to the present invention include: 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756); 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see EP-A-0526004); 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO98/49166); 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO99/54333); (+)-3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methylethoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4',3-d]pyrimidin-7-one, also known as . . . 95 of published international application WO95/19978, as well as the compound of

examples 1, 3, 7 and 8; 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)-1-sulphonyl]-phenyl]-5-methyl-7-propyl-3H-imidazo[5, 1-f][1,2,4]triazin-4-one (**ildenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine, i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433; and. . .

DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.  
 DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic.

L16 ANSWER 15 OF 48 USPATFULL on STN

Full Text

AN 2004:77410 USPATFULL  
 TI Method of colpoplasty  
 IN Matlock, David L., Los Angeles, CA, UNITED STATES  
 PI US 2004059190 A1 20040325  
 SUMM . . . on an understanding of the physiology of the male erectile response, recent advances in modern technology, including the commonly prescribed **sildenafil**, and recent interest in women's health issues, the study of female sexual dysfunction has gradually evolved. Study in this area. . .  
 DETD [0019] The term "climax" means orgasm whether by vulvar, vaginal, cervical or **clitoral stimulation**.  
 DETD . . . from the hypogastric plexus and the pelvic nerve and in which stimulation may result in climax apart from or including **clitoral stimulation**. It is understood that the anatomy of the GS area will be subject specific and may occupy varying locations and. . .  
 DETD . . . and/or testosterone cream for treatment of inhibited desire and/or vaginismus in pre-menopausal women. Potential benefits of this therapy include increased **clitoral sensitivity**, increased vaginal lubrication, increased libido, and heightened arousal. Potential side effects of testosterone administration, however, are significant, and whether topical. . .  
 DETD [0043] **Sildenafil**, the medication commonly known as Viagra®, serves to increase relaxation of clitoral and vaginal smooth muscle and blood flow to. . . J R, Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes. Int. J. Impot. Res. 10: 84-90 (1998). **Sildenafil**, in combination with other vasoactive substances, may be used for treatment of female sexual arousal disorder. In combination with colpoplasty. . .  
 DETD [0044] Clinical studies evaluating safety and efficacy **sildenafil** in women with SAD are in progress. Several studies are already published demonstrating efficacy of **sildenafil** for treatment of FSD secondary to Serum Serotonin Reuptake Inhibitor (SSRI) use. Park K, Goldstein I, Andry C, et al.: . . . and clitoral erectile insufficiency. Int. J. Impoten. Res. 9: 27-37 (1988); Nurnberg H G, Lodillo J, Hensley P, et al., **Sildenafil** for iatrogenic serotonergic antidepressant medication-induced sexual dysfunction in 4 patients. J. Clin. Psych. 60(1): 33 (1999).  
 DETD . . . often during sexual intercourse does the subject reach climax  
     50.7%                      82.7%  
 Time (min.) for does the subject to reach climax via **clitoral stimulation**  
     16.3 min                      10.0 min.  
 Was subject ever able to reach climax through stimulation of GS area  
     (33.3%/no) (40.0%/unsure) (13.3%/no) (6.7%/unsure)

L16 ANSWER 16 OF 48 USPATFULL on STN

Full Text

AN 2004:19457 USPATFULL  
 TI Treatment of female sexual dysfunction with phosphodiesterase inhibitors  
 IN Place, Virgil A., Kawaihae, HI, UNITED STATES  
     Wilson, Leland F., Menlo Park, CA, UNITED STATES  
     Doherty, Paul C., JR., Cupertino, CA, UNITED STATES  
     Hanamoto, Mark S., Belmont, CA, UNITED STATES  
     Spivack, Alfred P., Menlo Park, CA, UNITED STATES  
     Gesundheit, Neil, Los Altos, CA, UNITED STATES

Bennett, Sean R., Denver, CO, UNITED STATES  
Doherty, Jane, Cupertino, CA, UNITED STATES LR  
PI US 2004014761 A1 20040122

SUMM . . . It also includes decreases in the physiological response to sexual stimulation such as slowed or decreased erectile response of the female erectile tissues; slowed, decreased or absent lubrication of the vagina; slowed, decreased, or absent ability to have orgasms; decreased intensity of.

SUMM . . . Seiyaku Co., Ltd.), particularly (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-pyrimidinylmethyl)carbamoyl]pyrimidine, 2-(5,6,7,8-tetrahydro-1,7-naphthyridin-7-yl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-morpholinoethyl)carbamoyl]pyrimidine, and (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(1,3,5-trimethyl-4-pyrazolyl)carbamoyl]pyrimidine; zaprinast (1,4-dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo[4,5-d]pyrimidin-7-one); 1-(3-chloroanilino)-4-phenylphthalazine (MY5445); dipyridamole, vinpocetine; FR229934 (Fujisawa Pharmaceutical Co., Ltd.); 1-methyl-3-isobutyl-8-(methylamino)xanthine; **tadalafil** (IC-351; **Cialis**®); **ildenafil** (Bayer); 4-aryl-1-isoquinolinone derivatives such as methyl 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate dihydrochloride and the sulfate salt thereof (T-1032); 4-bromo-5-(pyridylmethylamino)-6-[3-(4-chlorophenyl)propoxy]-3(2H)pyridazinone; 1-[4-[(1,3-benzodioxol-5-ylmethyl)amino]-6-chloro-2-quinazolinyl]-4-piperidine-carboxylic acid, monosodium.

SUMM [0041] Particularly preferred Type V phosphodiesterase inhibitors for use in conjunction with the present invention are **sildenafil** (5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-dipyrimidin-7-one]), **tadalafil**, **ildenafil**, zaprinast, dipyridamole, and the compounds of WO 01/19802 to Aoyama, particularly those identified above.

SUMM . . . the physiological response to sexual stimulation such as, but not limited to, slowed, decreased or absent erectile response of the female erectile tissues; slowed, decrease or absent lubrication of the vagina; slowed decreased or absent ability to reach orgasm, and decreased intensity.

DETD [0096] A cream formulation is prepared for the topical administration of **sildenafil**. The cream includes the following components:

<b>Sildenafil</b>	500	mg
Beeswax	2.7	g
Carbopol ® 934 q.s.	100.0	g

DETD [0098] The procedure of Example 1 is repeated except that the following components are used:

<b>Sildenafil</b>	3.5	g
Polyethylene glycol 400	37.5	g
1,2,6-hexanetriol	20.0	g
Polyethylene glycol 4000 q.s.	100.0	g

DETD [0100] The procedure of Example 1 is repeated except that the following components are used:

<b>Tadalafil</b>	1.0	g
Polyethylene glycol 400	37.0	g
Polyethylene glycol 400 monostearate	26.0	g
Polyethylene glycol 4000 q.s.	100.0	g

DETD [0104] A vaginal suppository formulation is prepared for the administration of **sildenafil**. The suppository includes the following components:

<b>Sildenafil</b>	5.0	g
Polyethylene glycol 400	37.0	g
Glycerol gelatin	20.0	g
Polyethylene glycol 4000 q.s.	100.0	g

DETD [0106] A vaginal suppository formulation A gel preparation of **sildenafil** was prepared by admixing 2.5 g **sildenafil** with 100 g of high purity soybean lecithin (Sigma Chemical Company, St. Louis, Mo.).

Then, water was slowly added with.

DETD [0107] A liposomal solution is prepared as follows. Either an aqueous or oil-based solution of **tadalafil** and an optional additional active agent can be added to a liposomal mixture of, for example, 10 g of safflower. . . phosphatides, and 2.5 g of glycerin in a final volume of 100 ml (the remainder being water). Two mg of **tadalafil** may be added, and the resulting mixture then stirred until all components are dissolved. Liposomal solutions are particularly favored for. . .

CLM What is claimed is:

11. The pharmaceutical formulation of claim 10, wherein the Type V phosphodiesterase inhibitor is selected from **sildenafil** and acid addition salts thereof.

12. The pharmaceutical formulation of claim 8, wherein the Type V phosphodiesterase inhibitor is **tadalafil**.

15. The pharmaceutical formulation of claim 8, wherein the Type V phosphodiesterase inhibitor is **vardenafil**.

IT 139755-83-2, Sildenafil 171596-29-5, Tadalafil 330784-47-9  
(phosphodiesterase inhibitors for treatment of female sexual dysfunction)

IT 53-43-0, Dehydroepiandrosterone 57-85-2, Testosterone propionate 58-18-4, Methyltestosterone 58-20-8, Testosterone cypionate 58-22-0, Testosterone 58-55-9, Theophylline, biological studies 58-74-2, Papaverine 76-43-7, Fluoxymesterone 315-37-7, Testosterone enanthate 363-24-6, Pge2 521-18-6, 5 $\alpha$ -DihydroTestosterone 521-18-6D, 5 $\alpha$ -DihydroTestosterone, esters 745-65-3, Pge1 855-22-1, 5 $\alpha$ -DihydroTestosterone propionate 968-93-4, Testolactone 1045-69-8, Testosterone acetate 1164-91-6, 5 $\alpha$ -DihydroTestosterone acetate 1169-49-9, Testosterone isobutyrate 2381-64-8 5704-03-0, Testosterone phenylacetate 5721-91-5, Testosterone caprate 5949-44-0, Testosterone undecanoate 6493-05-6, Pentoxifylline 6804-12-2, 5 $\alpha$ -DihydroTestosterone undecanoate 19313-28-1, Pge0 28822-58-4, Ibmx 29925-17-5, Ro 20-1724 33776-88-4 37762-06-4, Zaprinast 51022-77-6, Etazolate 57076-71-8, Denbufylline 57361-80-5, Testosterone isocaproate 60719-84-8, Amrinone 61413-54-5, Rolipram 68475-42-3, Anagrelide 68550-75-4, Cilostamide 68728-46-1 73963-72-1, Cilostazol 74150-27-9, Pimobendan 78415-72-2, Milrinone 79030-08-3, Griseolic acid 79855-88-2, Trequinsin 81840-15-5, Vesnarinone 84490-12-0, Piroximone 86315-52-8, Isomazole 86798-59-6 89541-55-9 90880-94-7, Endothelium-derived relaxation factor 94192-59-3, Lixazinone 105165-22-8, Testosterone buciclate 112018-01-6, Bemoradan 114918-24-0, CP-77059 115344-47-3, Siguzodan 120223-30-5, EMD 54622 136145-07-8, Arofylline 151029-65-1 152814-89-6, RS-25344-00 224785-90-4, Vardenafil 330784-47-9 330785-79-0 488836-67-5 646505-32-0 646505-33-1  
(phosphodiesterase inhibitors for treatment of female sexual dysfunction)

L16 ANSWER 17 OF 48 USPATFULL on STN

Full Text

AN 2003:325098 USPATFULL

TI Indole derivatives as pde5-inhibitors

IN Orme, Mark W, Seattle, WA, UNITED STATES  
Sawyer, Jason Scott, Indianapolis, IN, UNITED STATES  
Schultze, Lisa M, Woodinville, WA, UNITED STATES

PI US 2003229080 A1 20031211  
US 6878711 B2 20050412

SUMM . . . prophylaxis of stroke, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and female erectile dysfunction, or diseases characterized by disorders of gut motility (e.g., IBS).

IT 171596-29-5P 171596-43-3P 422311-84-0P 422311-85-1P  
(prepn. of pyrazino[1',2':1,6]pyrido[3,4-b]indole derivs. as phosphoesterase inhibitors for use as therapeutic agents)

L16 ANSWER 18 OF 48 USPATFULL on STN

Full Text

AN 2003:300913 USPATFULL

TI Methods, compositions, and kits for enhancing female sexual desire and responsiveness  
 IN Neal, Gary W., Knoxville, TN, UNITED STATES  
 PI US 2003212139 A1 20031113  
 SUMM . . . . It also includes decreases in the physiological response to sexual stimulation such as slowed or decreased erectile response of the female erectile tissues; slowed, decreased or absent lubrication of the vagina; slowed, decreased, or absent ability to have orgasms; decreased intensity of. . . .  
 SUMM . . . . but not limited to caffeine, aminophylline, theophylline, amrinone, milrinone, vesnarinone, vinpocetine, pemobendan, cilostamide, enoximone, peroximone, rolipram, R020-1724, zaniprast, dipyridamole, and sildenafil, may also be effective in enhancing the efficacy of the present method and for prolonging the effect;

L16 ANSWER 19 OF 48 USPATFULL on STN

Full Text

AN 2003:294885 USPATFULL  
 TI 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for sexual disfunction  
 IN Wei, Edward T., Berkeley, CA, UNITED STATES  
 PI US 2003207903 A1 20031106  
 SUMM . . . . during sexual arousal, and consequent erection, is a fact of male experience and does not require further description. In females, clitoral stimulation results in increased clitoral length and diameter, increased blood flow and tumescence of associated structures such as the labia folds. . . .  
 SUMM . . . . 1980s, and now the use of transurethral alprostadil (Muse®), topical alprostadil with a enhancer of percutaneous absorption (Topiglan®), and oral sildenafil (Viagra®). The sales of Viagra® in 2001 are estimated to be U.S. \$1.5 billion, but Viagra® has little effect on. . . .

L16 ANSWER 20 OF 48 USPATFULL on STN

Full Text

AN 2003:294873 USPATFULL  
 TI Combination therapy for modulating the human sexual response  
 IN Podolski, Joseph S., The Woodlands, TX, UNITED STATES  
 PI US 2003207891 A1 20031106  
 SUMM [0020] Sildenafil, (Viagra.TM., Pfizer, Inc.) 5-[2-ethoxy-5-(4-methylpiperazine-1-ylsulfonyl)phenyl]-1-methyl-3-propyl-6,7-dihydro-1-H-pyrazolo[4,3-d]pyrimidin-7-one has also been shown to be useful as an oral treatment for male erectile dysfunction. [Martel et al., Sildenafil, Drugs of the Future, 22:138-143 (1997) which is incorporated in its entirety herein by reference.] See also, Boolell et al., . . . . (1996) and Boolell et al., Br.J. Urol., 78:257-261 (1996) both of which are incorporated herein in their entirety by reference. Sildenafil and related compounds are described in EP 0702555B1, which is incorporated herein by reference, is a phosphodiesterase V inhibitor and. . . .  
 SUMM . . . . the quality of the sexual response seen in patients, i.e., the relative rigidity of the erections achieved with for example Sildenafil is variable. [See, Boolell et al., Br. J. Urol., 78:257-261 (1996).] Therefore, there continues to exist a need in the. . . .  
 SUMM . . . . derivatives, amrinone, Vesnarinone, milrinone, rolipram, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, the 5-(2'-alkoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-ones i.e., Sildenafil, (Viagra.TM.) also referred to as 5-[2-ethoxy-5-(4-methylpiperazine-1-ylsulfonyl)phenyl]-1-methyl-3propyl-6,7 dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one (see, Drugs of the Future22(2):138-143 (1997)), or 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3 -propyl-1H-pyrazolo[4,3-d]pyrimidine-5-yl)phenylsulphonyl]4-methylpiperazine (see, Boolell et al., . . . .  
 SUMM . . . . of the present invention are preferably from about 5 mg to about 100 mg while preferred, doses of for example, Sildenafil, in the same tablet are preferably from about 5 mg to about 150 mg. Preferred doses of papaverine, when used. . . .  
 SUMM . . . . limited to xanthine derivatives, amrinone, milrinone, rolipram, Vesnarinone, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, Sildenafil and its citrate, and papaverine. Still other pharmaceutically active agents

useful in the compositions of the invention include dopaminergic antagonists.

- SUMM . . . milrinone, rolipram, Vesnarinone, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, the 5-(2'-alkoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-ones and, in particular, **Sildenafil**, and papaverine.
- SUMM [0057] Other agents that are useful in combination with the alpha-adrenergic antagonist (e.g., phentolamine) and a phosphodiesterase inhibitor (**Sildenafil**) include  $\alpha$ -adrenoceptor antagonists atipamezole, deacetylmoxisylyte HCl, and delequamine HCl. Other compositions include phentolamine and/or **Sildenafil** in combination with a dopaminergic agonist such as apomorpine.
- DETD [0067] Exemplary formulations of a rapidly dissolving tablet that includes phentolamine mesylate and **Sildenafil** are set out below.

TABLE 1

	mg/tablet
Phentolamine Mesylate, USP	40
<b>Sildenafil</b>	50
Silicon Dioxide, NF	8
Stearic Acid, NF	4
Lactose, NF	162
Microcrystalline Cellulose, NF	120
Croscarmellose Sodium, NF	16

- DETD [0074] Other illustrative formulations are set out below.

TABLE 2

	mg/tablet
Phentolamine Mesylate, USP	20
<b>Sildenafil</b> (Viagra .TM.)	50
Silicon Dioxide, NF	8
Stearic Acid, NF	4
Lactose, NF	182
Microcrystalline Cellulose, NF	120
Croscarmellose Sodium, . . .	

- DETD . . . present invention also includes a chewable tablet formulation shown in Table 4.

TABLE 4

	mg/tablet
Phentolamine Mesylate, USP	40
<b>Sildenafil</b>	50
Silicon Dioxide, NF	12
Stearic Acid, NF	12
Lactose, NF	100
Sweetrex	298
Aspartame	40
ProSweet	8
Peppermint Flavor. . . .	

- DETD . . . inhibitors include xanthine derivatives, amrinone, milrinone, rolipram, Vesnarinone, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, **Sildenafil** and papaverine.

- DETD [0093] **Sildenafil** has been shown to be effective at various doses including 25 mg and 50 mg (see Boolell et al., Br. . . .

- DETD . . . comprises about 5 mg to about 100 mg phentolamine mesylate in combination with about 5 mg to about 125 mg **Sildenafil**.

- DETD . . . administration of from about 5 mg to about 100 mg of phentolamine mesylate and about 5 to about 150 mg **Sildenafil** in a rapidly dissolving oral formulation of the present invention from about 1 minute to about 1 hour prior to, . . .

- DETD [0100] As in the case of male sexual response, in the absence of any clinically diagnosed dysfunction in the female erectile response, the methods of the present invention may be used to enhance the normal female sexual response. The "on demand". . . .

DETD . . . rapidly dissolving formulation as set out in Table 5 except that papaverine at the doses indicated below was substituted for Sildenafil. Dosages were as follows:

TABLE 5

	mg/tablet
Phentolamine Mesylate, (alone)	40
Papaverine (alone)	150
Phentolamine Mesylate plus Papaverine. . . .	40
CLM What is claimed is:	
4. The composition of claim 3 wherein the type V cyclic GMP-specific phosphodiesterase inhibitor is 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3d]pyrimidin-5-yl)phenylsulfonyl]-4-methylpiperazine (Sildenafil).	
5. A composition comprising from about 5 mg to about 100 mg phentolamine and from about 5 mg to about 150 mg 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3d]pyrimidin-5-yl)phenylsulfonyl]-4-methylpiperazine (Sildenafil) and a pharmaceutically acceptable carrier.	
. . . comprising from about 5 mg to about 100 mg phentolamine and from about 5 mg to about 150 mg 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3d]pyrimidin-5-yl)phenylsulfonyl]-4-methylpiperazine (Sildenafil) in an orally administrable tablet, the tablet having a disintegration time of less than about twenty minutes.	
IT 50-60-2, Phentolamine 58-00-4, Apomorphine 58-74-2, Papaverine 65-28-1, Phentolamine mesylate 73-05-2, Phentolamine hydrochloride 37221-79-7, Vasoactive intestinal peptide 139755-83-2, Sildenafil (combination therapy for modulating human sexual response)	

L16 ANSWER 21 OF 48 USPATFULL on STN

Full Text

AN 2003:271544 USPATFULL

TI Use of halogenated heterocyclic compounds in the treatment of sexual dysfunction and cardiovascular disease

IN Cutler, Neal R., Los Angeles, CA, UNITED STATES

PI US 2003191152 A1 20031009  
US 7041677 B2 20060509

SUMM [0013] Sildenafil citrate (Viagra) has also been utilized as a pharmacological treatment for impotence. However, sildenafil citrate has a lack of specificity for its target, enzyme phosphodiesterase 5 (PDE5), and exerts a definite inhibition on the. . . has been shown that the inhibition of PDE6 results in color vision defects as a side effect of treatment with sildenafil citrate. Furthermore, side effects such as flushing, headache, nasal congestion, and dyspepsia (heartburn) have also been associated with sildenafil citrate treatment of impotence. (See, Moreira et al., "Side-effect profile of sildenafil citrate (Viagra) in clinical practice," Urology, 56(3): 474-76 (2000)).

SUMM . . . flosequinan derivatives for improving blood flow and supply to female sexual organs, and more particularly, methods for the treatment of female erectile dysfunction. In selected embodiment the methods of the present invention comprise the utilization of these pharmaceutical compositions to induce clitoral. . .

DETD . . . of the penis and the associated facia which produce impotence, the inability to attain a sexually functional erection. In the female "erectile dysfunction" is associated with disorders (including but not limited to impaired blood flow to the clitoris) which impair or prevent.

DETD [0275] C. Diagnosis of Female Erectile Dysfunction

DETD [0282] D. Treatment of Male and Female Erectile Dysfunction

L16 ANSWER 22 OF 48 USPATFULL on STN

Full Text

AN 2003:181501 USPATFULL



TI 5-HT receptor ligands and uses thereof  
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES  
Novomisle, William A., Stonington, CT, UNITED STATES  
Welch, Willard M., JR., Mystic, CT, UNITED STATES  
Guzman-Perez, Angel, Stonington, CT, UNITED STATES  
DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES  
Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES  
Liu, Kevin K., East Lyme, CT, UNITED STATES  
PI US 2003125334 A1 20030703  
US 6894050 B2 20050517  
SUMM . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE<sub>1</sub>) that are injected or administered transurethraly in men and topically to the genitalia in women.  
SUMM . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or . . .  
SUMM [0171] More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methyl piperazine (see EP-A-0463756);  
SUMM [0174] (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples. . .  
SUMM [0175] 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433); and. . .  
SUMM [0176] According to a further aspect the present invention provides a composition for the treatment of MED comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.  
SUMM . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.  
SUMM [0206] According to a further aspect, the present invention provides a composition for the treatment of FSD comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.  
DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and clitoral sensitivity.  
DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic.

L16 ANSWER 23 OF 48 USPATFULL on STN

Full Text

AN 2003:153438 USPATFULL  
TI 5-HT receptor ligands and uses thereof  
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES  
Novomisle, William A., Stonington, CT, UNITED STATES  
Welch, Willard M., JR., Mystic, CT, UNITED STATES  
PI US 2003105106 A1 20030605  
US 6825198 B2 20041130  
SUMM . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE<sub>1</sub>) that are injected or administered transurethraly in men and topically to the genitalia in women.  
SUMM . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or . . .

SUMM [0233] More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);

SUMM [0236] (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2', 1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples.

SUMM [0237] 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433);.

SUMM . . . . . aspect the present invention provides a composition for the treatment of MED comprising a compound of the present invention and **sildenafil**.

SUMM . . . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.

SUMM . . . . . aspect, the present invention provides a composition for the treatment of FSD comprising a compound of the present invention and **sildenafil**.

DETD . . . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and clitoral sensitivity.

DETD . . . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic.

L16 ANSWER 24 OF 48 USPATFULL on STN

Full Text

AN 2003:134652 USPATFULL

TI Novel alpha adrenergic agents

IN Miller, Duane D., Germantown, TN, UNITED STATES  
Hong, Seoung-Soo, Cheongju, KOREA, REPUBLIC OF

PI US 2003092741 A1 20030515  
US 6919357 B2 20050719

SUMM . . . . . included pain, risk of infection, inconvenience, and interference with spontaneity. Within the past few years, Pfizer's orally active product Viagra® (**sildenafil** citrate) has become a break-through treatment for ED. **Sildenafil** is a potent and selective cGMP-specific type 5 phosphodiesterase inhibitor and now represents the first line therapy for the treatment of ED. Despite **sildenafil**'s success, however, numerous patients have not been successfully treated. In addition, **sildenafil** must be administered significantly prior to sexual activity ruining spontaneity and numerous side effects have been reported. The most significant.

SUMM [0022] As in the case of male sexual response, in the absence of a clinically diagnosed dysfunction in the female erectile response, the methods of the present invention may be used to enhance the normal female sexual response. The "on demand".

L16 ANSWER 25 OF 48 USPATFULL on STN

Full Text

AN 2003:4131 USPATFULL

TI Combination therapy for modulating the human sexual response

IN Podolski, Joseph S., The Woodlands, TX, UNITED STATES

PI US 2003004170 A1 20030102

SUMM [0020] **Sildenafil**, (Viagra.TM., Pfizer, Inc.) 5-[2-ethoxy-5-(4-methylpiperazine-1-ylsulfonyl)phenyl]-1-methyl-3-propyl-6,7-dihydro-1-H-pyrazolo[4,3-d]pyrimidin-7-one has also been shown to be useful as an oral treatment for male erectile dysfunction. [Martel et al., **Sildenafil**, Drugs of the Future, 22:138-143 (1997) which is incorporated in its entirety herein by reference.] See also, Boolell et al., . . . . . and Boolell et al., Br. J. Urol, 78:257-261 (1996) both of which are incorporated herein in their entirety by reference. **Sildenafil** and related compounds are described in EP 0702555B1, which

is incorporated herein by reference, is a phosphodiesterase V inhibitor and.

SUMM . . . the quality of the sexual response seen in patients, i.e., the relative rigidity of the erections achieved with for example **Sildenafil** is variable. [See, Boolell et al, Br. J. Urol., 78:257-261 (1996).] Therefore, there continues to exist a need in the.

SUMM . . . derivatives, amrinone, Vesnarinone, milrinone, rolipram, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, the 5-(2'-alkoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-ones i.e., **Sildenafil**, (Viagra.TM.) also referred to as 5-[2-ethoxy-5-(4-methylpiperazine-1-ylsulfonyl) phenyl]-1-methyl-3 propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one (see, Drugs of the Future22(2):138-143 (1997)), or 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidine-5-yl) phenylsulphonyl]4-methylpiperazine (see, Boolell et.

SUMM . . . of the present invention are preferably from about 5 mg to about 100 mg while preferred, doses of for example, **Sildenafil**, in the same tablet are preferably from about 5 mg to about 150 mg. Preferred doses of papaverine, when used.

SUMM . . . limited to xanthine derivatives, amrinone, milrinone, rolipram, Vesnarinone, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, **Sildenafil** and its citrate, and papaverine. Still other pharmaceutically active agents useful in the compositions of the invention include dopaminergic antagonists,.

SUMM . . . milrinone, rolipram, Vesnarinone, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, the 5-(2'-alkoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-ones and, in particular, **Sildenafil**, and papaverine.

SUMM [0056] Other agents that are useful in combination with the alpha-adrenergic antagonist (e.g., phentolamine) and a phosphodiesterase inhibitor (**Sildenafil**) include  $\alpha$ -adrenoceptor antagonists atipamezole, deacetylmoxisylyte HCl, and delequamine HCl. Other compositions include phentolamine and/or **Sildenafil** in combination with a dopaminergic agonist such as apomorpine.

DETD [0066] Exemplary formulations of a rapidly dissolving tablet that includes phentolamine mesylate and **Sildenafil** are set out below.

#### TABLE 1

mg/tablet

Phentolamine Mesylate, USP	40
<b>Sildenafil</b>	50
Silicon Dioxide, NF	8
Stearic Acid, NF	4
Lactose, NF	162
Microcrystalline Cellulose, NF	120
Croscarmellose Sodium, NF	16

DETD [0073] Other illustrative formulations are set out below.

#### TABLE 2

mg/tablet

Phentolamine Mesylate, USP	20
<b>Sildenafil</b> (Viagra .TM. )	50
Silicon Dioxide, NF	8
Stearic Acid, NF	4
Lactose, NF	182
Microcrystalline Cellulose, NF	120
Croscarmellose.	

DETD . . . present invention also includes a chewable tablet formulation shown in Table 4.

#### TABLE 4

mg/tablet

	Phentolamine Mesylate, USP	40
	<b>Sildenafil</b>	50
	Silicon Dioxide, NF	12
	Stearic Acid, NF	12
	Lactose, NF	100
	Sweetrex	298
	Aspartame	40
	ProSweet	8
	Peppermint Flavor. . . .	

DETD . . . . inhibitors include xanthine derivatives, amrinone, milrinone, rolipram, Vesnarinone, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, **Sildenafil** and papaverine.

DETD [0092] **Sildenafil** has been shown to be effective at various doses including 25 mg and 50 mg (see Boolell et al, Br. . . . .

DETD . . . . comprises about 5 mg to about 100 mg phentolamine mesylate in combination with about 5 mg to about 125 mg **Sildenafil**.

DETD . . . : administration of from about 5 mg to about 100 mg of phentolamine mesylate and about 5 to about 150 mg **Sildenafil** in a rapidly dissolving oral formulation of the present invention from about 1 minute to about 1 hour prior to, . . . .

DETD [0099] As in the case of male sexual response, in the absence of any clinically diagnosed dysfunction in the female erectile response, the methods of the present invention may be used to enhance the normal female sexual response. The "on demand". . . .

DETD . . . rapidly dissolving formulation as set out in Table 5 except that papaverine at the doses indicated below was substituted for **Sildenafil**. Dosages were as follows:

TABLE 5

mg/tablet

	Phentolamine Mesylate,	40
	(alone)	
	Papaverine (alone)	150
	Phentolamine Mesylate	40
	plus	
	Papaverine. . . .	

CLM What is claimed is:

4. The composition of claim 3 wherein the type V cyclic GMP-specific phosphodiesterase inhibitor is 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4,3d]pyrimidin-5-yl) phenylsulfonyl]-4-methyl piperazine (**Sildenafil**).

5. A composition comprising from about 5 mg to about 100 mg phentolamine and from about 5 mg to about 150 mg 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3d]pyrimidin-5-yl) phenylsulfonyl]-4-methyl piperazine (**Sildenafil**) and a pharmaceutically acceptable carrier.

. . . from about 5 mg to about 100 mg phentolamine and from about 5 mg to about 150 mg 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-[d]pyrimidin-5-yl)phenylsulfonyl]-4-methylpiperazine (**Sildenafil**) in an orally administrable tablet, the tablet having a disintegration time of less than about twenty minutes.

IT 50-60-2, Phentolamine 58-00-4, Apomorphine 58-74-2, Papaverine 65-28-1, Phentolamine mesylate 73-05-2, Phentolamine hydrochloride 37221-79-7, Vasoactive intestinal peptide 139755-83-2, **Sildenafil**  
(combination therapy for modulating human sexual response)

L16 ANSWER 26 OF 48 USPATFULL on STN

Full Text

AN 2002:338074 USPATFULL

TI Method and compositions for the treatment or amelioration of female sexual dysfunction

IN Heaton, Jeremy P. W., Gananoque, CANADA  
Adams, Michael A., Kingston, CANADA

PI US 2002193442 A1 20021219  
 US 6756407 B2 20040629

SUMM . . . treatment of hot flashes, prevention of osteoporosis, and  
 diminishment of the risk of heart disease. Estrogen replacement results  
 in improved **clitoral sensitivity**, increased libido and decreased  
 pain/burning during intercourse. Local or topical estrogen application  
 relieves symptoms of vaginal dryness, burning, urinary frequency. . . .

SUMM [0021] Sildenafil functions as a selective type 5 (i.e. c-GMP  
 specific) phosphodiesterase inhibitor, and acts to decrease the  
 metabolism of c-GMP, the . . . safe and effective in improving  
 erectile duration and rigidity. In females, nitric oxide/NOS exists in  
 human vaginal and clitoral tissue. Sildenafil may prove useful alone,  
 or possibly in combination with other vasoactive agents for the  
 treatment of vasculogenic female sexual dysfunction.. . .

L16 ANSWER 27 OF 48 USPATFULL on STN

Full Text

AN 2002:301556 USPATFULL

TI Treatment of sexual dysfunction

IN Gonzalez, Maria Isabel, Cambridge, UNITED KINGDOM  
 Higginbottom, Michael, Cambridge, UNITED KINGDOM  
 Stock, Herman Thijs, Wijchen, NETHERLANDS  
 Pritchard, Martyn Clive, Huntingdon, UNITED KINGDOM  
 Pinnock, Robert Denham, Cambridgeshire, UNITED KINGDOM  
 Van Der Graaf, Pieter Hadewijn, Kent, UNITED KINGDOM  
 Naylor, Alisdair Mark, Kent, UNITED KINGDOM  
 Wayman, Christopher Peter, Kent, UNITED KINGDOM

PI US 2002169101 A1 20021114

SUMM . . . be administered orally, therefore obviating the disadvantages  
 associated with i.c. administration. One such compound that is currently  
 being manufactured is **sildenafil** (Viagra).

DETD . . . to increased vaginal lubrication via plasma transudation,  
 increased vaginal compliance (relaxation of vaginal smooth muscle) and  
 increases in vaginal and **clitoral sensitivity**. Female sexual arousal  
 disorder (FSAD) is a highly prevalent sexual disorder affecting up to  
 40% of pre-, peri- and postmenopausal. . . .

DETD . . . treatment of sexual dysfunction include alprostadil or  
 phentolamine, NO (nitric oxide) enhancers such as L-arginine, and PDE5  
 inhibitors such as **sildenafil** or a pharmaceutically acceptable salt  
 thereof (Scrip's Complete Guide to Women's Healthcare, p.194-205,  
 2000)(Sachs B. D., 2000, Benet and Melman,. . . .

DETD [0460] 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-  
 n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**)  
 also known as 1-[[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-  
 d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see  
 EP-A-0463756);

DETD [0471] 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-  
 methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**vardeafil**)  
 also known as 1-[[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo  
 [5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine,  
 i.e. the compound of examples 20, 19, 337 and 336 of published  
 international application WO99/24433; . . . .

DETD . . . Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double  
 blind placebo controlled study with crossover to assess effect of  
**sildenafil** on physiological parameters of the female sexual response.  
 J. Urol., 161, 805.

L16 ANSWER 28 OF 48 USPATFULL on STN

Full Text

AN 2002:295077 USPATFULL

TI Method and compositions for the treatment or amelioration of female  
 sexual dysfunction

IN Heaton, Jeremy P. W., Kingston, CANADA  
 Adams, Michael A., Kingston, CANADA

PI US 2002165122 A1 20021107

SUMM . . . treatment of hot flashes, prevention of osteoporosis, and  
 diminishment of the risk of heart disease. Estrogen replacement results  
 in improved **clitoral sensitivity**, increased libido and decreased  
 pain/burning during intercourse. Local or topical estrogen application  
 relieves symptoms of vaginal dryness, burning, urinary frequency. . . .

SUMM [0020] Sildenafil functions as a selective type 5 (i.e. c-GMP  
 specific) phosphodiesterase inhibitor, and acts to decrease the

metabolism of c-GMP, the. . . safe and effective in improving erectile duration and rigidity. In females, nitric oxide/NOS exists in human vaginal and clitoral tissue. Sildenafil may prove useful alone, or possibly in combination with other vasoactive agents for the treatment of vasculogenic female sexual dysfunction.. . .

L16 ANSWER 29 OF 48 USPATFULL on STN

Full Text

AN 2002:266337 USPATFULL  
TI The treatment of sexual dysfunction with enantiomers  
IN Cutler, Neal R., Los Angeles, CA, UNITED STATES  
Sramek, John, Irvine, CA, UNITED STATES  
PI US 2002147217 A1 20021010  
SUMM [0012] Sildenafil citrate (Viagra) has also been utilized as a pharmacological treatment for impotence. However, sildenafil citrate has a lack of specificity for its target, enzyme phosphodiesterase 5 (PDE5), and exerts a definite inhibition on the. . . has been shown that the inhibition of PDE6 results in color vision defects as a side effect of treatment with sildenafil citrate. Furthermore, side effects such as flushing, headache, nasal congestion, and dyspepsia (heartburn) have also been associated with sildenafil citrate treatment of impotence. (See, Moreira et al., "Side-effect profile of sildenafil citrate (Viagra) in clinical practice," Urology, 56(3): 474-76 (2000)).  
DETD DIAGNOSIS OF FEMALE ERECTILE DYSFUNCTION  
DETD TREATMENT OF MALE AND FEMALE ERECTILE DYSFUNCTION  
DETD . . . example, a biochemical assay was performed to test the percentage of phosphodiesterase 6 (PDE6) inhibition of various molar concentrations of sildenafil citrate (Viagra) as compared to that of a 100 µM concentration of a racemic mixture of flosequinan as follows.

L16 ANSWER 30 OF 48 USPATFULL on STN

Full Text

AN 2002:262363 USPATFULL  
TI Carboline derivatives as cGMP phosphodiesterase inhibitors  
IN Bombrun, Agnes, Monnetier Mornex, FRANCE  
Gellibert, Fran.cedilla.oise, Paris Cedex, FRANCE  
PI US 6462047 B1 20021008  
WO 2000015639 20000323  
SUMM . . . diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, peptic ulcer, male and female erectile dysfunction, and diseases characterized by disorders of gut motility (e.g., irritable bowel syndrome).  
SUMM . . . heart failure, and other disease states because of their ability to facilitate the action of ANP and NO. For example, sildenafil, a PDE inhibitor showing little selectivity with respect to PDE6, has the structure: ##STR6##  
SUMM . . . prophylaxis of stroke, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and female erectile dysfunction, or diseases characterized by disorders of gut motility (e.g., IBS).

L16 ANSWER 31 OF 48 USPATFULL on STN

Full Text

AN 2002:243641 USPATFULL  
TI Treatment of erectile dysfunction  
IN Mills, Thomas M., Augusta, GA, UNITED STATES  
Wingard, Christopher J., Augusta, GA, UNITED STATES  
Webb, R. Clinton, Matinez, GA, UNITED STATES  
Lewis, Ronald W., Augusta, GA, UNITED STATES  
Chitaley, Kanchan, Augusta, GA, UNITED STATES  
PI US 2002132832 A1 20020919  
AB . . . to the treatment of sexual dysfunction by inhibition of vasoconstriction leading to the relaxation of smooth muscles in male or female erectile tissue. In one aspect, the invention comprises methods for treating male and female sexual dysfunction which comprises administering a composition. . .  
SUMM . . . of nitric oxide (NO), enabling relaxation of blood vessels in the cavernosal circulation during sexual stimulation. For example, the compound sildenafil (Viagra) is a type 5 phosphodiesterase inhibitor that potentiates the effects of local release of NO, thereby resulting

in vascular smooth muscle relaxation. Studies have found **sildenafil** to have an overall 60% efficacy rate in the promotion of NO-mediated cavernosal vasorelaxation (Virag, R., Urology 54, 1073-77, 1999). Still, in those patients with severe erectile dysfunction (such as that resulting from diabetes or prostate surgery), **sildenafil** treatment was associated with a modest satisfaction rate (Jarow, I. P. et al., J. Urology, 102, 722-725, 1999). Moreover, only 30% of patents studied chose **sildenafil** treatment alone (Virag, R., 1999).

SUMM . . . include U.S. Pat. No. 6,087,362, which describes treatment of sexual dysfunction by an oral therapy of administration of apomorphine and **sildenafil** which is directed to minimizing the side effects of each agent. Other patents describing treatments for sexual dysfunction include U.S. . . .

DETD . . . of blood. Several drugs used to treat erectile dysfunction work by prolonging the effect of NO. For example, the compound **sildenafil** (Viagra) is a type 5 phosphodiesterase inhibitor used for the treatment of erectile dysfunction. Phosphodiesterase type 5 (PDE5) is responsible. . . of cGMP in the corpus cavernosum. Thus, when sexual stimulation results in local release of NO, inhibition of PDE5 by **sildenafil** (Viagra) maintains increased levels of cGMP in the corpus cavernosum, resulting in vascular smooth muscle relaxation.

DETD . . . of phentolamine. Also, U.S. Pat. No. 6,087,362 describes the treatment of sexual dysfunction by an oral regimen of apomorphine and **sildenafil**, and U.S. Pat. No. 6,007,824 describes treatment of sexual dysfunction using an oral dosage of L-arginine, ginseng and Zizyphi fructus.

L16 ANSWER 32 OF 48 USPATFULL on STN

Full Text

AN 2002:133870 USPATFULL

TI Composition to boost libido

IN Reyes, Joe, Troy, MI, UNITED STATES

PI US 2002068728 A1 20020606

US 6803060 B2 20041012

SUMM . . . sufficient for satisfactory sexual performance, is estimated to affect up to 30 million men in the United States. See "Oral **Sildenafil** in the Treatment of Erectile Dysfunction", New England Journal of Medicine, 338:20:1397 (1998). There are numerous causes of male erectile. . .

SUMM . . . male erectile dysfunction, including vacuum-constriction devices, intracavernosal injections of vasoactive agents, transurethral delivery of prostaglandin E<sub>1</sub> (alprostadil), oral administration of **sildenafil** citrate (Viagra<sup>®</sup> available from Pfizer), implantation of penile prostheses, and venous or arterial surgery. Most of these treatments involve painful. . . candidates for one or more of these treatments as a result of their physiological condition. For example, oral administration of **sildenafil** citrate is contraindicated for individuals currently taking organic nitrates, such as nitroglycerine. See "VIAGRA<sup>®</sup> (**sildenafil** citrate) Tablets", Pfizer Labs, 7 (1998).

DETD . . . such as Catuba Bark, a compound to increase blood flow to the pelvic area (in the preferred embodiment this causes **clitoral sensitivity**), such as Muria Puama, a compound to cause the body to produce natural estrogen, such as Wild Yam Root, a. . .

CLM What is claimed is:

8. The composition according to claim 2, wherein said estrogen producing compound causes **clitoral sensitivity**.

L16 ANSWER 33 OF 48 USPATFULL on STN

Full Text

AN 2002:122643 USPATFULL

TI Method and compositions for the treatment or amelioration of female sexual dysfunction

IN Adams, Michael A., Kingston, CANADA

Heaton, Jeremy P. W., Gananoque, CANADA

PI US 6395744 B1 20020528

SUMM . . . treatment of hot flashes, prevention of osteoporosis, and diminishment of the risk of heart disease. Estrogen replacement results in improved **clitoral sensitivity**, increased libido and decreased pain/burning during intercourse. Local or topical estrogen application relieves symptoms of vaginal dryness, burning, urinary frequency. . .

SUMM **Sildenafil** functions as a selective type 5 (i.e. c-GMP specific)

phosphodiesterase inhibitor, and acts to decrease the metabolism of c-GMP, the. . . safe and effective in improving erectile duration and rigidity. In females, nitric oxide/NOS exists in human vaginal and clitoral tissue. **Sildenafil** may prove useful alone, or possibly in combination with other vasoactive agents for the treatment of vasculogenic female sexual dysfunction.. . .

L16 ANSWER 34 OF 48 USPATFULL on STN

Full Text

AN 2002:8529 USPATFULL  
TI METHODS, COMPOSITIONS, AND KITS FOR ENHANCING FEMALE SEXUAL DESIRE AND RESPONSIVENESS  
IN NEAL, GARY W., KNOXVILLE, TN, UNITED STATES  
PI US 2002004529 A1 20020110  
SUMM . . . . It also includes decreases in the physiological response to sexual stimulation such as slowed or decreased erectile response of the **female erectile tissues**; slowed, decreased or absent lubrication of the vagina; slowed, decreased, or absent ability to have orgasms; decreased intensity of. . .  
SUMM . . . . but not limited to caffeine, aminophylline, theophylline, amrinone, milrinone, vesnarinone, vinpocetine, pemobendan, cilostamide, enoximone, peroximone, rolipram, R020-1724, zaniprast, dipyridamole, and **sildenafil**, may also be effective in enhancing the efficacy of the present method and for prolonging the effect;

L16 ANSWER 35 OF 48 USPATFULL on STN

Full Text

AN 2001:212470 USPATFULL  
TI Methods, compositions, and kits for enhancing female sexual desire and responsiveness  
IN Neal, Gary W., Knoxville, TN, United States  
PI US 2001044467 A1 20011122  
US 6593369 B2 20030715  
SUMM . . . . It also includes decreases in the physiological response to sexual stimulation such as slowed or decreased erectile response of the **female erectile tissues**; slowed, decreased or absent lubrication of the vagina; slowed, decreased, or absent ability to have orgasms; decreased intensity of. . .  
SUMM . . . . but not limited to caffeine, aminophylline, theophylline, amrinone, milrinone, vesnarinone, vinpocetine, pemobendan, cilostamide, enoximone, peroximone, rolipram, R020-1724, zaniprast, dipyridamole, and **sildenafil**, may also be effective in enhancing the efficacy of the present method and for prolonging the effect;

L16 ANSWER 36 OF 48 USPATFULL on STN

Full Text

AN 2001:158350 USPATFULL  
TI Prostaglandin E1/F2 in combination with prostaglandin F2 $\alpha$  for enhancing female sexual arousal  
IN Scott, Nathan Earl, 610 Laguna Rd., Fullerton, CA, United States 92835  
PI US 6291528 B1 20010918  
SUMM Most recently Pfizer has made **sildenafil** citrate available in oral dosages as a treatment for impotence under the trade name, **Viagra**<sup>®</sup>. However, **Viagra**<sup>®</sup> is counter indicated. . . addition, a new warning has been added to labeling for **Viagra**<sup>®</sup> warning of a possible occurrence of priapism. Also since **sildenafil** citrate is administered orally, the effect of the drug is systemic and not restricted, as in direct delivery to the. . .  
DETD . . . . appears to be associated with deeper pelvic contractions and to be more pleasurable from "G-spot" stimulation than orgasm resulting from clitoral stimulation alone.

L16 ANSWER 37 OF 48 USPATFULL on STN

Full Text

AN 2000:150177 USPATFULL  
TI Chemical compounds  
IN Daugan, Alain Claude-Marie, Marly le Roi Cedex, France  
LaBaudiniere, Richard Frederick, Collegeville, PA, United States  
PI US 6143757 20001107  
SUMM . . . . thrombocythemia, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and



female erectile dysfunction, and diseases characterized by disorders of gut motility (e.g., irritable bowel syndrome or IBS).

SUMM . . . heart failure, and other disease states because of their ability to facilitate the action of ANP and NO. For example, sildenafil, a PDE inhibitor showing little selectivity with respect to PDE6, has the structure: ##STR5## and has shown efficacy in oral. . .

SUMM . . . prophylaxis of stroke, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and female erectile dysfunction, or diseases characterized by disorders of gut motility (e.g., IBS).

L16 ANSWER 38 OF 48 USPATFULL on STN

Full Text

AN 2000:150166 USPATFULL

TI Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use

IN Daugan, Alain Claude-Marie, Marly le Roi Cedex, France  
Gellibert, Françoise, Marly le Roi Cedex, France

PI US 6143746 20001107

SUMM . . . thrombocytopenia, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and female erectile dysfunction, and diseases characterized by disorders of gut motility (e.g., irritable bowel syndrome).

SUMM . . . heart failure, and other disease states because of their ability to facilitate the action of ANP and NO. For example, sildenafil, a PDE inhibitor showing little selectivity with respect to PDE6, has the structure: ##STR12## and has shown efficacy in oral. . .

SUMM . . . prophylaxis of stroke, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and female erectile dysfunction, or diseases characterized by disorders of gut motility (e.g., IBS).

IT 171488-01-0P 171488-02-1P 171488-03-2P 171488-04-3P 171488-05-4P  
171488-06-5P 171488-07-6P 171488-08-7P 171488-09-8P 171488-10-1P  
171488-11-2P 171488-12-3P 171488-13-4P 171488-14-5P 171488-15-6P  
171488-16-7P 171488-17-8P 171488-18-9P 171488-19-0P 171488-20-3P  
171488-21-4P 171488-22-5P 171488-23-6P 171488-24-7P 171488-25-8P  
171488-26-9P 171488-27-0P 171488-28-1P 171488-29-2P 171488-30-5P  
171488-31-6P 171488-32-7P 171488-33-8P 171488-34-9P 171488-35-0P  
171488-36-1P 171488-37-2P 171488-38-3P 171488-39-4P 171488-40-7P  
171488-41-8P 171488-42-9P 171488-43-0P 171488-44-1P 171488-45-2P  
171488-46-3P 171488-47-4P 171488-48-5P 171488-49-6P 171488-50-9P  
171488-51-0P 171488-52-1P 171488-53-2P 171488-54-3P 171488-55-4P  
171488-56-5P 171488-57-6P 171488-58-7P 171488-59-8P 171488-60-1P  
171488-61-2P 171488-62-3P 171488-63-4P 171488-64-5P 171488-65-6P  
171488-66-7P 171488-67-8P 171488-68-9P 171488-69-0P 171488-70-3P  
171488-71-4P 171488-72-5P 171488-73-6P 171488-74-7P 171488-75-8P  
171488-76-9P 171488-77-0P 171488-78-1P 171488-79-2P 171488-80-5P  
171488-81-6P 171488-82-7P 171488-84-9P 171488-85-0P 171488-86-1P  
171488-87-2P 171488-88-3P 171488-89-4P 171488-90-7P 171488-91-8P  
171488-92-9P 171488-94-1P 171488-95-2P 171488-96-3P 171488-97-4P  
171488-98-5P 171488-99-6P 171489-01-3P 171489-02-4P 171489-03-5P  
171489-04-6P 171596-27-3P 171596-28-4P 171596-29-5P  
171596-30-8P 171596-31-9P 171596-32-0P 171596-33-1P 171596-34-2P  
171596-35-3P 171596-36-4P 171596-37-5P 171596-38-6P 171596-39-7P  
171596-40-0P 187935-15-5P 187939-81-7P 303984-31-8P 303984-32-9P  
303984-33-0P 303984-34-1P 303984-35-2P 303984-36-3P 303984-37-4P  
(tetracyclic cyclic GMP-specific phosphodiesterase inhibitors and their use in disease treatment)

L16 ANSWER 39 OF 48 USPATFULL on STN

Full Text

AN 2000:37808 USPATFULL

TI Carboline derivatives

IN Bombrun, Agnes, Paris, France

PI US 6043252 20000328

SUMM . . . diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, peptic ulcer, osteoporosis, preterm labor, benign prostatic hypertrophy, male and female erectile dysfunction, and diseases characterized by disorders of gut motility (e.g., irritable

bowel syndrome or IBS).

SUMM . . . heart failure, and other disease states because of their ability to facilitate the action of ANP and NO. For example, **sildenafil**, a PDE inhibitor showing little selectivity with respect to PDE6, has the structure: ##STR8## and has shown efficacy in oral. . .

SUMM . . . prophylaxis of stroke, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and female erectile dysfunction, or diseases characterized by disorders of gut motility (e.g., IBS).

L16 ANSWER 40 OF 48 USPAT2 on STN

Full Text

AN 2005:38129 USPAT2

TI 5-HT receptor ligands and uses thereof

IN Chiang, Phoebe, East Lyme, CT, UNITED STATES  
Novomisle, William A., Stonington, CT, UNITED STATES  
Welch, Jr., Willard M., Mystic, CT, UNITED STATES

PI US 6995159 B2 20060207

DETD . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE<sub>1</sub>) that are injected or administered transurethrally in men and topically to the genitalia in women.

DETD . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or. . .

DETD More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);

DETD (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples. . .

DETD 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5, 1-f][1,2,4]triazin-4-one (**vardeafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5, 1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433);. . .

DETD . . . aspect the present invention provides a composition for the treatment of MED comprising a compound of the present invention and **sildenafil**.

DETD . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.

DETD . . . aspect, the present invention provides a composition for the treatment of FSD comprising a compound of the present invention and **sildenafil**.

DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.

DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic.

L16 ANSWER 41 OF 48 USPAT2 on STN

Full Text

AN 2003:325098 USPAT2

TI Indole derivatives as PDE5-inhibitors

IN Orme, Mark W., Seattle, WA, UNITED STATES  
Sawyer, Jason Scott, Indianapolis, IN, UNITED STATES  
Schultze, Lisa M., Woodinville, WA, UNITED STATES

PI US 6878711 B2 20050412  
WO 2002036593 20020510

DETD . . . prophylaxis of stroke, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm

labor, benign prostatic hypertrophy, male and female erectile dysfunction, or diseases characterized by disorders of gut motility (e.g., IBS).

IT 171596-29-5P 171596-43-3P 422311-84-0P 422311-85-1P  
(prepn. of pyrazino[1',2':1,6]pyrido[3,4-b]indole derivs. as phosphoesterase inhibitors for use as therapeutic agents)

L16 ANSWER 42 OF 48 USPAT2 on STN

Full Text

AN 2003:271544 USPAT2  
TI Use of monochloroflosequinan in the treatment of sexual dysfunction  
IN Cutler, Neal R., Los Angeles, CA, UNITED STATES  
PI US 7041677 B2 20060509  
SUMM **Sildenafil** citrate (Viagra) has also been utilized as a pharmacological treatment for impotence. However, **sildenafil** citrate has a lack of specificity for its target, enzyme phosphodiesterase 5 (PDE5), and exerts a definite inhibition on the. . . has been shown that the inhibition of PDE6 results in color vision defects as a side effect of treatment with **sildenafil** citrate. Furthermore, side effects such as flushing, headache, nasal congestion, and dyspepsia (heartburn) have also been associated with **sildenafil** citrate treatment of impotence. (See, Moreira et al., "Side-effect profile of **sildenafil** citrate (Viagra) in clinical practice," Urology, 56(3): 474-76 (2000)).  
SUMM . . . flosequinan derivatives for improving blood flow and supply to female sexual organs, and more particularly, methods for the treatment of female erectile dysfunction. In selected embodiment the methods of the present invention comprise the utilization of these pharmaceutical compositions to induce clitoral. . .  
DETD . . . of the penis and the associated facia which produce impotence, the inability to attain a sexually functional erection. In the female "erectile dysfunction" is associated with disorders (including but not limited to impaired blood flow to the clitoris) which impair or prevent.  
DETD C. Diagnosis of Female Erectile Dysfunction  
DETD D. Treatment of Male and Female Erectile Dysfunction

L16 ANSWER 43 OF 48 USPAT2 on STN

Full Text

AN 2003:181501 USPAT2  
TI 5-HT receptor ligands and uses thereof  
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES  
Novomisle, William A., Stonington, CT, UNITED STATES  
Welch, Jr., Willard M., Mystic, CT, UNITED STATES  
Guzman-Perez, Angel, Stonington, CT, UNITED STATES  
DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES  
Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES  
Liu, Kevin K., East Lyme, CT, UNITED STATES  
PI US 6894050 B2 20050517  
DETD . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE<sub>1</sub>) that are injected or administered transurethraly in men and topically to the genitalia in women.  
DETD . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or. . .  
DETD More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methyl piperazine (see EP-A-0463756);  
DETD (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples. . .  
DETD 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**vardeafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application

WO99/24433); and.

DETD According to a further aspect the present invention provides a composition for the treatment of MED comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.

DETD . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.

DETD According to a further aspect, the present invention provides a composition for the treatment of FSD comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.

DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.

DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic.

L16 ANSWER 44 OF 48 USPAT2 on STN

Full Text

AN 2003:153438 USPAT2

TI 5-HT receptor ligands and uses thereof

IN Chiang, Phoebe, East Lyme, CT, United States  
Novomisle, William A., Stonington, CT, United States  
Welch, Jr., Willard M., Mystic, CT, United States

PI US 6825198 B2 20041130

DETD . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE<sub>1</sub>) that are injected or administered transurethrally in men and topically to the genitalia in women.

DETD . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or.

DETD More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);

DETD (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2', 1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples.

DETD 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**varidenafil**) also known as 1-[[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5, 1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433);

DETD . . . aspect the present invention provides a composition for the treatment of MED comprising a compound of the present invention and **sildenafil**.

DETD . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.

DETD . . . aspect, the present invention provides a composition for the treatment of FSD comprising a compound of the present invention and **sildenafil**.

DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.

DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic.

L16 ANSWER 45 OF 48 USPAT2 on STN

Full Text

AN 2003:134652 USPAT2  
 TI  $\alpha$  adrenergic agents  
 IN Miller, Duane D., Germantown, TN, UNITED STATES  
 Hong, Seoung-Soo, Cheongju, KOREA, REPUBLIC OF  
 PI US 6919357 B2 20050719  
 SUMM . . . included pain, risk of infection, inconvenience, and interference with spontaneity. Within the past few years, Pfizer's orally active product Viagra<sup>®</sup> (sildenafil citrate) has become a break-through treatment for ED. Sildenafil is a potent and selective cGMP-specific type 5 phosphodiesterase inhibitor and now represents the first line therapy for the treatment of ED. Despite sildenafil's success, however, numerous patients have not been successfully treated. In addition, sildenafil must be administered significantly prior to sexual activity ruining spontaneity and numerous side effects have been reported. The most significant. . .  
 DETD As in the case of male sexual response, in the absence of a clinically diagnosed dysfunction in the female erectile response, the methods of the present invention may be used to enhance the normal female sexual response. The "on demand". . .

L16 ANSWER 46 OF 48 USPAT2 on STN

Full Text

AN 2002:338074 USPAT2  
 TI Method and compositions for the treatment or amelioration of female sexual dysfunction  
 IN Heaton, Jeremy P. W., Gananoque, CANADA  
 Adams, Michael A., Kingston, CANADA  
 PI US 6756407 B2 20040629  
 SUMM . . . treatment of hot flashes, prevention of osteoporosis, and diminishment of the risk of heart disease. Estrogen replacement results in improved clitoral sensitivity, increased libido and decreased pain/burning during intercourse. Local or topical estrogen application relieves symptoms of vaginal dryness, burning, urinary frequency. . .  
 SUMM Sildenafil functions as a selective type 5 (i.e. c-GMP specific) phosphodiesterase inhibitor, and acts to decrease the metabolism of c-GMP, the. . . safe and effective in improving erectile duration and rigidity. In females, nitric oxide/NOS exists in human vaginal and clitoral tissue. Sildenafil may prove useful alone, or possibly in combination with other vasoactive agents for the treatment of vasculogenic female sexual dysfunction.. . .

L16 ANSWER 47 OF 48 USPAT2 on STN

Full Text

AN 2002:133870 USPAT2  
 TI Composition to boost libido  
 IN Reyes, Joe, 1175 Chicago Rd., Troy, MI, United States 48083  
 PI US 6803060 B2 20041012  
 SUMM . . . sufficient for satisfactory sexual performance, is estimated to affect up to 30 million men in the United States. See "Oral Sildenafil in the Treatment of Erectile Dysfunction", New England Journal of Medicine, 338:20:1397 (1998). There are numerous causes of male erectile. . .  
 SUMM . . . male erectile dysfunction, including vacuum-constriction devices, intracavernosal injections of vasoactive agents, transurethral delivery of prostaglandin E<sub>1</sub> (alprostadil), oral administration of sildenafil citrate (Viagra<sup>®</sup> available from Pfizer), implantation of penile prostheses, and venous or arterial surgery. Most of these treatments involve painful. . . candidates for one or more of these treatments as a result of their physiological condition. For example, oral administration of sildenafil citrate is contraindicated for individuals currently taking organic nitrates, such as nitroglycerine. See "VIAGRA<sup>®</sup> (sildenafil citrate) Tablets", Pfizer Labs, 7 (1998).  
 DETD . . . such as Catuba Bark, a compound to increase blood flow to the pelvic area (in the preferred embodiment this causes clitoral sensitivity), such as Muria Puama, a compound to cause the body to produce natural estrogen, such as Wild Yam Root, a. . .

L16 ANSWER 48 OF 48 USPAT2 on STN

Full Text

AN 2001:212470 USPAT2  
 TI Methods, compositions, and kits for enhancing female sexual desire and responsiveness

IN Neal, Gary W., Knoxville, TN, United States  
 PI US 6593369 B2 20030715  
 SUMM . . . It also includes decreases in the physiological response to sexual stimulation such as slowed or decreased erectile response of the **female erectile** tissues; slowed, decreased or absent lubrication of the vagina; slowed, decreased, or absent ability to have orgasms; decreased intensity of. . .  
 SUMM . . . but not limited to caffeine, aminophylline, theophylline, amrinone, milrinone, vesnarinone, vinpocetine, pemobendan, cilostamide, enoximone, peroximone, rolipram, R020-1724, zaniprast, dipyridamole, and **sildenafil**, may also be effective in enhancing the efficacy of the present method and for prolonging the effect;

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

121.17

146.66

STN INTERNATIONAL LOGOFF AT 21:16:57 ON 06 APR 2007